Protocol for 
 
Official Title of Study 
A Phase 2 Randomized, Double-Blind , Placebo-Controlled Study of the Safety and 
Efficacy of BMS-986165 in Subjects with Moderate to Severe Ulce rative Colitis  
[STUDY_ID_REMOVED] 
April 14, 2021 
Page: 1
Protocol Number: IM011024
Date; Version: 14-Apr-2021, Protocol Amendment 03
CLINICAL PROTOCOL IM011024
A Phase 2 Randomized, Double-Bli nd, Placebo-Controlled Study of  the Safety and Efficacy of 
BMS-986165 in Subjects with Moderate to Severe Ulcerative Colit is
Short Title : Safety and Efficacy of BMS-986165 in Subjects with Moderate t o Severe 
Ulcerative Colitis
24-hr Emergency Telephone Number
USA: 
International: 
Bristol-Myers Squibb Company
3401 Princeton Pike
Lawrenceville, NJ 08648
Avenue de Finlande 4
B-1420 Braine-l‚ÄôAlleud, Belgium
6-5-1 Nishi-Shinjuku, Shinjuku-ku,
Tokyo, 163- 1328, Japan
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr -2021 BMS Confidential 2REGULATORY AGENCY IDENTIFIER NUMBER(S)
EUDRACT Number: 2018-004694-27
This document is the confidential and proprietary information o f Bristol-Myers Squibb Company 
and its global affiliates (BMS). By reviewing this document, yo u agree to keep it confidential and to 
use and disclose it solely for the purpose of assessing whether  your organization will participate in 
and/or the performance of the proposed BMS sponsored study. Any permitted disclosures will be 
made only on a confidential "need to know" basis within your organization or to your independent ethics committee(s). Any other use, copying, disclosure, or diss emination of this information is strictly 
prohibited unless expressly authorized in writing by BMS. Any s upplemental information (eg, 
amendments) that may be added to this document is also confident ial and proprietary to BMS and 
must be kept in confidence in the same manner as the contents o f this document. Any person who 
receives this document without due authorization from BMS is requested to return it to BMS or promptly destroy it. All other rights reserved. References to B MS in this protocol may apply to 
partners to which BMS has transferred obligations, eg, a Contract Research Organization (CRO).
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr -2021 BMS Confidential 3DOCUMENT HISTORY
Document Date of Issue Approver(s) Summary of Changes
Protocol
Amendment 03
(Global Revised 
Protocol 12_v4.0) 
im011024-
protamend0314-Apr-2021‚Ä¢Added information, instructions,and measures to be taken relatedto SARS-CoV-2 infection/
COVID-19, including the
following:
oAmended exclusion
criterion 5)l
oAdded diagnostic test at
screening
‚Ä¢Removed fasting requirement for
blood tests at screening
‚Ä¢Amended wording of note fromAdministrative Letter 1 regarding
consistent endoscopy procedures
‚Ä¢Updated study endpoints and
endpoint definitions
‚Ä¢Clarified that study data may beused for additional analysesrelated to UC and otherinflammatory diseases
‚Ä¢Updated text in multiple sections of the protocol due to changes inBMS protocol standards
Revised 
Protocol 02a
France-specific
(Revised Protocol 
11a)
im011024-
revprot02a-fr-
specific22-Jun-2020This country-specific revised protocol 
applies to all subjects enrolled in 
France. It encompasses the removal of the first bullet point of inclusion criterion 2)h) and modification of APPENDIX 5, which allowed subjects with only an inadequate response, loss of response, 
or intolerance to a standard course of 
oral 5-aminosalicylates (5-ASAs) to be included in the trial.
Administrative 
Letter 116-Jan-2020Includes clarifications and minor 
typographical error corrections.
Amendment 10
v3.0
(Japan)08-Jan-2020This country-specific amendment 
applies to all subjects enrolled in 
Japan. 
Modifications include: 
‚Ä¢Changes made in Global Revised
Protocol v3.0
‚Ä¢Revisions based on the updatedJapan hepatitis guideline
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr -2021 BMS Confidential 4Document Date of Issue Approver(s) Summary of Changes
Revised Protocol 09
v3.0
(Germany)19-Dec-2019This country-specific revised protocol 
applies to all subjects enrolled in 
Germany. The purpose of this revised 
protocol is to incorporate the changes 
from Revised Protocol 06 (global 
version 3.0) into the Germany-
specific Revised Protocol 05 (global 
version 2.0). Additionally, a new 
exclusion crit erion was added to 
Section 5.2 to exclude subjects with 
hereditary galac tose intolerance, total 
lactase deficiency, or glucose-
galactose malabsorption.
Revised Protocol 08
v3.0
(Czech Republic)19-Dec-2019This country-specific revised protocol 
applies to all subjects enrolled in the Czech Republic. The purpose of this 
revised protocol is to incorporate the 
changes from Revised Protocol 06 
(global version 3.0) into the Czech 
Republic‚Äìspecific Revised Protocol 
04 (global version 2.0).  
Revised Protocol 07
v3.0
(South Korea)18-Dec-2019This country-specific revised protocol 
applies to all subjects enrolled in 
South Korea. The purpose of this 
revised protocol is to incorporate the 
changes from Revised Protocol 06 
(global version 3.0) into the South 
Korea-specific Revised Protocol 03 
(global version 2.0). Additionally, 
new language regarding biopsy 
sampling was added to reflect South 
Korea‚Äìspecific endoscopic 
procedures.
Global Revised 
Protocol 06
v3.028-Oct-2019Includes the following modifications:
‚Ä¢Add a 52-wee k open-label
extension period to provide the
option of additional treatment tosubjects deriving clinical benefitat Week 52;
‚Ä¢Modify the type and/or frequencyof various study assessments toimprove subject safety andminimize subject burden; provideadditional detail for each of thestudy periods, including clearguidance for management of
Week 12 responders and
nonresponders in themaintenance period andadditional hepatitis B Virus(HBV) and hepatitis C Virus
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr -2021 BMS Confidential 5Document Date of Issue Approver(s) Summary of Changes
(HCV) screening and monitoring information;
‚Ä¢Modify several inclusion and
exclusion criteria to increase
subject eligibility, and addspecific randomization criteria toaid in final determination ofeligibility;
‚Ä¢Incorporate several elements
from the South Korea and
Germany specific v2.0amendments regarding age ofmajority, and follow-up afterdiscontinuation and adverseevents;
‚Ä¢Revise or clarify the definitionsof key study terms and endpoints;
‚Ä¢Revise or clarify the following
study elements: prohibited and
restricted treatments; use andtapering of corticosteroids duringall study periods; criteria definingtreatment failure; criteria leadingto discontinuation; and criteriadefining inadequate response,loss of response, and intoleranceto previous biologic therapy;
‚Ä¢Clarify sample size calculation
;
‚Ä¢Remove or modify severalcontraception requirements toreflect recent toxicology dataconsistent with these changes;
‚Ä¢Implement other revisionsincluding modification of textregarding safety reportingrequirements; and addition ofseveral new appendices toevaluate UC disease activity
Amendment 05
(Germany)
v2.029-Aug-2019This country-specific amendment applies to all subjects enrolled in Germany. Modifications include: 
‚Ä¢Exclusion Criterion 7)a) has been
revised to exclude prisoners or
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr -2021 BMS Confidential 6Document Date of Issue Approver(s) Summary of Changes
subjects who are involuntarily incarcerated from trial participation. 
‚Ä¢Section 7.1.1 (Post-StudyTreatment Follow-up) has beenrevised to state that participantswho discontinue study treatmentwill be followed for 28 days orlonger, as required, and in linewith Section 8.2.3.
‚Ä¢Section 8.2.1 and APPENDIX 3have been revised to state thatserious adverse events (AEs)need to be reported‚Äòimmediately‚Äô to Sponsor ordesignee but no later than 24hours after awareness of theevent.
‚Ä¢Section 8.2.5 (Pregnancy) hasbeen revised to state that studydrug treatment must bediscontinued immediately in caseof pregnancy and that thepregnancy must be reportedwithin 24 hours of awareness ofthe pregnancy.
‚Ä¢APPENDIX 3 has been revised tostate that nonserious AEs thatcause interruption ordiscontinuation of studytreatment must be followed to
resolution or stabilization.
Amendment 04
(Czech Republic)
v2.001-Aug-2019This country-specific amendment 
applies to all subjects enrolled in the 
Czech Republic. The purpose of this 
Amendment is to adjust the maximum 
age of subjects from 80 to 70 years of 
age, and to align Section 8.2.5 
Pregnancy with local regulatory 
requirements for Czech Republic 
sites.
Amendment 03
(South Korea)
v2.031-Jul-2019Adding ‚Äúor age of majority‚Äù to 
inclusion criterion to align with local 
regulatory requirements for South 
Korean sites
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr -2021 BMS Confidential 7Document Date of Issue Approver(s) Summary of Changes
Amendment 02
(Japan)
v2.009-Apr-2019This country-specific amendment 
applies to all subjects enrolled in 
Japan. The purpose of this 
Amendment is to incorporate local 
regulatory requirements for Japanese 
sites.
Global Revision 01
v2.026-Mar-2019Includes modifications to the 
Schedule of Activities  
added new 
Section 8.1.1 and language 
throughout protocol regarding central 
read versus local read of endoscopy; 
clarified corticosteroid use as a rescue 
medication; and added 
discontinuation criteria and study 
stopping rule  
Original Global 
Protocol v1.017-Dec-2018 Not applicable
aDocument naming conventions have been updated. Legacy numbering  is provided for consistency.
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
OVERALL RATIONALE FOR GLOBAL PROTOCOL AMENDMENT 03
The primary purpose of this revised protocol is to include the following updates:
‚Ä¢Addition of severe acute respiratory syndrome coronavirus 2 (SARS -CoV-2) diagnostic
testing, as well as an exclusion criterion and study procedures p ertaining to SARS-CoV-2
infection
‚Ä¢Inclusion of coronavirus disease 2019 (COVID-19) benefit-risk in formation and vaccination
guidelines
‚Ä¢Update to study e ndpoints pri or to database lock for primary en dpoint analysis
The revised protocol will be implemented after the Investigator receives all appr opriate agency 
and IRB/EC approvals.
Generally, only major additions and deletions are provided in t his summary of changes document, 
and all minor grammatical, formatting, rephrasing, stylistic changes, or clarifications, as well as 
organizational changes are not included. All changes applied to  the protocol body were applied to 
the protocol synopsis, as necessary; synopsis changes are not i ncluded in the summary of key 
changes table. 
The rationale for the change to this Revised Protocol is provid ed in the summary of key changes 
table, as shown below:
SUMMARY OF KEY CHANGES FOR PROTOCOL AMENDMENT 03
Section Number & Title Description of Change Brief Rationale
2 Schedule of Activities , Tables 1-4
3.3 Benefit/Risk Assessment
6.2 Exclusion Criteria , 5) Immune and 
Infectious Disease Exclusion Criteria7.7.1 Prohibited and/or Restricted  
Treatments
8.2.1 Temporary Discontinuation  (new 
section)
9.8 SARS-CoV-2 Testing (new section)
Appendix 19 COVID-19 Vaccines 
(new appendix)Added information, instructions, 
and measures to be taken related 
to SARS-CoV-2 infection/COVID-19, including the following:
Amended exclusion criterion 5)l
Added diagnostic test at 
screening  Provides guidance to investigators 
related to SARS-CoV-2 
2 Schedule of Assessments, Table 1 Removed fasting requirement for 
blood tests at screening Reduces subject burden
Protocol Amendment No.: 03
Date: 14-Apr-2021 8
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
SUMMARY OF KEY CHANGES FOR PROTOCOL AMENDMENT 03
Section Number & Title Description of Change Brief Rationale
2 Schedule of Assessments, Tables 2 -4 Amended wording of note from 
Administrative Letter 1
regarding consistent endoscopy proceduresClarified aim of previously added 
text
4 Objectives and Endpoints , Tables 5 -7 Updated study endpoints and 
endpoint definitionsAdds histologic and histologic-endoscopic endpoints and definitions to reflect consensus guidelines on the measure of efficacy in UC. Due  to the study‚Äôs 
small sample size we do not wish to add additional multiplicity-controlled endpoints and therefore find histologic improvement as a better measure of efficacy than endoscopic remission
9 Study Assessments and Procedures Clarified that study data may be 
used for additional analyses 
related to UC and other inflammatory diseasesClarifies potential future analyses
Study Acknowledgment/Disclosure
6.5 Screen Failures7.3.2 Circumstances for Unblinding
7.8 Treatment After the End of the  
Study9.2.1 Time Period and Frequency for 
Collecting AE and SAE Information
9.2.5 Pregnancy
Appendix 2 Study Governance 
Considerations
Appendix 3 Adverse Events and 
Serious Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up and Reporting
Appendix 4 Women of Childbearing 
PotentialUpdated text in multiple sections of the protocol due to changes in BMS protocol standardsReflects current BMS procedures, policies, and guidelines
Protocol Amendment No.: 03
Date: 14-Apr-2021 9
Approved 1.0 v Approved 1.0 v
7$%/( 2)&217(176
7,7/( 3$*(
'2&80(17+,6725<
29(5$//5$7,21$/()25*/2%$/35272&2/$0(1'0(17
6800$5<2).(<&+$1*(6)2535272&2/$0(1'0(17
7$%/( 2) &217(176
35272&2/6800$5< 
6\QRSVLV
6FKHPD
 6&+('8/( 2) $&7,9,7,(6
 6FUHHQLQJ 3HULRG $FWLYLWLHV DQG $VVHVVPHQWV 
2.1.1 Induction Period Activities and Assessments ........................................... 
2.1.2 Maintenance Period Activities and Assessments ..................................... 
2.1.3 Open-label Extension Period Activities and Assessments ....................... 
,1752'8&7,21
6WXG\ 5DWLRQDOH
 %DFNJURXQG 
3.2.1 Nonclinical Toxicology ............................................................................ 
3.2.2 Early Clinical Experience ........................................................................ 
%HQHILW5LVN$VVHVVPHQW 
2%-(&7,9(6$1'(1'32,176
 678'< '(6,*1
 2YHUDOO 'HVLJQ 
5.1.1 Screening Period ...................................................................................... 
5.1.1.1 Therapeutic Drug Monitoring......................................................... 
5.1.2 Induction Period ...................................................................................... 
5.1.3 Maintenance Period ................................................................................. 
5.1.3.1 Week 12 (Day 85), End of Induction Period ................................... 
5.1.3.2 Week 12 Responders: Disease Worsening in the Maintenance 
Period .................................................................................................... 
5.1.3.3 Week 12 Nonresponders: Disease Worsening in the Maintenance 
Period .................................................................................................... 
5.1.3.4 Week 52 (Day 365): End of Maintenance Period ........................... 
5.1.4 Open-label Extension Period ................................................................... 
5.1.4.1 Post-treatment Follow-up ............................................................... 
5.1.5 Corticosteroid Use and Tapering Schedules ........................................... 
5.1.5.1 Corticosteroid Use in the Induction Period .................................... 
5.1.5.2 Corticosteroid Tapering in the Maintenance Period ...................... 
5.1.5.3 Corticosteroid Tapering in the Open-label Treatment Arm ........... 
5.1.6 Treatment Failure .................................................................................... 
5.1.7 Data Monitoring Committee and Other External Committees ................ 
1XPEHU RI 6XEMHFWV
 (QG RI 6WXG\ 'HILQLWLRQ
 6FLHQWLILF 5DWLRQDOH IRU 6WXG\ 'HVLJQ
 -XVWLILFDWLRQ IRU 'RVH































&OLQLFDO 3URWRFRO
%06,0
7<. ,QKLELWRU
3URWRFRO $PHQGPHQW 1R 'DWH $SU 
Approved 1.0 v
Approved 1.0 v
678'< 3238/$7,21 
,QFOXVLRQ &ULWHULD
 ([FOXVLRQ &ULWHULD
 5DQGRPL]DWLRQ &ULWHULD
/LIHVW\OH 5HVWULFWLRQV
 6FUHHQ )DLOXUHV 
6.5.1 Retesting During the Screening Period and Rescreening ........................ 
75($70(17 
 7UHDWPHQWV $GPLQLVWHUHG 
 0HWKRG RI 7UHDWPHQW $VVLJQPHQW 
%OLQGLQJ
7.3.1 Maintaining the Blind .............................................................................. 
7.3.2 Circumstances for Unblinding ................................................................. 
 'RVDJH 0RGLILFDWLRQ DQGRU ,QWHUUXSWLRQ 
 3UHSDUDWLRQ+DQGOLQJ6WRUDJH$FFRXQWDELOLW\ 
7.5.1 Retained Samples for Bioavailability/Bioequivalence ............................. 
 7UHDWPHQW &RPSOLDQFH 
 &RQFRPLWDQW 7KHUDS\
7.7.1 Prohibited and/or Restricted Treatments................................................. 
7.7.2 Existing Therapies for Ulcerative Colitis ................................................ 
 7UHDWPHQW $IWHU WKH (QG RI WKH 6WXG\ 
 ',6&217,18$7,21 &5,7(5,$ 
'LVFRQWLQXDWLRQ IURP 6WXG\ 7UHDWPHQW
8.1.1 Post-Study Treatment Study Follow-Up .................................................. 
 'LVFRQWLQXDWLRQ IURP WKH 6WXG\ 
8.2.1 Temporary Discontinuation ..................................................................... 
/RVW WR )ROORZ8S
 5HSODFHPHQW RI 6XEMHFWV 
 'LVFRQWLQXDWLRQ RI 6WXG\ &RQGXFW6WXG\ 6WRSSLQJ 5XOHV 
678'<$66(660(176$1'352&('85(6 
(IILFDF\ $VVHVVPHQWV
9.1.1 Clinical Response Assessment ................................................................. 
$GYHUVH (YHQWV
9.2.1 Time Period and Frequency for Collecting AE and SAE Information .... 
9.2.2 Method of Detecting AEs and SAEs ......................................................... 
9.2.3 Follow-up of AEs and SAEs ..................................................................... 
9.2.4 Regulatory Reporting Requirements for SAEs ......................................... 
9.2.5 Pregnancy ................................................................................................ 
9.2.6 Laboratory Test Result Abnormalities ..................................................... 
9.2.7 Potential Drug-Induced Liver Injury (DILI) ............................................ 
9.2.8 Adverse Events of Interest (Clinical Safety Program) ............................. 
9.2.9 Other Safety Considerations .................................................................... 
 2YHUGRVH 
6DIHW\
9.4.1 Physical Examinations ............................................................................. 
9.4.2 Tuberculosis Screening and Chest X-ray ................................................. 




































&OLQLFDO 3URWRFRO
%06,0
7<. ,QKLELWRU
3URWRFRO $PHQGPHQW 1R 'DWH $SU 
Approved 1.0 v
Approved 1.0 v
9.4.3 Clinical Safety Laboratory Assessments .................................................. 
9.4.4 Imaging Safety Assessment ...................................................................... 
9.4.5 Vital Signs ................................................................................................ 
9.4.6 Electrocardiograms ................................................................................. 
6$56&R9 7HVWLQJ
67$7,67,&$/&216,'(5$7,216 
 6DPSOH 6L]H 'HWHUPLQDWLRQ 
 3RSXODWLRQV IRU $QDO\VHV
(QGSRLQWV
6WDWLVWLFDO $QDO\VHV
10.4.1 Efficacy Analyses ................................................................................... 
10.4.1.1 Subgroup Analyses ........................................................................ 
10.4.2 Safety Analyses....................................................................................... 
10.4.2.1 Adverse Events .............................................................................. 
10.4.2.2 Vital Signs and ECGs.................................................................... 
10.4.2.3 Clinical Laboratory Tests ............................................................. 
10.4.4 Interim Analyses ..................................................................................... 
10.4.5 Analysis and Reporting .......................................................................... 
5()(5(1&(6 
 $33(1',&(6
$33(1',;$%%5(9,$7,216$1'75$'(0$5.6 
$33(1',;678'< *29(51$1&(&216,'(5$7,216 
$33(1',;$'9(56((9(176$1'6(5,286$'9(56((9(176
'(),1,7,216$1'352&('85(6)255(&25',1*(9$/8$7,1*
)2//2:83 $1' 5(3257,1*
$33(1',;  :20(1 2) &+,/'%($5,1* 327(17,$/ '(),1,7,216 $1'
0(7+2'6 2) &2175$&(37,21 
$33(1',;  &5,7(5,$ 72 '(),1( ,1$'(48$7( 5(63216( 35,0$5<
/2662)5(63216(6(&21'$5<$1',172/( 5$1&(7235(9,286
67$1'$5'2)&$5( 0(',&$7,216
$33(1',;&20021/<86('&257,&267(52,' (48,9$/(176
$33(1',;(;$03/(62):$6+2877,0(65(48,5('35,2572
5$1'20,=$7,21 
$33(1',;  +%9 $1' +&9 7(67 5(68/7 ,17(535(7$7,21
$33(1',;0$<26&25(&20321(17 68%6&25(6$1'(/(&7521,&
68%-(&7 ',$5< (175<,16758&7,216























&OLQLFDO 3URWRFRO
%06,0
7<. ,QKLELWRU
3URWRFRO $PHQGPHQW 1R 'DWH $SU 
Approved 1.0 v
Approved 1.0 v
$33(1',;&29,'9$&&,1(6 &OLQLFDO 3URWRFRO
%06,0
7<. ,QKLELWRU
3URWRFRO $PHQGPHQW 1R 'DWH $SU 
Approved 1.0 v
Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
1 PROTOCOL SUMMARY
1.1 Synopsis
Protocol Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of  the Safety 
and Efficacy of BMS-986165 in Subjects with Moderate to Severe Ulcerative Colitis
Short Title : Safety and Efficacy of BMS-986165 in Subjects with Moderate t o Severe Ulcerative 
Colitis
Study Phase: 2
Rationale: Study IM011024 is a Phase 2 randomized, double-blind study to assess the safety and 
efficacy of oral (PO) BMS-986165 6 mg twice daily (BID) in subjects with moderate to severe 
ulcerative colitis (UC). BMS 986165 will be compared to placebo  to evaluate its effect on clinical 
remission of UC following 12 weeks of study treatment.
UC is a chronic inflammatory disease of the gastrointestinal tr act that causes significant morbidity, 
impact on quality of life, and heal thcare expenditures. Outcome s for patients with UC have 
improved significantly over the last several years due to bette r treatment strategies and the 
emergence of highly targeted bio logical therapies , yet significant therapeutic challenges still 
remain with this and other inflammatory bowel diseases (IBDs).Tyrosine kinase 2 (TYK2) is an intracellular signaling kinase t hat mediates cytokine-driven 
immune and proinflammatory signaling pathways that are crit ical in the c ycle of c hronic 
inflammation central to a number of immune-mediated diseases. TY K2 inhibition selectively 
blocks interleukin (IL)-23, IL-12, and Type I interferon-driven  responses but not cytokine 
responses mediated by other Janus kinases (JAK), such as IL-6, hematopoietic growth factors, and 
the IL-2 family. TYK2-dependent pathways and the cytokine networ ks they modul ate have been 
implicated in the pathophysiology of multiple immune-mediated d iseases, including UC, Crohn‚Äôs 
disease (CD), psoriasis, psoriatic arthritis, systemic lupus er ythematosus, and 
spondyloarthropathies.
BMS-986165 is an orally administered selective TYK2 inhibitor w ith a unique mechanism of 
action distinct from other JAK inhibitors and has the potential to treat a wide spectrum of immune-
mediated diseases. Inhibition of TYK2 is expected to provide th erapeutic benefit for patients with 
UC for multiple reasons: 1) IL-12 and IL-23 have been implicate d in the pathogenesis of
UC; 2) Biologic agents targeting IL-23p19 and IL-12/IL-23p40 cyt okines have been shown to be 
efficacious in UC and CD, and ustekinumab targeting IL-12/IL-23 p40 has been approved for the 
treatment of CD and UC; and 3) BMS-986165 has been shown to be efficacious in psoriasis, an 
IL-23-mediated disease, in a recent Phase 2 study.Study Population: Key inclusion criteria ( Section 6.1 ) include:
‚Ä¢Male and female subjects, 18 years (or age  of majo rity) to 80 years of age, inclusive, at the
time of screening
‚Ä¢Documented diagnosis (endoscopic and histological) of UC of at least 3 months‚Äô duration prior
to screening
Protocol Amendment No.: 03
Date: 14-Apr-2021 14
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
‚Ä¢Active moderate to severe UC, defined by a modified Mayo score of 5 to 9 points, inclusive  
(modified Mayo score range = 0 to 9 points), which includes all o f the following subscore  
values:
oA stool frequency (SF) subscore of ‚â• 2, and
oA rectal bleeding (RB) subscore ‚â• 1, and
oAn endoscopic (ES) subscore of ‚â• 2 (screening endoscopy)
‚Ä¢Active UC extending ‚â• 15 cm from the anal verge and confirmed by a screening/baseline  
colonoscopy/sigmoidoscopy pr ior to the randomization visit
‚Ä¢Documentation of an inadequate r esponse, loss of response, or i ntolerance to a treatment course 
of 1 or more of the  following standard of care medications; spec ific criteria and dosing details  
are in APPENDIX 5 :
‚Ä¢Oral 5-aminosalicylic acids (5-ASAs) (eg, mesalamine, sulfasala zine, olsalazine, or  
balsalazide)
‚Ä¢Corticosteroids (eg, prednisone [or equivalent] or budesonide [ or equivalent])
‚Ä¢Immunomodulators (eg, azathioprine  [AZA], 6-mercaptopurine [6-M P], or  
methotrexate [MTX])
‚Ä¢Anti-tumor necrosis factor-alpha (TNF-Œ±) agents (eg, infliximab , adalimumab, or  
golimumab)
‚Ä¢Integrin inhibitors (eg, vedolizumab)
‚Ä¢Anti-IL-12/IL-23p40 antibodies (eg, ustekinumab); subjects can only be included if 
they were intolerant to treatment. Inadequate response or loss o f response is 
exclusionary.
Key exclusion criteria ( Section 6.2 ) are as follows:
‚Ä¢Previous/current documented diagnosis of CD, indeterminate coli tis, ischemic colitis, or  
pseudomembranous colitis (other than associated with Clostridium difficile [C. difficile ])
‚Ä¢Stool positive for C. difficile toxin at screening visit; subjects may be rescreened 30 days aft er 
completion of an institutional standard of care course with ant ibiotics, and subsequent negative  
testing for C. difficile stool toxin and a C. difficile nucleic acid amplification test
‚Ä¢Current or recent (within 12 weeks prior to the rando mization visit) evidence of fu lminant  
colitis, abdominal abscess, toxic megacolon, or bowel perforati on
‚Ä¢History or evidence of any extensive colonic resection, subtota l or total colectomy, with or  
without presence of a stoma or ileoanal pouch. Current need for, or anticipated need for,  
surgical interve ntion for  UC during the study
‚Ä¢History of diverticulitis within 60 days prior to the randomizat ion visit. (Previous diverticulitis  
that has been successfully treated with a local standard course  of antimicrobial therapy is  
permitted; however, the course of antimicrobial therapy must be  completed at least 60 days 
prior to the randomization visit.)
‚Ä¢Current colonic adenomas, dysplasia, or past confirmed colonic dysplasia that has not been 
eradicated (subjects who have had UC > 8 years should have had a  colonoscopy to screen for  
dysplasia within 1 year prior to the randomization visit, or thi s can be performed as part of  
screening colonoscopy). A subject with prior history of adenomatous polyps will be eligible if  
Protocol Amendment No.: 03
Date: 14-Apr-2021 15
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
the polyps have been completely removed (documented), and the s ubject is free of polyps and 
without evidence of dysplasia on histology at randomization. 
‚Ä¢Prior exposure to treatment with TYK2 inhibitors
‚Ä¢Inadequate response or loss of response to medications that tar get the same pathway as 
BMS-986165, such as anti-IL-12/IL-23p40 antibodies (eg, ustekin umab, briakinumab) or 
anti-IL-23p19 antibodies (eg, guselkumab, risankizumab, tildrak izumab, brazikumab 
[MEDI2070], and mirikizumab [LY3074828]). 
oSubjects who have been exposed to the med ications listed a bove, but who have not had a 
treatment failure (ie, an inade quate response or loss of response) may be eligible for 
inclusion. 
oSubjects who have experienced intolerance to the medications li sted above (eg, an infusion 
reaction) without a treatment failure may be eligible for inclu sion.
‚Ä¢Failure or loss of response to JAK inhibitors, such as tofacitinib. Prior e xposure is not 
exclusionary.
‚Ä¢Use of other investigational agents within 4 weeks or 5 half-lives, whichever is longer, prior 
to randomization
‚Ä¢Use of immunomodulators (AZA, 6 -MP, or MTX) within 4 weeks prior to randomization
‚Ä¢Use of a biologic agent within the minimum washout period prior to rando mization 
(APPENDIX 7 )
oFecal transplant is considered a n "investigational‚Äù biologic agent and the washout period 
must be ‚â• 4 weeks prior to randomization
‚Ä¢Use of topical r ectal treatment w ith 5-ASA or corticosteroid within 2 weeks prior to 
randomization
‚Ä¢Current use of corticosteroid at a dose of > 20 mg/day for prednisone (or equivalent) or 
> 9 mg/day for budesonide (Multi- Matrix System [MMX¬Æ] colonic-release technology; eg, 
Uceris¬Æor equivalent)
Protocol Amendment No.: 03
Date: 14-Apr-2021 16
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Objectives and Endpoints:
Efficacy (primary and secondary) and safety objectives and endp oints (Section 4 ) are summarized
below:
Objectives Endpoints
Efficacy
Primary
‚Ä¢To assess the effect of BMS-986165 on 
clinical remission at the end of the induction period‚Ä¢Clinical r emission (modified Mayo 
scorea)bat Week 12 
Secondary
‚Ä¢To assess the effect of BMS-986165 on clinical response at the end of the induction 
period‚Ä¢Clinical responsecat Week 12 
‚Ä¢To assess the effect of BMS-986165 on 
endoscopic response at the end of the 
induction period‚Ä¢Endoscopic responsedat Week 12 
‚Ä¢To assess the effect of BMS-986165 on histologic improvement at the end of the 
induction period‚Ä¢Histologic improvementeat Week 12 
Safety
‚Ä¢To assess the safety and tolerability of 
BMS-986165 in subjects w ith moderate to 
severe UC ‚Ä¢Number and proportion of subjects experiencing AEs, SAEs, AEs leading to 
study discontinuation, and AEs of interest 
(AEIs)
‚Ä¢Number and proportion of subjects experiencing abnormali ties in laboratory 
testing, ECG, physical examination, and vital sign parameters over time
AE = adverse event; AEI = adverse event of interest; ECG = electrocardiogram; SAE = serious adverse event; 
UC = ulcerative colitis
aModified Mayo Score (0 to 9 point s) is the sum of 3 components: stool frequency (SF) (0 to 3), rectal bleeding
(RB) (0 to 3), and endoscopic (ES ) (0 to 3) subscores.
bClinical remission is defined as: Mayo SF subscore ‚â§ 1, with ‚â• 1-po int decrease from baseline, and Mayo RB
subscore = 0, and Mayo ES subscore ‚â§ 1 (obtained from centrally read endoscopy; mod ified, excludes friability).
cClinical response is defined as: A decrease from baseline in th e modified Mayo score of ‚â• 2 points, anda decrease 
from baseline in the modi fied Mayo score ‚â• 30%, and a decrease in Mayo RB subscore of ‚â• 1 point or absolute 
RB subscore ‚â§ 1.
dEndoscopic response is defined as: Mayo ES subscore ‚â§ 1 (obtained from centrally read endoscopy)
eHistologic improvement is defined as: Geboes score ‚â§ 3.1
Protocol Amendment No.: 03
Date: 14-Apr-2021 17
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Overall Design:
‚Ä¢Study design: Parallel, placebo controlled, multicenter, proof of concept
‚Ä¢Blinding: Double-blind, matching placebo oral tablets
‚Ä¢Treatment assignment method/stratification: 
oSubjects who have completed screening procedures (up to 28 days d uration) and met 
inclusion/exclusion criteria will be randomized on Week 0 (Day 1) o f the induction period.
oSubjects will be ra ndomized in a 2:1 ratio using interactive response technology (I RT) to 
receive oral BMS-986165 6 mg BID or placebo BID during the induc tion period of 
12 weeks.
oRandomization will be stratified based on corticosteroid use (y es/no) and prior exposure to 
biologics indicated for the treatment of U C (ie, no pri or exposure, exposure to 1 biologic, 
or exposure to > 1 biologic). JAK inhibitors are cons idered as a biologic for stratification 
purposes. (Note: Failure or loss of response to JAK inhibitors is exclusionary, but prior 
exposure is not exclusionary.)
‚Ä¢Study periods: oScreening: up to 4 weeks (28 days)
oInduction: 12 weeks (84 days)
oMaintenance: 40 weeks (280 days)
oOpen-label extension: 52 weeks (364 days)
oPost-treatment follow-up: 4 weeks (28 days) 
‚Ä¢Study assessments:oEndoscopic (colonoscopy/sigmoi doscopy) evaluations and collecti on of colonic tissue 
biopsies will be performed during the screening period, at the end of the i nduction period 
(Week 12), at the end of the  maintenance period (Week 52), and at the end of the open-
label extension peri od (Week 104). Endoscopy s hould also be performed at unscheduled 
visits (if clinically indicated). Endoscopy is required at early  termination (ET) visits that 
occur between Week 4 and Week 12. Endoscopy is recommended for ET  visits occurring 
from Week 16 through Week 52 and Week 56 through Week 104. Endoscopic proced ures
will be video recorded and score d for disease activity by a bli nded central reader. 
Histologic scoring of gastrointestinal tissue specimens will al so be performed by a blinded 
central reader. 
oAt Week 12, local assessment of the endoscopy will be utilized t o derive the ES subscor e 
of the modified Mayo score used for determination of treatment assignment during th e 
maintenance peri od. The central read of the endoscopy will be use d for efficacy  analysis 
at all time points ( Section 2 and APPENDIX 9 ).
oElectronic diaries will be maintained by subjects throughout the study to collect daily stoo l 
frequency and rectal bleeding data; this will enable Mayo score  calculations used in th e 
determination of the primary and secondary efficacy endpoints ( APPENDIX 9).
Protocol Amendment No.: 03
Date: 14-Apr-2021 18
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
oAssessment of adverse events (AEs), physical examinations, vital sign measurements, 
12-lead electrocardiogram (ECG), and clinical laboratory evalua tions will be performed at 
selected times throughout the study ( Section 2 ). 
oDisease worsening will be assessed at each visit during the main tenance period using SF
and RB subscores as defined in  Table 5 .
‚Ä¢Corticosteroid use and tapering:
oInduction period: Prednisone or colonic-release budesonide are a llowed, provided the dose 
is stable for 2 weeks prior to randomization, and thereafter sta ble during the induction 
period. Corticosteroid taperi ng is not allowed during the induc tion period.
oMaintenance period: Subjects receiving corticosteroids during t he induction period must 
initiate a corticosteroid taper. This is described in Section 5.1.5 for different treatment 
arms.
‚Ä¢Treatment failure: Subjects who require corticosteroid rescue th erapy due to increased UC 
activity, fail to taper corticosteroids , or require an alterna tive, efficacious therapy for UC will 
be defined as a treatment failure ( Section 5.1.6 ). 
‚Ä¢Discontinuation from the study: Subjects who discontinue study treatment will remain in the 
study and are required to continue to be follo wed for protocol- specified post-treatment follow-
up procedures. The only exception to this is when a subject spe cifically withdraws consent for 
any further contact with him/her or persons previously authoriz ed by the subject to provide 
this information.
‚Ä¢An independent Data Monitoring Committee (DMC) will be institut ed to perform safety 
monitoring by unblinded treatment group ( Section 5.1.7 ).
Number of Subjects : Approximately 120 subjects are planned to be randomized in a 2:1 ratio to 
receive BMS-986165 6 mg BID (80 subjects) or placebo (40 subjects) during the i nductio n period 
of 12 weeks.
Treatment Arms and Duration: 
Induction Period: On Week 0 (Day 1) of the 12-week, double-blind i nduction period, subjects will 
be randomized to receive 1 of the following study treatments:
‚Ä¢BMS-986165 6 mg BID
‚Ä¢Placebo
Maintenance Period: At Week 12, all subjects who complete the i nduction period will be eligible 
to enter the 40-week maintenance period; the treatment assignment  will be based on their clinical 
response (assessed using the modified Mayo score with a locally read endoscopy). 
Protocol Amendment No.: 03
Date: 14-Apr-2021 19
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Subjects who achieve clinical response at Week 12 will be catego rized as a responder at Week 12, 
and they will enter 1 of the following study treatment arms:
‚Ä¢Responders at Week 12 continuing blinded treatment:
oBMS-986165 6 mg BID ‚Üí BMS-986165 6 mg BID
oPlacebo ‚Üí Placebo
Subjects who do not achieve clinical response at Week 12 w ill be categorized as a nonresponder 
at Week 12, and they w ill enter 1 of the following study tr eatment arms (or they w ill be 
discontinued from the study per investigator discretion):
‚Ä¢Nonresponders at Week 12 continuing open-label treatment:
oBMS-986165 6 mg BID ‚Üí BMS-986165 6 mg BID
oPlacebo ‚Üí BMS-986165 6 mg BID
Open-label Extension Period: After Week 52, sub jects who continue to safely derive clinical 
benefit (as judged by the investigator) and receive open-label treatment during the 52-week, 
open-label extensio n peri od of the  study w ill enter 1 of the following study treatment arms: 
‚Ä¢Responders at Week 12, clinical benefit at Week 52 continuing o pen-label treatment:
oBMS-986165 6 mg BID ‚Üí BMS-986165 6 mg BID‚Üí BMS-986165 6 mg BID
oPlacebo ‚Üí Placebo‚Üí BMS-986165 6 mg BID
‚Ä¢Nonresponders at Week 12, clinical benefit at Week 52 continuin g open-label treatment:
oBMS-986165 6 mg BID ‚Üí BMS-986165 6 mg BID‚Üí BMS-986165 6 mg BID
oPlacebo ‚Üí BMS-986165 6 mg BID ‚Üí BMS-986165 6 mg BID
The total duration of study pa rticipation is approximately 112 weeks (784 days) in 5 periods.
Study Treatment:
Study Treatment for IM011024
Study Treatment Potency/DoseBlinded or 
Open labelIP/Non-IP
BMS-986165 oral tablet 6 mg Blinded IP
Placebo matching BMS-986165 oral 
tabletNot applicable Blinded IP
BMS-986165 oral tablet 6 mg Open-label IP
IP = investigational product
Statistical Methods: Approximately 120 subjects w ill be ra ndomized in a 2:1 ratio to 
BMS-986165 6 mg BID or placebo, respectively (80 subjects on BMS -986165 and 40 on placebo). 
In this proof of concep t study, if the obse rved response rates are the same as the assumed rates 
reported in current UC investigative trials, the total number of 120 subjects will provide 
approximately 82% power to detect a 15% treatment difference in  clinical remissi on at Week 12 
with a 1-sided 0.1 level of significance.
Protocol Amendment No.: 03
Date: 14-Apr-2021 20
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Categorical data w ill be su mmarized as frequency counts and percentages. Continuous data wi ll 
be summarized using n, mean, standard deviation, median, minimum, and maximum, unless 
otherwise specified.
Efficacy data will be su mmarized using the full analysis set population, unless otherwise stated, 
and listed by study pe riod and treatment group.
The primary efficacy analysis model for clinical r emission (responder/nonresponder) will be 
analyzed at Week 12 using a str atified Cochran-Mantel-Haenszel test stratified by corticosteroid 
use (yes/no) and prior exposure to biologics (0, 1, > 1). JAK inhibitors are considered as a biologic 
for stratification purposes. If expected cell counts are not su fficient for each strata level, then strata 
levels will be combined for analysis. The assessment of statist ical significance will be based upon 
a 1-sided, 0.1 alpha, which is in alignment with the sample siz e calculation. The odds ratio and 
corresponding 2-sided 95% con fidence interval (CI) w ill be  provided for descriptive purposes.
Supportive analyses using logistic regression may be performed to incorporate additional 
covariates of interest and to confirm primary analysis results.  The model will include tr eatment, 
geographic region, corticosteroid use (yes/no), prior exposure to biologics (0, 1, > 1), as w ell as 
other covariates as applicable. The odds ratio and the correspon ding 2-sided 95% CI will also be 
provided.
Statistical analysis of the secondary endpoints will use the sa me approach as the primary endpoint 
analysis with missing data being imputed as nonresponders. Test ing strategy of secondary 
endpoints will be performed in a hierarchical fashion to control for Type I error rate inflation. The 
statistical testing of the primary endpoint will be the serial gatekeeper for proceeding to the testing 
of the secondary endpoints. Each secondary endpoint w ill be tested sequentially in a 
fixed-sequence order using a 1-sided alpha = 0.1 for significance  testing. No furt her testing will 
be performed once a test fails to show significance at the alph a level stated above.
Safety endpoint analyses will be descriptive in nature.
Protocol Amendment No.: 03
Date: 14-Apr-2021 21
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
1.2 Schema
The study design schematic for the induction and maintenance pe riods is presented below:
BID = twice daily; OL = open-label; OLE = open-label extension; R = ran domization
At Week 12, clinical response is determined using the modified Mayo score (see Table 5 and Section 9.1.1). Subjects who achieve clinical response at Week 12 
and continue into the maintenance period will continue to recei ve their double-blind treatment from the induction period. Subj ects who subsequently experience 
disease worsening ( Table 5 ) can enter the Week 12 responder open-label arm at any time fro m Week 13 through Week 52. 
Subjects who do not achieve clinical response at Week 12 are eli gible to enter the Week 12 nonresponder open-label arm. 
Protocol Amendment No.: 03
Date: 14-Apr-2021 22
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
The study design schematic for the  open-label extension period is presented below:
BID = twice da ily; IP = investigational product; OL = open-label
aSubjects in t his arm are those who achieved clinical response at Week 12 of the i nductio n peri od, but they subsequently lost clinical resp onse to IP between 
Week 13 and Week 52 of the maintenance period and switched to the Week 12 responder open-label arm ( Section 5.1.3.2 ). 
bSubjects in t his arm are those who did not achieve clinical response at Week 12 of the induction period and switched to the Week 12 nonr esponder open-label 
arm.
Protocol Amendment No.: 03
Date: 14-Apr-2021 23
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
2 SCHEDULE OF ACTIVITIES 
The schedules of procedures are described in Table 1 for the screening period, Table 2 for the 
induction peri od, Table 3 for the maintenance period, and Table 4 for the open-label extension
period.
Protocol Amendment No.: 03
Date: 14-Apr-2021 24
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
2.1 Screening Period Activities and Assessments
Table 1 Screening Procedural Outline (IM011024)
ProcedureScreening
Visit 
Day -28 to -1 Notes
Eligibility and Disease 
Assessments
Informed Consent X A subject will be considered enrolled only whe n the ICF is signed.
Enroll subject X Obtain number from IRT; contact IRT to screen fail those not eligible.
Inclusion/Exclusion criteria X Section 6
Medical history X Include any toxicities or allergy related to pr evious treatments.
Ulcerative colitis (UC) disease historyX
Dispense electronic subject diary X
Subject diary training XIncludes training for entry of stool frequency (SF) and rectal bleeding (RB) assessments into the 
electronic subject diary. Instructions for recording the number  of stools and worst rectal bleeding (each 
over a 24-hour period) are in Table 26 ( APPENDIX 9 ). 
Baseline SF XEstablish the baseline SF. This is determined based on the numb er of stools a subject has in a 24-hour 
period when in remission from UC symptoms; or if a subject has not been in remission, he/she should 
be asked to identify the number of stools he/she had in a 24-hou r period before initial onset of signs and 
symptoms of UC ( APPENDIX 9 ).
Enter SF and RB subscores for 
baseline Mayo score calculationsXSF and RB subscores are calculated using the electronic subject diary and entered into the eCRF (APPENDIX 9 ). 
Endoscopy 
(colonoscopy/sigmoidoscopy)XColonoscopy/sigmoidoscopy examination must be performed within Day - 21 and Day - 1 of the 
screening period and should be scheduled as close as possible t o the Week 0 (Day 1) visit. 
The Week 0 (Day 1) visit must occur within 14 days of the screeni ng endoscopy. 
Instructions for review of SF and RB diary entries to assess if  a subject is likely to meet inclusion 
criteria and should continue screening prior to commencing bowel preparation for the endoscopy are in 
APPENDIX 9 .
Protocol Amendment No.: 03
Date: 14-Apr-2021 25
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Table 1 Screening Procedural Outline (IM011024)
ProcedureScreening
Visit 
Day -28 to -1 Notes
At the screening endoscopy, collection of colonic tissue biopsi es will be performed as described in the 
rows below. Full colonoscopy will be required in these situatio ns:
‚Ä¢If normal margins are not apparent from sigmoidoscopy or if pro ximal colonic involvement is 
suspected
‚Ä¢In subjects with a history of UC ‚â• 8 years, if one was not perfor med in the prior 12 months
Colon histology  XTwo biopsy samples will be obtained from each of the 4 colonic segments (rectum, descending 
colon/sigmoid, transverse colon, ascending colon) if colonoscop y is performed or from each of the 
2 segments (rectum, descending colon/sigmoid) if sigmoidoscopy is performed for the histologic 
assessments (Section 9.1 )  
. 
 
Baseline modified Mayo score 
calculationXThe modified Mayo score is used to determine subject eligibilit y. A score of 5 to 9 points, inclusive, is 
required at screening, and it must include all of the following  subscores:
‚Ä¢A stool frequency (SF) subscore of ‚â• 2 and
‚Ä¢A rectal bleeding (RB) subscore of ‚â• 1, and  
‚Ä¢A screening endoscopic (ES) subscore (central read) of ‚â• 2
Instructions for calculating the modified Mayo score for eligib ility are provided in  APPENDIX 9 . 
Protocol Amendment No.: 03
Date: 14-Apr-2021 26
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Table 1 Screening Procedural Outline (IM011024)
ProcedureScreening
Visit 
Day -28 to -1 Notes
Confirm washout of prohibited 
medication and dose stabilization of allowed medication (if 
applicable)XProhibited medications are described in  Section 7.7.1 . Washout periods for specific immunomodulatory 
and biologic agents required before a participant can be randomi zed are in APPENDIX 7 ; the use of 
therapeutic drug monitoring (TDM) to confirm washout is also described in APPENDIX 7 .
Note: The washout periods shown in APPENDIX 7 may be longer than the 4-week screening period. 
This needs to be considered at enrollment. Prednisone dose stab ilization requirements are described in 
Section 5.1.5.1 . The dose equivalents to prednisone of commonly used corticost eroids are provided in 
APPENDIX 6 .
Tobacco use history X
Prior and current concomitant 
medicationsXSection 7.7
Safety Assessments
Physical examination XGeneral, head, eyes, ears, nose, throat, neck, cardiovascular, lungs, abdominal, extremities, neurologic, 
skin, musculoskeletal. If the screening physical examination is performed within 7 days prior to dosing 
on Week 0 (Day 1), then a single exam may count as both the scree ning and predose evaluation.
Physical measurements X Height and weight
Vital signs XBody temperature, respiratory rate, and seated blood pressure, a nd heart rate. Blood pressure and heart 
rate should be measured after the subject has been resting quie tly for at least 5 minutes. 
Electrocardiogram X Single 12-lead ECG reading recorded after the  subject has been supine for at least 5 minutes 
Chest x-ray X Also acceptable within 6 months of the screening vis it with documentation on file
Diagnostic testing for 
SARS-CoV-2XTo be performed locally, as close as possible to randomization.  Diagnostic testing for SARS-CoV-2 
infection refers to a molecular test (eg, PCR or NAAT) or antigen test. PCR testing is preferred 
(Section 9.8 ).
Monitor for SAEs or nonserious AEsXSAE reporting begins at the time of signing of the ICF; nonserious AEs are collected starting with the initiation of study treatment ( Section 9.2 and APPENDIX 3 ). 
Protocol Amendment No.: 03
Date: 14-Apr-2021 27
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Table 1 Screening Procedural Outline (IM011024)
ProcedureScreening
Visit 
Day -28 to -1 Notes
However, all AEs related to SARS-CoV-2 infection should be collected from time of signing the ICF.
Breast and cervical cancer 
screening XInvestigators are encouraged to confirm if screening is up-to-d ate according to local guidelines (women 
only). Screening for cervical and breast cancer prior to randomization is encouraged as per local 
guidelines due to the small inherent risk of increased malignan cy with immunomodulatory agents, but 
this screening is at the investigator‚Äôs discretion.
Laboratory Tests
Hematology, chemistry, 
urinalysis, and coagulation XBlood and urine samples (must be repeated and verified to ensure that subjects meet study inclusion 
criteria and no exclusion criteria if performed more than 28 day s prior to randomization) ( Section 
9.4.3).
Serology XHepatitis B Virus (HBV): HBsAg, HBsAb, HBcAb with reflex to HBV DNA in subjects with HBsAg 
negative, HBcAb positive serology. ( APPENDIX 8 ) 
Hepatitis C Virus (HCV): Anti-HCV; if positive or indeterminate,  HCV RNA testing will be performed 
using a separate blood draw ( APPENDIX 8 ). 
Human Immunodeficiency Virus (HIV): HIV-1 and -2 antibody ( Section 6.2 ); HIV-1 and -2 serology 
may be performed centrally, or locally in regions where central  laboratory testing for HIV is not 
available.
Tuberculosis screening X In accordance with standard testing (det ails are provided in  Section 6.2 and 9.4.2 )
Pregnancy test (urine or serum) XWOCBP only ( APPENDIX 4 ). If the urine pregnancy test is positive, a serum pregnancy t est should be 
done for confirmation prior to enrolling the subject. Study treatment should not be administered until 
the results of the confirmatory test are known.
Follicle-stimulating hormone (FSH)XPostmenopausal women only to confirm status ( APPENDIX 4 )
Stool culture (performed locally) XIf a subject is positive  for enteric pathogens (not including flora that are considered commensal within a 
study region), he/she can be rescreened 30 days after completing  a full course of standard treatment for 
bacterial enterocolitis and being deemed clinically improved by the investigator. 
Stool C. difficile toxin (performed centrally)X If a subject is pos itive for C. difficile toxin, he/she can be res creened as described in  Section 6.5.1 .
Protocol Amendment No.: 03
Date: 14-Apr-2021 28
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Table 1 Screening Procedural Outline (IM011024)
ProcedureScreening
Visit 
Day -28 to -1 Notes
Therapeutic drug monitoring 
(TDM)XOptional test for subjects who recently received infliximab, ad alimumab, golimumab, vedolizumab 
(> 14 weeks treatment duration), or ustekinumab (> 12 weeks treat ment duration) and are subject to a 
washout period for those medications ( APPENDIX 7 ). This washout period will be waived for subjects 
who have an undetectable drug level for that specific medicatio n on TDM testing at screening or prior 
to screening.
AE = adverse event; anti-HCV = hepatitis C virus antibody; C. difficile = Clostridium difficile ; DNA = deoxyribonucleic acid; ECG = electrocardiogram; 
eCRF = electronic case report form; ES = endoscopic; FSH = follicle-s timulating hormone; HBcAb = hepatitis B core antibody; HBsAb = hepa titis B surface 
antibody; HBsAg = hepatitis B surface antigen; HBV = hepatitis B virus; HIV-1 and -2 = human immunodeficiency virus -1 and -2;  ICF = informed consent form; 
 IRT = interactive response technology; NAAT = nucleic acid amp lification test; PCR = polymerase chain reaction; RB = rectal 
bleeding; RNA = ribonucleic acid; SAE = serious adverse event; SARS -CoV-2 = severe acute respiratory syndrome coronavirus 2; SF = stool  frequency; TDM = 
therapeutic drug monitoring; UC = ulcerative colitis; WOCBP = women  of childbearing potential
Protocol Amendment No.: 03
Date: 14-Apr-2021 29
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
2.1.1 Induction Period Activities and Assessments
Table 2 Induction Period On-treatment Procedural Outline Up to We ek 12 (Day 85) (IM011024)
Procedure/Visit Weeks (Days)0 
(1)a2
(15)4 
(29)8 
(57)12 
(85)Notes
Visit window (¬± n days) 03333
Study Treatment
Eligibility/randomization criteria XConfirm eligibility criteria ( Section 6.1 and Section 6.2 ) and assess 
randomization criteria ( Section 6.3 ). All procedures to be completed 
before dosing unless otherwise specified.
Dispense clinical drug supplies 
(blinded)X XXXSubjects are to receive blinded IP twice daily PO ( Section 5.1.2). 
See Section 5.1.3.1 and5.1.3.2 regarding IP based on clinical response 
at Week 12.
Study treatment (blinded) X------------------------------------- ----------X
Review study drug compliance XXXX Section 7.6
Safety Assessments
Physical examination X Xb General, head, eyes, ears, nose, throat, neck, cardiovascular, lungs, 
abdominal, extremities, neurologic, skin, musculoskeletal. 
Physical measurement X XbWeight only
Vital signs X X X X Xb See Note in the screening period procedures ( Table 1 ).
Electrocardiogram Xb Single 12-lead ECG should be recorded after the subject has bee n 
supine for at least 5 minutes.
Concomitant medication use X XXXX Section 7.7
Tobacco use X XXXX
Monitor AEs X XXXX M o n i t o r i ng for AEs will occur at every study visit ( Section 9.2 ). 
M o n i t o r  S A E s XXXXXMonitoring for SAEs will occur at every study visit ( Section 9.2 ). All 
SAEs will be followed until resolution, until the condition stabilizes, 
Protocol Amendment No.: 03
Date: 14-Apr-2021 30
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Table 2 Induction Period On-treatment Procedural Outline Up to Week 12 ( Day 85) (IM011024)
Procedure/Visit Wee ks (Days)0 
(1)a2
(15)4 
(29)8 
(57)12 
(85)Notes
until the event is otherwise explained, or until the subject is lost to 
follow-up (Section 8.3). 
Laboratory Tests
Hematology, chemistry, 
urinalysis, and coagulationXXXX Xb
HBV DNA X X XbTo be performed only in subjects with the following HBV serolog y at 
screening: HBsAg negative, HBcAb positive, HBV DNA undetectable  
(APPENDIX 8 )
Serum Igs X X XbIgG, IgM, IgA, and IgE
TBNK panel X X Xb
Serum hsCRP X X X X Xb
Fasting lipid panel X Xb Subjects are required to fast for ‚â• 10 hours prior to the collect ion of 
specimens for the fasting lipid panel.
Fasting glucose X Xb Subjects are required to fast for ‚â• 10 hours prior to the collect ion of 
specimens for the fasti ng glucose evaluation.
Pregnancy test (urine or serum) X XXXXWOCBP only ( APPENDIX 4 ). If the urine pregnancy test is positive, a 
serum pregnancy test should be done for confirmation prior to discontinuing the subject. Study treatment should not be administered 
until the results of the confirmatory test are known. 
Protocol Amendment No.: 03
Date: 14-Apr-2021 31
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Table 2 Induction Period On-treatment Procedural Outline Up to Week 12 ( Day 85) (IM011024)
Procedure/Visit Weeks (Days)0 
(1)a2
(15)4 
(29)8 
(57)12 
(85)Notes
Efficacy Assessments
Review subject diary for SF and 
RB valuesXXXXXPrior to each scheduled visit, review subject diary to ensure S F and RB 
data have been entered daily. 
Prior to each scheduled visit at which Mayo scores are to be calculated, 
ascertain whether an adequate number of days of diary entries have 
been made ( APPENDIX 9 ). If adequate entries have not been made, the 
Protocol Amendment No.: 03
Date: 14-Apr-2021 32
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Table 2 Induction Period On-treatment Procedural Outline Up to Week 12 ( Day 85) (IM011024)
Procedure/Visit Weeks (Days)0 
(1)a2
(15)4 
(29)8 
(57)12 
(85)Notes
site should contact the subject to reschedule the visit, and the subject 
should be counseled about proper study procedures. 
Enter SF and RB subscores for Mayo score calculation XAPPENDIX 9
Endoscopy 
(colonoscopy/sigmoidoscopy) XAfter bowel preparation, endoscopic examination will be perform ed 
within a 7-day window prior to the Week 12 (Day 85) visit.Endoscopy is required at ET visits that occur between Week 4 an d 
Week 12.
If colonoscopy is conducted at screening assessment, every effo rt 
should be made to ensure colonoscopy is done at subsequent 
assessment. Screening and surveillance as per local guidelines may be 
completed during study related colonoscopy.
Colon histology  XTwo biopsy samples will be obtained from each of the 4 colonic 
segments (rectum, descending colon/sigmoid, transverse colon, 
ascending colon ) if colonoscopy is performed or from each of the 2 segments (rectum, descending colon/sigmoid) if sigmoidoscopy i s 
performed for the histologic assessments ( Section 9.1 )  
.
Efficacy/Mayo Scoring
Modified Mayo score XComposite score of ES (central read), SF, and RB subscores. SF and RB subscores will be calculated using electronic subject diary data. 
See Section 9.1 and APPENDIX 9.
Protocol Amendment No.: 03
Date: 14-Apr-2021 33
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Table 2 Induction Period On-treatment Procedural Outline Up to Week 12 ( Day 85) (IM011024)
Procedure/Visit Wee ks (Days)0 
(1)a2
(15)4 
(29)8 
(57)12 
(85)Notes
aWeek 0/Day 1/Ra ndomization Visit
bThis assessment can be performed at either the Week 12 endoscopy visit orthe Week 12 visit. NOTE: All other assessments are to be pe rformed only at the 
Week 12 visit, except for the endoscopy and related procedures, whic h are to be performed within a 7-day window prior to the Week 1 2 (Day 85) visit.
AE = adverse event; DNA = de oxyribonucleic acid; ECG = electrocardiogram;  ES = endoscopic; E T = early 
termination; HBcAb = h epatitis B virus core antibody; HBsAg = hepatitis B surface antigen; HBV = hepatitis B virus; hsCRP = high- sensitivity C-reactive protein; 
IBD = inflammatory bowel disease;  Ig = immunoglobulin; IgA = immunoglobulin A; IgE = immunoglobulin 
E; IgG = immunoglobulin G; IgM = immunoglobulin mu;  IP = investigat ional product;  
 PO = oral; 
 RB = rectal bleeding;  SAE = serious adverse event;  
 SF = stool frequency; TBNK = T cells, B cells, and natural killer cells; UC = ulcerative colitis; WOCBP = women of 
childbearing potential; 
In the event multiple procedures are required at a single time point, the ECG may be obtained up to 20 minutes earlier, vital s igns may 
be obtained up to 20 minutes earlier or later, and clinical labor atory sample may be obtained up to 10 minutes earlier than the n ominal 
time poin .
Protocol Amendment No.: 03
Date: 14-Apr-2021 34
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
2.1.2 Maintenance Period Activities and Assessments
Table 3 Maintenance Period On-treatment Procedural Outline Up to Week 52 (IM011024)
Procedure/Visit Weeks (Days) 16 
(113)20 
(141) 24 
(169)32 
(225)40 
(281)52 
(365) Notes
Visit window (¬± n days) 333333
Study Treatment
Dispense clinical drug supplies 
(blinded)* XXXXXSection 5.1.3
*At Week 52, open-label IP will be dispensed to subjects who 
enter the OLE period.  
Dispense clinical drug supplies 
(open-label)XXXXX XOpen-label IP will only be dispensed to subjects who have entered an open-label treatment arm during the maintenance period. Blinded IP must be dispensed to all other subjects 
(Section 5.1.3 ).
At Week 52, open-label IP will only be dispensed to subjects 
who enter the OLE period.
Study treatment (blinded or open-label)X----------------------------------------------------------X See  Notes above in ‚ÄúDispense Clinical Drug Supplies.‚Äù
Review study treatment complianceXXXXXX Section 7.6
Safety Assessments
Physical examination X X X X X XGeneral, head, eyes, ears, nose, throat, neck, cardiovascular, 
lungs, abdominal, extremities, neurologic, skin, 
musculoskeletal 
Physical measurement X X Weight only
Vital signs X X X X X X See Notes in the screening period procedures ( Table 1 ).
Electrocardiogram X See Notes in the induction period procedures (Table 2 ).
Concomitant medication use X X X X X X
Tobacco use X X X X X X
Protocol Amendment No.: 03
Date: 14-Apr-2021 35
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Table 3 Maintenance Period On-treatment Procedural Outline Up to Week 52 (IM011024)
Procedure/Visit Weeks (Days) 16 
(113)20 
(141) 24 
(169)32 
(225)40 
(281)52 
(365) Notes
Visit window (¬± n days) 333333
Monitor AEs X X X X X XMonitoring for AEs will occur at every study visit 
(Section 9.2 ).
Monitor SAEs X X X X X XMonitoring for SAEs will occur at every study visit 
(Section 9.2 ). All SAEs will be followed until resolution, until 
the condition stabilizes, until the event is otherwise explaine d, 
or until the subject is lost to follow-up ( Section 8.3).
Laboratory Tests
Hematology, chemistry, 
urinalysis, and coagulationXXXXXX
HBV DNA 
(Week 12 responder arms)XX XFor subjects with the following HBV serology at screening: HBsAg negative, HBcAb positive, HBV DNA undetectable 
(APPENDIX 8 )
HBV DNA 
(Week 12 responder arms, with 
subsequent disease worsening and entry to the open-label treatment 
arm)See Note For subjects with the following HBV serology at screening: 
HBsAg negative, HBcAb positive, HBV DNA undetectable. Subjects who have a clinical response at Week 12 and who subsequently experience disease worsening and enter the open-label treatment arm: Obtain HBV DNA at the following 3 study visits, and the reafter according to the schedule for the  
Week 12 responder arm (see above). ( APPENDIX 8 )
HBV DNA 
(Week 12 nonresponder arm)XXXXXFor subjects with the following HBV serology at screening: 
HBsAg negative, HBcAb positive, HBV DNA undetectable 
(APPENDIX 8 )
Serum Igs X X X X X IgG, IgM, IgA, and IgE
TBNK panel X X
Serum hsCRP X X X X X X
Fasting lipid panel X X X See Notes in the induction period procedure s (Table 2 ).
Protocol Amendment No.: 03
Date: 14-Apr-2021 36
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Table 3 Maintenance Period On-treatment Procedural Outline Up to Week 52 (IM011024)
Procedure/Visit Weeks (Days) 16 
(113)20 
(141) 24 
(169)32 
(225)40 
(281)52 
(365) Notes
Visit window (¬± n days) 333333
Fasting glucose X X X See Notes in the induction peri od procedures ( Table 2 ).
Pregnancy test (urine or serum) X X X X X XWOCBP only ( APPENDIX 4 ). If the urine pregnancy test is 
positive, a serum pregnancy tes t should be done for 
confirmation prior to discontin uing the subject. Study 
treatment should not be admini stered until the results of the 
confirmatory test are known.
Efficacy Assessments
Protocol Amendment No.: 03
Date: 14-Apr-2021 37
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Table 3 Maintenance Period On-treatment Procedural Outline Up to Week 52 (IM011024)
Procedure/Visit Weeks (Days) 16 
(113)20 
(141) 24 
(169)32 
(225)40 
(281)52 
(365) Notes
Visit window (¬± n days) 333333
Review subject diary for 
SF and RB valuesXXXXXXPrior to each scheduled visit, review subject diary t o ensure 
SF and RB data have been entered daily. 
Prior to each scheduled visit at which Mayo scores  are to be 
calculated, ascertain whether an adequate number o f days of 
diary entries have been made ( APPENDIX 9 ). If adequate 
entries have not been made, the site should contact the subject 
to reschedule the visit, and the subject should be co unseled 
about proper study procedures.
Enter SF and RB subscores for Mayo score calculation X APPENDIX 9
Enter SF and RB subscores for disease worsening XXXXXXDisease worsening is defined as an increase of the sum of the 
SF and RB subscores ‚â• 2 compared to Week 12 ( Table 5 and 
Sections 5.1.3.2 and 5.1.3.3 )
Endoscopy 
(colonoscopy/sigmoidoscopy)XAfter bowel preparation, endoscopic examination w ill be 
performed within a 7-day window of the Week 52 (Day 365) visit.
Protocol Amendment No.: 03
Date: 14-Apr-2021 38
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Table 3 Maintenance Period On-treatment Procedural Outline Up to Week 52 (IM011024)
Procedure/Visit Weeks (Days) 16 
(113)20 
(141) 24 
(169)32 
(225)40 
(281)52 
(365) Notes
Visit window (¬± n days) 333333
Endoscopy is recommended at ET visits that occur between 
Weeks 16 and 52.  
If colonoscopy is conducted at screening assessment, every 
effort should be made to ensure colonoscopy is done at subsequent assessment. Screening and surveillance as per local guidelines may be completed during study related 
colonoscopy.
Colon histology  
 XSee Notes in the induction period procedures ( Table 2 ). 
 
Efficacy/Mayo Scoring
Modified Mayo score XComposite score of ES (central read), SF, and RB subscores. 
SF and RB subscores will be calculated using electronic subject diary data. 
See Section 9.1 and APPENDIX 9 .
AE = adverse event; DNA = deoxyribonucleic acid; ES = endoscopic;  ET = early t ermination;  
HBcAb = hepatitis B virus core an tibody; HBsAg = h epatitis B surfa ce antigen; HBV =  hepatitis B virus; hsCRP = high-sensitivity C-reactive protein ; 
IBD = inflammatory bowel disease;  Ig = immunoglobulin; IgA = immunoglobulin A; IgE = immunoglobulin 
E; IgG = immunoglobulin G; IgM = immunoglobulin mu;  IP = investiga tional product; OLE = open-label extension;  
 
Protocol Amendment No.: 03
Date: 14-Apr-2021 39
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
 RB = rectal bleeding;  SAE 
= serious adverse event;  SF = stool frequency; TBNK = T cells, B cells, and natural killer cells; 
UC = ulcerative colitis; WOCBP = women of childbearing potential;  
In the event multiple procedures are required at a single time point, the ECG may be obtained up to 20 minutes earlier, vital s igns may 
be obtained up to 20 minutes earlier or later, and clinical labo ratory sample may be obtained up to 10 minutes earlier than the nominal 
time poin .
Protocol Amendment No.: 03
Date: 14-Apr-2021 40
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
2.1.3 Open-label Extension Period Activities and Assessments
Table 4 Open- label Extension Period On-treatment Procedural Outline Up to We ek 104 (IM011024)
Procedure/Visit Weeks 
(Days)56
(393)60
(421)64
(449)78
(547)90
(631)104
(729)/E
T108 (757) 
or Post-
treatment 
Follow-upUnschedule
d Visit a
Notes
Visit Window (¬± n days)3 3333 3
Study Treatment
Dispense clinical drug supplies (open-label) XXXXX
Study treatment X---------------------------------------------- ----X
Review study treatment complianceXXXXX X X Section 7.6
Safety Assessments
Physical examination X X X X X X X XGeneral, head, eyes, ears, nose, throat, neck, cardiovascular, lungs, abdominal, extremities, neurologic, skin, 
musculoskeletal 
Physical measurement X X X Weight only
Vital signs X X X X X X X XSee Notes in the screening period procedures ( Table 1 ).
Electrocardiograms X XSee Notes in the induction period procedures ( Table 2 ).
Concomitant medication useXXXXX X X X
Tobacco use X X X X X X X
Monitor for AEs X X X X X X X XMonitoring for AEs will occur at every study visit (Section 9.2 ). 
Protocol Amendment No.: 03
Date: 14-Apr-2021 41
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Table 4 Open-label Extension Period On-treatment Procedural Outline Up to Week 104 (IM011024)
Procedure/Visit Week s 
(Days)56
(393)60
(421)64
(449)78
(547)90
(631)104
(729)/E
T108 (757) 
or Post-
treatment 
Follow-upUnschedule
d Visit a
Notes
Visit Window (¬± n 
days)33333 3
Monitor for SAEs X X X X X X X XMonitoring for SAEs will occur at every 
study visit (Section 9.2 ). All SAEs will be 
followed until resolution, until the condition stabilizes, until the event is otherwise explained, or until the subject is lost to 
follow-up (Section 8.3). 
Laboratory TestsSee notes in the screening period 
procedures ( Table 1 ) and Section 9.4.3 .
Hematology, chemistry, urinalysis, and 
coagulation*XXXXX X X X*Coagulation is to be collected at Week 56 
only. 
HBV DNA X X X X X X XFor subjects with the following HBV serology at screening: HBsAg negative, HBcAb positive, HBV DNA undetectable 
(APPENDIX 8 )
Tuberculosis testing X XIn accordance with standard testing (details 
are provided in Section 5.2 4 )and 
Section 9.4.2)
Serum Igs X X X IgG, IgM, IgA, and IgE
TBNK panel X X X
Serum hsCRP X X X X X X X
Fasting lipid panel X X XSubjects are required to fast for ‚â•10 hours 
prior to the collection of specimens for the 
fasting lipid panel.
Protocol Amendment No.: 03
Date: 14-Apr-2021 42
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Table 4 Open-label Extension Period On-treatment Procedural Outline Up to Week 104 (IM011024)
Procedure/Visit We eks 
(Days)56
(393)60
(421)64
(449)78
(547)90
(631)104
(729)/E
T108 (757) 
or Post-
treatment 
Follow-upUnschedule
d Visit a
Notes
Visit Window (¬± n 
days)33333 3
Fasting glucose X X XSubjects are required to fast for ‚â• 10 hours 
prior to the collection of specimens for the 
fasting glucose panel.
Pregnancy test (urine or 
serum)XXXXX X X XWOCBP only ( APPENDIX 4 ). If the urine 
pregnancy test is positive, a serum pregnancy test should be done for confirmation prior to discontinuing the subject. Study treatment should not be 
administered until the results of the confirmatory test are known
Protocol Amendment No.: 03
Date: 14-Apr-2021 43
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Table 4 Open-label Extension Period On-treatment Procedural Outline Up to Week 104 (IM011024)
Procedure/Visit Weeks 
(Days)56
(393)60
(421)64
(449)78
(547)90
(631)104
(729)/E
T108 (757) 
or Post-
treatment 
Follow-upUnschedule
d Visit a
Notes
Visit Window (¬± n days)33333 3
Efficacy Assessments
Review subject diary for SF and RB valuesXXXXX XPrior to each scheduled visit, review subject 
diary to ensure SF and RB data have been 
entered daily. 
Prior to each scheduled visit at which Mayo 
scores are to be calculated, ascertain 
whether an adequate number of days of 
diary entries have been made ( APPENDIX 
9.). If adequate entries have not been made, 
the site should contact the subject to reschedule the visit, and the subject should be counseled about proper study 
procedures.
Enter SF and RB 
subscores for Mayo score 
calculationXS ee APPENDIX 9
Protocol Amendment No.: 03
Date: 14-Apr-2021 44
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Table 4 Open-label Extension Period On-treatment Procedural Outline Up to Week 104 (IM011024)
Procedure/Visit  Weeks 
(Days)56
(393)60
(421)64
(449)78
(547)90
(631)104
(729)/E
T108 (757) 
or Post-
treatment 
Follow-upUnschedule
d Visit a
Notes
Visit Window (¬± n 
days)33333 3
Enter SF and RB 
subscores for disease 
worseningXXXXX XDisease worsening is defined as an increase 
of the sum of the SF and RB subscores ‚â• 2 
compared to Week 12 ( Table 5 )
Endoscopy 
(colonoscopy/
sigmoidoscopy)XAfter bowel preparation, endoscopic 
examination will be performed within a 
7-day window of the Week 104 (Day 729) visit.Endoscopy is recommended at ET visits 
that occur between Weeks 56 and 104.
If colonoscopy is conducted at screening 
assessment, every effort should be made to ensure colonoscopy is done at subsequent assessment. Screening and surveillance as per local guidelines may be completed 
during study related colonoscopy.
Colon histolog  
 XSee Notes in the induction period 
procedures ( Table 2 ). 
 
Efficacy/Mayo Scoring
Protocol Amendment No.: 03
Date: 14-Apr-2021 45
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Table 4 Open-label Extension Period On-treatment Procedural Outline Up to Week 104 (IM011024)
Procedure/Visi t Weeks 
(Days)56
(393)60
(421)64
(449)78
(547)90
(631)104
(729)/E
T108 (757) 
or Post-
treatment 
Follow-upUnschedule
d Visit a
Notes
Visit Window (¬± n 
days)33333 3
Modified Mayo score XComposite score of ES (central read), SF, 
and RB subscores. SF and RB subscores will be calculated using electronic subject diary data. See  Section 9.1 and APPENDIX 
9.
aAdditional procedures/assessments will be done per investigator ‚Äôs discretion
AE = adverse event; DNA = deoxyribonucleic acid; ECG = electroc ardiogram;  EOT = end of treatment; 
ES = endoscopic; ET = early ter mination; HBcAb = h epatitis B virus core antibody; HBsAg = hepatitis B surface antigen; HBV = hepatitis B virus; hsCRP = high-
sensitivity C-reactive protein; IBD = inflammatory bowel diseas e;  Ig = immunoglobulin; 
IgA = immunoglobulin A; IgE = immunoglobulin E; IgG = immunoglobulin G; IgM = immunoglobulin M;  
RB = rectal bleeding; 
 SAE = serious adverse event;  SF = stool frequency; TBNK = T cells , 
B cells, and natural killer cells;  WOCBP = women of childbearing potential
In the event multiple procedures are required at a single time point, the ECG may be obtained up to 20 minutes earlier, vital si gns may 
be obtained up to 20 minutes earlier or later, and clinical labo ratory sample may be obtained up to 10 minutes earlier than the nominal 
time poin .
Protocol Amendment No.: 03
Date: 14-Apr-2021 46
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
3 INTRODUCTION
3.1 Study Rationale
Study IM011024 is a Phase 2 ra ndomized, double-blind study desig ned to assess the safety and 
efficacy of oral (PO) BMS-986165 6 mg twice daily (BID) in subjects with moderate to severe 
ulcerative colitis (UC). The primary objective is to assess the  effect of BMS-986165 on the primary 
endpoint of clinical r emission, which is defined as a modified Mayo score with the fo llowing 
subscores: stool frequency (SF) subscore ‚â§ 1 with ‚â• 1 point decrease from baseline, r ectal bleeding 
(RB) subscore = 0, and endoscopic (ES) subscore ‚â§ 1 (modified, exclu des friability); at the end of 
the induction period (Week 12).
3.2 Background
Ulcerative colitis (UC) is a chronic inflammatory disease of th e gastrointestinal tract that causes 
significant morbidity, impact on quality of life, a nd healthcare expenditures . Outcomes for patients 
with UC have improved significantly over the last several years due to better treatment strategies 
and the emergence of highly ta rgeted biol ogical therap ies, yet significant therapeutic challenges 
still remain with this and other inflammatory bowel diseases (I BDs). The current treatment 
regimens often fail, induce only a partial res ponse, or are poorly toler ated. For example, studies 
with tumor necrosis factor inhibitors (TNFi) report 10% to 30% of subjects do not respond to their 
first treatment and 23% to 46% of subjects lose their response over time.1Therefore, there is still 
a critical unmet need for novel, safe, well-tolerated, and oral ly administered therapies with a 
different mechanism of action that can effectively modify the d isease course.
Tyrosine kinase 2 (TYK2) is a protein involved in interleukin (I L)-12, IL- 23, and Type I interferon 
(IFN) signaling, and it is required for the activation of downs tream signaling pathways.2TYK2 is 
a widely expressed, non-receptor tyrosine kinase that catalyzes  the phosphorylation of signal 
transducer and activator of transcription (STAT) proteins downs tream of the receptors for the p40-
containing cytokines IL-12 and IL-23, as well as the Type I IFN receptor. This results in the 
activation of STAT-dependent transcription and functional respo nses specific for these cytokines.3, 
4, 5TYK2-dependent cytokines (eg, IL -12, IL-23 and Type I IFNs) are  distinct from those 
dependent on closely related  Janus kinase (JAK) f amily memb ers JAK1, JAK3 (eg, IL-2, IL-15, 
IL-7, IL-6) or JAK2 (eg, eryth ropoietin, thrombopoietin, and granulocyte-monocyte colony-
stimulating factor). Consequently, a TYK2 inhibitor is expected to have a highly differentiated profile from inhibitors of other JAK family kinases. TYK2 depen dent pathways and the cytokine 
networks they modulate (eg, IL- 23, IL-17, IFNŒ±) have been impli cated in the pathophysio logy of 
multiple immune-mediated diseases, including UC, Crohn‚Äôs diseas e (CD), psoriasis, psoriatic 
arthritis, systemic lupus eryth ematosus (SLE) and spondyloarthro pathies.
BMS-986165 is an orally administered selective TYK2 inhibitor. A comprehensive in vitro and in 
vivo characterization of BMS-986165 has been established and supports the development of this 
compound in humans.
6, 7Inhibition of TYK2 is expected to provide therapeutic benefit f or patients 
with UC for multiple reasons: 1) IL-12 and IL-23 have been impl icated in the pathogenesis of 
Protocol Amendment No.: 03
Date: 14-Apr-2021 47
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
UC8, 9, 10, 11; 2) Biologic agents targeting IL-23p19 and IL-12/IL-23p40 cytokines have been 
shown to be efficacious in UC and CD, and ustekinumab targeting  IL-12/IL-23p40 has been 
approved for the treatment of CD12and UC13; and 3) BMS-986165 has been shown to be 
efficacious in psoriasis, an IL-23-mediated disease, in a recen t Phase 2 study.14
This Phase 2 study (IM011024) will provide safety and efficacy data for BMS-986165 in subjects 
with moderate to severe UC. Approximately 120 subjects will be randomized in this study. After 
a 28-day screening period, eligible subjects will be  randomized in a 2:1 ratio to receive o ral 
BMS-986165 6 mg BID or placebo BID during the induction period o f 12 weeks. Randomization 
will be stratified based on corticosteroid use (yes/no) and pri or exposure to biologics indicated for 
the treatment of UC (ie, no prior exposure, exposure to 1 biolo gic, or exposure to > 1 biologic). 
JAK inhibitors are considered as a biologic for stratification purposes. (Note: Failure or loss of 
response to JAK inhibitors is exclusionary, but prior exposure is not exclusionary.) The induction 
period lasts from Week 0 th rough Week 12. The primary  outcome for the study will be assessed 
at Week 12 (Day 85).
The maintenance period lasts from Week 12 t hrough Week 52. This study has a treat-through study 
design. Subjects who achieve clinical response at Week 12 (Day 85), with an appropriate safety 
profile, are eligible to continue into the maintenance peri od, during which they will continue to 
receive the same blinded study  treatment regimen (BMS-986165 6 m g BID or place bo BID) that 
they received during the induction peri od. An open-label study arm is available within the 
maintenance period for subjects who do not achieve a clinical r esponse at Week 12 and for subjects 
in the treat-through study arms who experience disease worsenin g between Week 13 and Week 52. 
The open-label extension period lasts from Week 52 th rough Week 104 and is available to subjects 
who complete per protocol assessments and who continue to deriv e clinical benefit from the 
investigationa l product (IP), as judged by the investigator, at t hat time.
A detailed description of the chemistry, pharmacology, efficacy , and safety of BMS-986165 is 
provided i n the Investigator‚Äôs Brochure (IB).15
3.2.1 Nonclinical Toxicology
The projected systemic exposure multiples presented in this sec tion are expressed relative to the 
highest an ticipated mean s teady-state systemic exposure in human following oral dosing at  
6 mg BID (mean AUC[0-24h] = 857 ng‚Ä¢h/mL) and were calculated as anim al sex-combined mean 
AUC √∑ human sex-combined mean AUC at the no-observed-adverse-eff ect level (NOAEL) or 
level associated with adverse findings in the pivotal toxicolog y studies.
In single-dose oral toxicity studies, B MS-986165 was well toler ated up to the highest administered 
doses of 75, 100, and 30 mg/kg in rats, dogs, and monkeys, respectively. 
In repeat-dose oral toxicity studies in rats, BMS- 986165 was tolerated at all doses (5, 15, or 
75 mg/kg/day for 1 month; 2, 5, or 15 mg/kg/day for 3 months; and 5, 15, or 50 mg/kg/day for 
6 months). All doses were associated with on-target pharmacodyna mic (PD) effects. Systemic 
exposures to BMS-986165 increased approximately dose proportion ally, with no substantial sex 
differences, accumu lation, or loss of exposure in all studies. In the 6-month rat toxicity study with 
Protocol Amendment No.: 03
Date: 14-Apr-2021 48
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
2-month postdose recovery period, BMS-986165 was tolerated by r ats for 6 months at  oral doses 
‚â§ 50 mg/kg/day (mean sex-combined AUC[0-24h] ‚â§ 117 Œº g‚Ä¢h/mL; ‚â§ 137-fold AUC multiple). 
Consistent with BMS-986165-mediated pharmacologic immunomodulat ion, the primary findings 
at ‚â• 5 mg/kg/day were decreased peripheral blood lymphocyte count s, lymphoid cellularity in 
lymph nodes and spleen, and/or suppression of T -cell dependent antibody response (TDAR) to 
keyhole limpet hemocyanin (KLH) immunogen. No BMS-986165-relate d infections were noted. 
Additional BMS-986165-related findings considered adverse at ‚â• 1 5 mg/kg/day (mean 
sex-combined AUC[0-24h] ‚â• 19.7 Œºg ‚Ä¢h/mL; ‚â• 23-fold AUC multiple) i ncluded decreased mean 
body weights and body weight gains, decreased red blood cell (RBC) mass param eters, 
reticulocytes, platelets, and bone marrow cellularity. All BMS-986165-related changes were 
reversible except for the decreased food consumption and body w eights, decreased spleen weights, 
and nonadverse increased incidence of macrophage aggregation in  the lung. In conclusion, based 
on the absence of adverse findings, the NOAEL was considered to  be 5 mg/kg/day (mean sex-
combined AUC[0-24h] 4.31 Œºg‚Ä¢h/mL; 5-fold AUC multiple).
In repeat dose (‚â§ 3 months) oral toxicity studies in monkeys, BM S-986165 was well tolerated at 
all doses (0.5, 1.5, or 5 mg/kg/day for 1 month; 0.75, 1.5, or 5 mg/kg/day for 3 months). All doses 
were associated with on-target PD effects. Exposures to BMS-986 165 increased approximately 
dose proportionally, with no substantial sex differences, loss of exposure or accumulation noted. 
There were no BMS-986165-related mortalities at any dose during any monkey toxicity studies. 
In the 9-month monkey toxicity study (doses of 0, 1, 3, or 10 mg /kg/day; the 10-mg/kg dose was 
changed to 5 mg/kg due to observed toxicity) with 2 month postd ose recovery period, the principal 
BMS-986165-related findings at all doses included generally dos e-dependent skin changes, which 
were likely infectious in etiology, and secondary to BMS 986165 -mediated pharmacologic 
immunomodulation. The various skin changes (swollen, dry, lesio n, flaking, papule, red, white, 
scab) were located throughout the body, and could be seen as ea rly as Week 1 in some monkeys. 
The skin changes were noted at necropsy as abrasions, discolora tion, foci, nodule, scab, scale, 
and/or thick, and correlated with microscopic findings in the e pidermis (hyperkeratosis, erosi on, 
and/or crusts) and/or dermis (mixed cell infiltrates and/or sub acute inflammatio n). Although no 
definitive microbial pathogens were confirmed as the causative agents, the skin changes were 
considered likely infectious in etiology, as they improved foll owing antibiotic and antiseptic 
treatments, and were present in the context of BMS-986165 media ted immunomodulation. 
Additional findings at all doses included transient slight to s evere liquid feces, which improved 
clinically with veterinar y treatments, dose- dependent decreased  RBC mass param eters, and 
suppression of TDAR to KLH, and at ‚â• 3 mg/kg/day (mean sex-combin ed AUC[0-24h] 
‚â• 15.4 Œºg‚Ä¢h /mL; ‚â• 18-fold AUC multiple) decreased activity, hunche d posture, pale gums, and 
increased body temperature, with decreased platelets and occult  blood in urine at 10 followed by 
5 mg/kg/day (mean sex-combined AUC[0-24h] 30.7 Œºg‚Ä¢h/mL; 36-fold A UC multiple). Following 
the 2-month recovery period, all BMS- 986165-related findings were partially or fully reversible. 
The NOAEL was not identified due to the presence of adverse ski n findings at doses ‚â• 1 mg/kg/day 
(mean sex-combined AUC[0-24h] ‚â• 3.38 Œºg‚Ä¢h/mL; ‚â• 4-fold AUC multiple). Although the 
NOAEL was not determined in this study, the skin findings did n ot result in any unscheduled 
Protocol Amendment No.: 03
Date: 14-Apr-2021 49
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
euthanasia or preterminal deaths, were clinically monitorable, manageable with veterinary 
treatments, and trended toward reversibility during the 2-month post-dose recovery.
The totality of the toxicity ass essments demonstrates that BMS- 986165, at doses associated with 
robust PD effects, has a favorable dose-related safety profile in both rodents and nonrodents, 
toxicological findings that are either fully reversible or tren ding toward recovery, and are clinically 
monitorable and manageable. 
Additional details regarding the nonclinical toxicology results  are provided in the current IB.15
3.2.2 Early Clinical Experience
BMS-986165 has a favorable pharmacokinetic (PK) profile charact erized by consistent oral 
absorption, dose-r elated increase in  exposure and no evident time-dependency. The oral absorption 
is rapid with maximal plasma concentrations achieved in 1 to 2 h ours and a high absolute 
bioavailability (approximately 99% with a 12 mg oral dose). No s ignificant interaction was 
observed when BMS-986165 was administered with food (high fat/h igh calorie meal) or with pH-
modulating agents like famotidi ne. A study is currently underwa y to evaluate the effect of 
rabeprazole on BMS-986165. BMS-986165 is moderately bound to pl asma proteins and is 
therefore unlikely to be displaced by drugs that have a greater  binding affinity. 
The terminal half-life of BMS-986165 is ~10 to 15 hours and that  of the active metabolite 
(BMT-153261) is ~12 hours. BMS-986165 accumulates ~1.5-fold wit h repeated administration. 
BMS-986165 is eliminated via multiple well-balanced mechanisms including Phase I and II 
metabolis m along with dir ect renal and possibly fecal eliminati on. Addition ally, multiple enzymes 
(CYP1A2, CES2, and UGT1A9) are involved in its elimination. The  active metabolite, 
BMT-153261, whose whole blood potency is 50% of the parent, is formed via CYP1A2 
metabolism. The formation of the BMT-334616 metabolite is media ted by UGT1A9. The 
formation of the BM T-158170 metabolite is  mediated by CES2.
The clinical data available to date supporting the safety, PK, and PD of BMS-986165 are from 
8 Phase 1 studies of BMS-986165 in healthy volunteers (IM011002,  IM011015, IM011016, 
IM011025, IM011031, IM011039, IM011048 and IM011071) and a Phas e 2 study in adult 
subjects with moderate to severe plaque psoriasis (IM011011). I n addition to the current study, 
Phase 2 studies in CD (IM011023), psoriatic arthritis (IM011084) , SLE (IM011021, IM011074), 
and lupus ne phritis (IM011073), and Phase 3 studies in psoriasi s (IM011046, IM011047, 
IM011065, IM011066, IM011075) are currently ongoing.
Study IM011002 (Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, 
PK, and PD of BMS-986165 in Healthy Subjects) used 1, 3, 10, 20 , and 40 mg doses for the 
single-dose part, and 2, 4, 6, or 12 mg BID or 12 mg every day (Q D) for 14 days for the multiple 
ascending dose part. All reported adverse events (AEs) were mil d or moderate in severity, and 
approximately half of subjects overall had at least 1 AE that was considered potentially related to study treatment. The most frequently reported AEs with single do sing were headache and 
dyspepsia. The most frequently reported AEs with multiple dosin g were headache, skin rash and 
acne, and upper respiratory tract infection. Dose- limiting AEs in the form of skin rashes and 
Protocol Amendment No.: 03
Date: 14-Apr-2021 50
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
acneiform lesions were observed. These observations were largel y reported for subjects in the 
24 mg/day (12 mg BID) group and were reported for most subjects do sed at this level. These AEs 
were mild or moderate in nature and resolved with topical treat ments (corticosteroid applications, 
benzoyl peroxide cream, clindamycin solution, chlorhexidine oin tment). All events requiring 
treatment responded a ppropriately, and rarely resulted in disco ntinuation of st udy drug. Ov erall, 
BMS-986165 was fo und to have an acceptable safety profile in hea lthy volunteers, and the 
acneiform lesions that were seen at the highest doses were mana geable with topical treatments, 
were reversible, and were not serious or severe.
The study to evaluate the cardiodynamic effects of BMS-986165 w as conducted at 12 mg and 
36 mg, and included a positive control (moxifloxacin) and placeb o. The study demonstrated that 
BMS-986165 at these doses does not have a clinically relevant effect on electrocardiogram (ECG)
parameters. Using concentration-QTc analysis, a QTcF effect (‚àÜ‚àÜ QTcF) exceeding 10 msec can 
be excluded up to BMS-986165 plasma concentrations of ~500 ng/m L. Assay sensitivity was 
demonstrated by the QT effect of moxifloxacin with a s tatist ically signi ficant slope of the 
concentration-ŒîŒîQTc relationship and the lower bound of the 2-s ided 90% confidence interval 
(CI) of the predicted effect at the observed geometric Cmax abo ve 5 msec. The study there fore 
constitutes a negative TQT study.
Study IM011011 was a Phase 2, multicenter, randomized, double-blind, placebo-controlled, 
parallel group Phase 2 study to evaluate the clinical efficacy,  safety, and PD  of BMS- 986165 after 
12 weeks of treatment with 4 weeks‚Äô follow-up in 267 subjects with  moderate to severe plaque 
psoriasis.14The study met its primary and secondary eff icacy endpoint s of clinically relevant 
improvement in Psoriasis Activity and Severity Index (PASI) and  static Physician Global 
Assessment (PGA) scores for 4 of t he 5 doses investigated  (only the 3 mg every other day dose 
did not meet the primary endpoint). Treatment with BMS-986165 a t doses of > 3 mg once daily 
were associated with significantly greater clinical responses c ompared with placebo at Week 12, 
as measured by a ‚â• 75% reduction in the Psoriasis Area and Sever ity Index (PASI 75) score. At 
Week 12, the percentage of patients with a PASI 75 response was  7% (3 of 45 patients) with 
placebo, 39% (17 of 44 patients) with 3 mg QD, 69% (31 of 45 pa tients) with 3 mg BID, 67% 
(30 of 45 patients) with  6 mg BID, and 75% (33 of 44 patients) wit h 12 mg QD (P value < 0.001 
for each comparison). Treatment with BMS-986165 at doses > 3 mg B ID was also associated with 
a numerically greater proport ion of patients achieving ‚â• 90% reduction in PASI score (PASI 90), 
compared with placebo at Week 12. The most common AEs re ported overall were nasopharyngitis, 
upper respiratory tract infection, diarrhea, and nausea. The ma jority of the AEs reported in the 
study were mild or moder ate in intensity. AEs of acneiform dermatitis were observed in a few 
subjects that appeared to be dose-related, and most were reported for subjects at the 2 highest dose 
groups. Most of the lesions were completely res olved (a few wer e almost comp letely resolved) 
with topical tr eatments and did not result in discontinuation of the study tre atment. In summary, 
BMS-986165 has demonstrated pro mising clinical e fficacy in the treatment of subjects with 
moderate to severe plaque psoriasis.14
Protocol Amendment No.: 03
Date: 14-Apr-2021 51
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
3.3 Benefit/Risk Assessment
BMS-986165 is being developed as an oral treatment for UC, CD, psoriasis, psoriatic arthritis, 
SLE, and lupus nephritis. Based on its mechanism of action as a n inhibitor of TYK2-mediated 
signaling pathways downstream of well-characterized pharmaceuti cal targets for the tr eatment of 
UC, the IL-12/T H1 and IL-23/T H17 axis, it is predicted that subjects with UC may benefit from  
treatment with BMS-986165. Further, the first-in-human (FIH) st udy of BMS-986165 
(Study IM011002) in h ealthy sub jects demonstrated IL-12 signaling inhibition by BMS-986165. 
These data suggest that subjects  with UC are likely to derive c linical benefit after treatment with 
BMS-986165.
The effects of TYK2 inhibiti on by BMS- 986165 have been documented in pharmacology studies, 
and the potential for benefit in UC is supported through in viv o studies showing BMS-986165 is 
efficacious in murine models for lupus, colitis, and psoriasis.  In all models, efficacy was observed 
at doses providing continuous coverage of the mouse whole blood  half-maximal inhibitor 
concentration (IC50) value over the dosing interval. 
The proposed dosing regimen reflects implementation of appropri ate safety margins and is within 
the range of doses tested in the FIH study and within exposure margins based on comparisons of 
systemic exposure and body surface area. The dose of BMS-986165  6 mg BID is also being 
investigated in clinical trials for other indications.BMS-986165 was safe whe n investigated in the FIH study IM011002  with healthy sub jects at 
single doses up to 40 mg and multiple doses of 24 mg/day (12 mg BID) for 14 days. However, 
BMS-986165 did elicit dose-dependent, mild-to-moder ate acneiform skin reactions particularly 
after multiple doses of 24 mg/day (12 mg BID). Importantly, all sk in-related AEs were mild or 
moderate, with no signs or symptoms of circulatory impairment o r respiratory distress in these 
subjects; required topical treatment in only a few cases, responded quickly and appropriately when treatment was require d, and rarely required discontinuation of study drug. Based on these findings, 
the highest proposed dose for the Phase 2 study IM011024 in subj ects with UC will be 6 mg BID. 
In case of the occurrence of skin-related events, subjects may receive treatment per standard 
practice according to investig ator‚Äôs discretion and followed un til resolution. 
The risk for PK drug-drug interactions (DDIs) with BMS-986165 w as assessed using Food and 
Drug Administration (FDA) and European Medicines Agency guidanc e documents for DDI 
assessments. At the maximum concentrations expected in this stu dy (in portal vein or systemic 
circulation, as appropriate), the potential for DDIs involving cytochrome P450 (CYP450) enzymes 
and most transporters is low. BMS-986165 has low turnover in in vitro metabolism studies, and a 
number of enzymes are involved in its metabolism. Additionally,  BMS-986165 is not an inhibitor 
or inducer of CYP450 enzymes at the expected clinical concentrations. Therefore, the potential for DDIs resulting from CYP450 inhibition or induction is low. BMS- 986165 is a breast cancer 
resistance protein (BCRP) inhib itor with an in v itro IC50 = 0.31 ŒºM . However, due to overlapping 
substrate specificity between BCRP and other transporters not a ffected by BMS-986165 at the 
expected concentrations, the impact of BMS-986165 on the exposu res of potential comedications 
that are BCRP substrates, such as rosuvastatin, was expected to be low. Based on data from 
Protocol Amendment No.: 03
Date: 14-Apr-2021 52
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
IM011015 DDI study, co-adminis tration of 12 mg QD BMS-986165 and  10 mg rosuvastatin had 
no impact on the exposure of rosuvastatin. Data from a st udy evaluating the impact of 
BMS-986165 in women taking oral  contraceptives  found no impact on exposure of ethinyl 
estradiol or norethindrone.
Because BMS-986165 is a potential immunomodulator and in line w ith standard practice for 
immunosuppressive therapies, this study has been designed with s tudy visits that allow for close 
monitoring and with inclusion/exclusion criteria aimed at minim izing the risk for serious infections 
and malignancies.Additionally, the current study (Study IM011024) has been desig ned to closely monitor study 
subjects‚Äô safety th roughout the duration of the study. At the i nvestigator‚Äôs discretion, rescue 
therapy can be initiated ( Section 5.1.5 ), or dosing of study medication can be discontinued at any 
time during the st udy ( Section 8.1 ). In addition to a comprehensive monitoring of safety with 
oversight by the investigators, medical monitors from both BMS and the partner organization, 
 and the BMS Safety Physician, the safety of subjects will also  be monitored 
by an independent Data Monitoring Committee (DMC). 
In summary, existing preclinical data and clinical experience i n healthy subjects in combination 
with the design and dose selected for this Phase 2 study indicate  an overall favorable benefit-risk 
assessment of investigati ng BMS- 986165 as an oral treatment for  subjects with UC.
Additional detailed information on the known and expected benef its and risks and reasonably 
anticipated AEs of BMS-986165 is provided in the IB.
15
The global coronavirus disease 2019 (COVID-19) pandemic has bee n identified as a potential risk 
to clinical trial s ubjects in general, and it may particularly affect individuals with underlying 
chronic diseases. The risk of severe acute re spiratory syndrome  coronavirus 2 (SARS-CoV-2) 
infection in participants taking BMS-986165 is unknown. The ind ividual benefit-risk 
considerations regarding COVID-19 infection remains the responsibility of the investigator.BMS-986165 is an immunomodulatory IP. The inclusion ( Section 6.1 ) and exclusion ( Section 6.2 ) 
criteria have been designed to exclude people with active infecti ons and people at higher risk of 
malignancies. In order to reduce the risk of asymptomatic SARS-CoV-2 at baseline, subjects will 
be tested for SARS-CoV-2 during the screening period, as close as possible prior to randomization 
(refer to Section 9.8 ).
The study has been designed with study visits that allow for cl ose monitoring of study subjects‚Äô 
safety throughout the study, and additional data collection wil l be triggered if AEs of interest 
(AEIs) are observed in this study. Each study visit will include  a clinical assessment for signs 
and/or symptoms of intercurrent  illness, including COVID-19 and other infections. Subjects will 
also be encouraged to contact the investigator if they develop a n intercurrent illness between study 
visits.
The Sponsor has developed guidance for investigators on how to manage a subject with a clinical 
suspicion of, or a diagnosis of, COVID-19. This includes criter ia for temporary discontinuation of 
IP in the context of clin ical suspicion o f COVID-19, or a positive diagnostic test for SARS-CoV-2. 
Protocol Amendment No.: 03
Date: 14-Apr-2021 53
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
This also includes criteria for potentially recommencing IP upo n complete resolution of a 
COVID-19 infection, confirmed by a negative diagnostic test (Section 8.2.1 ).
The study captures treatment-emergent AEs (occurring after rand omization). In order to facilitate 
enhanced reporting of SARS-CoV-2‚Äìrelated AEs that occur during th e study, these AEs (and 
SAEs) must be reported from the time of consent ( Section 9.2.1 ). 
4 OBJECTIVES AND ENDPOINTS
Primary and secondary endpoints and related study terms are defined in Table 5 .
Table 5 Primary and Secondary Endpoint and Related Study Term 
Definitions
Endpoint Definition
Primary
Clinical remission
(modified Mayo score)A modified Mayo scoreawith the following:
‚Ä¢SF subscore ‚â§ 1, with ‚â• 1 point decrease from baseline, and
‚Ä¢RB subscore = 0, and
‚Ä¢ES subscore
b‚â§ 1 (modified, excludes friability)
Secondary
Clinical responsec‚Ä¢A decrease from baseline in the modified Mayo scorea
of ‚â• 2 points, and
‚Ä¢A decrease from baseline in the modified Mayo scorea
‚â• 30%, and
‚Ä¢A decrease in RB subscore of ‚â• 1 point or absolute 
RB subscore ‚â§ 1
Endoscopic response Mayo ES subscoreb‚â§1
Histologic improvement Geboes score ‚â§ 3.1
Study Term Definition
Disease worsening An increase of the sum of the SF and RB subscores 
‚â• 2 compared to Week 12
ES = endoscopic; RB = rectal bleeding; SF = stool frequency
aThe modified Mayo score (0 to 9 points) is the sum of 3 componen ts: the SF, RB, and ES subscores (see Section 9.1
and APPENDIX 9 ).
bObtained from centrally read endoscopy ( Section 9.1.1 )
cEfficacy analyses will use the modified Mayo score calculated w ith centrally read endoscopy. At Week 12, 
treatment assignment in the maintenance period will be determined using clinical response based on the modified 
Mayo score calculated with a locally read endoscopy ( Section 9.1.1 ).
Protocol Amendment No.: 03
Date: 14-Apr-2021 54
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr-2021 55
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
The study objectives a nd endpoints are in Table 7 . 
Additional endpoints and analyses will be described in the stat istical analysis plan (SAP), the 
Endoscopy Image Review Charter or the Histopathology Image Review Charter.
Protocol Amendment No.: 03
Date: 14-Apr-2021 56
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Table 7 Study Objectives and Endpoints
Objectives Endpoints
Efficacy
Primary
‚Ä¢To assess the effect of BMS-986165 on 
clinical r emission at the end of the 
induction period‚Ä¢Clinical remission (modified Mayo score) at Week 12 
Secondary
‚Ä¢To assess the effect of BMS-986165 on clinical response at th e end of the induction 
period‚Ä¢Clinical response at Week 12 
‚Ä¢To assess the effect of BMS-986165 on endoscopic response at the end of the 
induction period ‚Ä¢Endoscopic response at Week 12 
‚Ä¢To assess the effect of BMS-986165 on 
histologic improvement at the end of the induction period‚Ä¢Histologic improvement at Week 12 
Safety
‚Ä¢To assess the safety and tolerability of BMS-986165 in sub jects with moderate to 
severe UC ‚Ä¢Number and proportion of subjects experiencing AEs, SAEs, AEs leading to 
study discontinuation, and AEs of interest 
(AEIs)
‚Ä¢Number and proportion of subjects experiencing abnormali ties in laboratory 
testing, ECG, physical examination, and vital sign parameters over time
Protocol Amendment No.: 03
Date: 14-Apr-2021 57
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Table 7 Study Objectives and Endpoints
Objectives Endpoints
Protocol Amendment No.: 03
Date: 14-Apr-2021 58
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Table 7 Study Objectives and Endpoints
Objectives Endpoints
Protocol Amendment No.: 03
Date: 14-Apr-2021 59
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Table 7 Study Objectives and Endpoints
Objectives Endpoints
Protocol Amendment No.: 03
Date: 14-Apr-2021 60
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Table 7 Study Objectives and Endpoints
Objectives Endpoints
Protocol Amendment No.: 03
Date: 14-Apr-2021 61
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Table 7 Study Objectives and Endpoints
Objectives Endpoints
AE = adverse event; AEI = adverse event of interest; ECG = elec trocardiogram;  
 hsCRP = high-sensitivity C-reactive protein;  
IgG = immunoglobulin G;  
 
RB = rectal bleeding;  
 SAE = serious adverse event;  
SF = stool frequency; UC = ulcerative colitis;  
5 STUDY DESIGN
5.1 Overall Design
This is a Phase 2 randomized, double-blind, placebo-controlled,  multicenter clinical trial to assess 
the safety and efficacy of BMS-986165 6 mg BID in subjects with  moderate to severe active UC. 
The primary objective is to assess the effect of BMS-986165 on clinical remission at Week 12. 
Protocol Amendment No.: 03
Date: 14-Apr-2021 62
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
The duration of study participation is approximately 112 weeks (784 days) in 5 periods, as follows:
‚Ä¢Screening Period: up to 4 weeks (28 days; Section 5.1.1 )
‚Ä¢Induction Period: 12 weeks (84 days; Section 5.1.2 ) 
‚Ä¢Maintenance Period: 40 weeks (280 days; Section 5.1.3 )
‚Ä¢Open-label Extension Period: 52 weeks (364 days; Section 5.1.4 )
‚Ä¢Post-treatment Follow-up Period: 4 weeks (28 days;  Section 5.1.4.1 ) 
Physical examinations, vital sign measurements, 12-lead ECG, an d clinical laboratory evaluations 
will be performed at selected times throughout the study, as indicated in the Schedule of Activities 
(Section 2 ). Subjects will be closely monitored for AEs th roughout the study.  
 
Clinical efficacy is assessed using the modified Mayo score, wh ich uses a combination of patient-
reported outcomes (PRO) (SF and RB captured by the subject in the ir electronic diary) and 
endoscopic assessments (centrally read endoscopy). Subjects shou ld receive and be trained on an 
electronic patient diary at the screeni ng visit. Subjects are expected to complete the electronic diar y 
on a daily basis  through the screening peri od, and then throughout their ongoing participation in 
the study.
Endoscopic (colonoscopy/sigmoidoscopy) evaluations and co llection of colonic tissue biopsies 
will be performed during the screening period, at Weeks 12, 52,  and 104, at unscheduled visits (if 
clinically indicated) and at early termination (ET) visits that  occur at least 4 weeks after the last 
per protocol-required endoscopy. Endoscopic assessment is requi red for ET visits occurring 
between Week 4 and Week 12 (induction peri od) and optional but recommended for ET visits 
occurring between Weeks 16 and Week 52 (maintenance period), an d between Weeks 56 and 104 
(open-label extension [OLE] period). Endoscopic procedures w ill be video rec orded and scored 
for disease activity by a blinded central reader. Histologic sc oring of gastrointestinal tissue 
specimens will also be performed by a blinded central reader.  
 
Subjects who meet the criteria for treatment failure will perma nently discontinue IP and enter the 
post-treatment follow-up period ( Section 5.1.4.1 ).
An independent DMC will be instituted to assess safety data by u nblinded treatment group
(Section 5.1.7 ).
The study design schematics fo r the induction/ maintenance perio ds and the open-label extension 
period are in Figure 1 and Figure 2 , respectively.
Protocol Amendment No.: 03
Date: 14-Apr-2021 63
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Figure 1 Study Design Schematic: Induction and Maintenance Periods
BID = twice daily; OL = open-label; OLE = open-label extension; R = ran domization
At Week 12, clinical response is determined using the modified Mayo score (see Table 5 and Section 9.1.1 ). Subjects 
who achieve clinical response at Week 12 and continue into the maintenance period will continue t o receive their 
double-blind treatment from the induction period. Subjects who subsequently experience disease worsening ( Table 5 ) 
can enter the Week 12 responder open-label arm at any time from  Week 13 through Week 52. 
Subjects who do not achieve clinical response at Week 12 are el igible to enter the Week 12 nonresponder open-label 
arm.
Protocol Amendment No.: 03
Date: 14-Apr-2021 64
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Figure 2 Study Design Schematic: Open-label Extension Period
BID = twice daily; IP = investigational product; OL = open-label
a Subjects in this arm are those who achieved clinical response  at Week 12 of the induction period, but they 
subsequently lost clinical  response to IP between Week 13 and Week 52 of the maintenance peri od and switched to 
the Week 12 responder open-label arm ( Section 5.1.3.2 ). 
b Subjects in this arm are those who did not achieve clinical response at Week 12 of the induction period and switched 
to the Wee k 12 nonres ponder open-label arm.
5.1.1 Screening Period
Once subjects sign the informed cons ent form (ICF), they are co nsidered "enrolled" in the study, 
and they enter the screening period. During the screening perio d, subjects will complete the study 
procedures and baseline assessments outlined in the Schedule of  Activities ( Table 1 ) to determine 
if they continue to meet eligibility criteria ( Section 6 ). 
To be eligible for the study, a subject must meet minimum disea se activity criteria outlined in the 
inclusion criteria ( Section 6.1 ), including a modified Mayo score of 5 to 9 points, inclusive.
Subjects are expected to complete a daily diary throughout the screening period. SF and RB data 
recorded in the d aily diary contribute to disease activity assessmen t throughout the  study. The 
minimum daily diary requirements for modified Mayo score calculations are outlined in 
APPENDIX 9 . To ensure that a subject can  be successfully randomized, sites should confirm prior 
to each study visit that subjects are successfully entering and uploading daily diary data (see 
APPENDIX 9 and Table 26).
A screening endoscopy (sigmoidoscopy or colonoscopy) will be per formed to determine if a 
subject has active intestinal inflammation (assessed by central reading) and to obtain biopsies for 
histological  assessment . In order to avoid unnecessary endoscopies, 
best practice is to complete other screening investigations fir st, and to check the results of those 
Protocol Amendment No.: 03
Date: 14-Apr-2021 65
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
investigations for abnormalities before a subject begins bowel preparation for endoscopy. This 
ensures that a subject continue s to be potenti ally eligible for  the study before they commence 
bowel preparation. Subjects must  be randomized within 14 calend ar days of the screening 
endoscopy.
Note: a full colonoscopy will be required 1) if normal margins are not apparent from 
sigmoidoscopy or proximal colonic involvement is suspected; or 2) in subjects with a history of 
UC > 8 years, if endoscopy was  not performed in t he prior 12 month s. 
When operationalizing the screening period, please consider the  following:
i. Study procedures cannot be performed before the subject signs  the ICF. Once the ICF is 
signed at the screening vis it, sites should consider obtaining a  medical hist ory, vital signs 
and physical examination, and other per protocol screening visi t investigations such as 
blood tests, ECG, and che st x-ray (if required); giving the subject the electronic study diary 
and training on the diary; and also scheduling the screening en doscopy and Week 0 (Day 1) 
visit. Sites should consider the turnaround time for the centr ally read endoscopy result 
when scheduling the endosc opy and Week 0 (Day 1) visits.
ii. The study diary requirements for the calculation of t he modified Mayo score are outlined 
in APPENDIX 9 . To ensure that a modified Mayo s core can be determined, sites should 
confirm prior to each study visit that subjects are succ essfully entering and uploading daily 
diary data and that an appropriate number of valid entr y days is available for the calculation 
of the SF and RB subscores ( APPENDIX 9).
iii. Sites s hould chec k the results of screening investigati ons to confirm that a subject remains 
potentially eligible  for inclusio n before they commenc e bowel preparation for the screening 
endoscopy. 
iv. Once the screening endoscopy is performed, subjects  must be randomized within 14 days. 
To be eligible for randomization, subjects must have had an i nadequate response, loss of response, 
or intolerance to a standard treatment course of 1 or more  of the medications outlined in the 
Inclusion Criteria in Section 6.1 2) Type of Subject and Targ et Disease Characteristics . 
Detailed criteria defining inadequate response, loss of respon se, or intolerance to biologic therapy 
are described in APPENDIX 5 . The prior medication failure o r intolerance used to qualify a subject 
for inclusion as defined in Section 6.1 must be recorded  in source documents and the UC 
medications el ectronic case re port form (eCRF). 
The medications outlined in APPENDIX 7 must be discontinued prior to randomization on 
Week 0 (Day 1) and include immunomodulators (eg, methotr exate [MTX], 5-azathioprine [AZA], 
6-mercaptopurine [6-MP]) and biologic medications (eg, i nfliximab, adalimumab, golimumab, 
vedolizumab, and ustekinumab). To be eligible for randomiz ation, subjects taking the medications 
listed in APPENDIX 7 must discontinue them prior to randomization and comply with the required 
washout periods listed in APPENDIX 7 .
Protocol Amendment No.: 03
Date: 14-Apr-2021 66
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Corticosteroids (prednis one ‚â§ 20 mg QD PO or equivale nt [APPENDIX 6 ] or budesonide ‚â§ 9 mg 
QD PO Multi-Matrix System [MMX¬Æ] colonic-delivery  technology; eg, Uceris¬Æor equivalent), 
probiotics, and 5-ami nosalicylic acids (5-ASAs) are all owed, subject to dose sta bilization rules 
outlined in Section 6.3 . 
5.1.1.1 Therapeutic Drug Monitoring
Some subjects w ill require adequ ate washout of biologics to be eligible for randomization. 
Therapeutic drug monitoring (TDM) assays that test for drug lev els of these biologic medications 
can be commercially available in routine clinical practice and also available as an optional test 
during the screening peri od. The was hout period for the following biologics can be waive d in 
subjects who have an undetectable drug level on a TDM assay, performed either in routine clinical 
practice or during th e screening period: (i) infliximab, (ii) a dalimumab, (iii) golimumab, 
(iv) vedolizumab (> 14 weeks of v edolizumab therapy), or (v) uste kinumab (> 12 weeks of 
ustekinumab therapy). If a TDM assay is used to waive the washout period for any of the biologics listed above, the result of the TDM assay must be available in source documents, andthe subject 
cannot receive another dose of that biologic prior to randomiza tion. 
5.1.2 Induction Period
On Week 0 (Day 1) of the  inductio n period, sub jects who have completed the screening procedures 
and met the inclusion/exclusion criteria will be randomized in a 2:1 ratio to receive BMS-986165 
6 mg BID or placebo BID, respectively (see  Section 6.3 for randomization criteria). During the 
induction peri od, sub jects will receive study t reatment over 12 weeks. Allowed conco mitant 
medication for UC (eg, 5-ASAs, probiotics, oral corticosteroids) must remain at the 
prerandomization stable dose, unless reduced or discontinued du e to an AE. Corticosteroid use 
during the induction period is detailed in Section 5.1.5.1.
Endoscopy for the assessment of efficacy at We ek 12 will occur withi n a window of 7 days prior 
to the Week 12 visi t. The subject st udy diary r equirements for t he calculation of the modified 
Mayo score are outli ned in APPENDIX 9 .
At Week 12, the centrally read endoscopy w ill be used for determination of efficacy within the 
study. However, cli nical res ponse calculated us ing the locally read endoscopy w ill be used to 
determine treatment assignment of a subject in th e maintenance period (See  Section 9.1.1 ).
Rescue therapy is not offered during the inductio n period. If, in t he opinion of the investigat or, a 
subject requires rescue therapy for UC during the induction per iod, the subject must permanently 
discontinue study treatment ( Section 8.1 ), complete an ET visit, a nd enter the post-treatment 
follow-up period (see Section 5.1.6 and Section 5.1.4.1 ). Endoscopy is required at the ET visit for 
subjects who permanently discontinue study medication between W eeks 4 and 12. Discontinuation
  
criteria are further detailed in Section 8.
Some study-related procedures may be performed on the day of endoscopy prior to the Week 12 
visit. Please refer to the Schedule of Activity  table ( Table 2 ) for timing of specific Week 12 
assessments. 
Protocol Amendment No.: 03
Date: 14-Apr-2021 67
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Subjects who discontinue study treatment will remain in the stu dy and continue to be followed for 
protocol-specified post-treatment follow-up procedures. The only exception to this is when a 
subject specifically withdraws consent for any further contact w ith him/her or persons previously 
authorized by subject to provide this information (see  Section 8).
5.1.3 Maintenance Period
The maintenance period will last up to 40 weeks. 
During the maintenance period, subjects who were on a stable do se of corticosteroids must begin 
a dose taper by Week 14. See  Section 5.1.5.2 and Table 8 for recommended tapering schedules. 
Subjects who require prohibited re scue treatment for UC (ie, ou tside of the protocol allowance; 
see Section 5.1.6 and Section 7.7.1 ) during the maintenance period must permanently discontinue 
study treatment, complete an ET visit, and enter post-treatment follow-up ( Section 5.1.4.1) .A n  
exit endoscopy is recommende d for all subjects who undergo an E T visit between Weeks 16 and 
52 (i.e. exit endoscopy is not required for ET visits within 4 weeks of the Week 12 endoscopy).
5.1.3.1 Week 12 (Day 85), End of Induction Period
Subjects who achieve a protocol -defined clinical response at Wee k 12 (assessed using the modified 
Mayo score with a locally read endoscopy) are eligible to enter the maintenance period and 
continue to receive the same blinded study regimen they receive d in the induction period. Blinded 
study treatment will continue until the subject completes Week 5 2, experiences disease worsening 
(Section 5.1.3.2 ) and switches to open-label treatment, or discontinues from th e study. 
At Week 12, subjects who do not achieve a clinical response wil l be offered the opportunity to 
switch to open-lab el BMS-986165 treatm ent (6 mg BID PO), regard less of the initial tr eatment 
regimen received during the induction peri od. Subjects r eceiving corticosteroids during the 
induction period who enter this open-label tr eatment arm must  initiate a cor ticosteroid taper by 
Week 24, or earlier. See Section 5.1.5.3 and Table 8 for recommended tapering schedules.
5.1.3.2 Week 12 Responders: Disease Worsening in the Maintenance PeriodSubjects who achieve clinical res ponse at Week 12 and continue on blinded study treatment will 
be judged to have disease worsening (as defined in Table 5 ) if they experience a worsening of 
clinical disease activity between Weeks 13 and 52.
These subjects are eligible to enter the Week 12 responder open- label arm, during which they will 
receive BMS-986165 6 mg BID PO through Week 52.
Subjects who switch to open-label treatment and experience dise ase worsening based on the 
definition in Table 5 should discontinue from the study ( Section 8.1 ). Investigators should have a 
low threshold for evaluating whether these subject should conti nue based on their clinical 
judgment. 
Protocol Amendment No.: 03
Date: 14-Apr-2021 68
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
5.1.3.3 Week 12 Nonresponders: Disease Worsening in the Maintenance Period
Subjects who do not achieve clinical response at Week 12 are eligible to enter the open-label 
BMS-986165 6 mg BID PO arm and continue into the maintenance per iod th rough Week 52. 
Alternatively, nonresponder subjects may be discontinued from t h e  s t u d y  p e r  i n v e s t i g a t o r  
discretion. 
Nonresponder subjects who switch to open-label treatment and ex perience disease worsening 
between Weeks 13 and 52 ( Table 5 ) should discontinue from the study ( Section 8.1 ). 
See Section 5.1.5.3 regarding subjects receiving corticosteroids in this open-label  treatment arm 
who experience disease worsening at Week 36 (and thereafter).
5.1.3.4 Week 52 (Day 365): End of Maintenance Period
Endoscopy for the assessment of efficacy at Week 52 will occur w ithin a window of 7 days prior 
to the Week 52 visit. The  subject st udy diary requirem ents for the calculation of the modified 
Mayo score are outlined in  APPENDIX 9 . 
5.1.4 Open-label Extension Period
Subjects who continue to  safely derive a clinical benefi t from IP at Week 52, as judged by the 
investigator, are eligible to  receive BMS-986165 6 mg BI D PO in the open-label extension period. 
The open-label extension period will last 52 weeks, to W eek 104. Study visits in this period occur 
every 4 weeks for the first 3 months, then approximately every 3 months afterwards, to Week 104. 
Subjects in the open-label extension period who meet any  of the discontinuation criteria as defined 
in Section 8.1 should disco ntinue from the study ( Section 8.2 ). An exit endoscopy is recommended 
for all sub jects who undergo an ET visit between Weeks 56 and 104. 
The final endoscopy for t he assessment of efficacy at W eek 104 w ill occur within a wi ndow of 
7 days prior to the Week 1 04 visit. The subject study dia ry requirements for the calculation of the 
modified Mayo score are outlined in APPENDIX 9 .
5.1.4.1 Post-treatment Follow-up
Subjects who complete the Week 104 visit, or who permanently dis continue study drug at any time 
during the study ( Section 8 ), will enter a 4-w eek post-treatment follow-up period.
For subjects who continue to demonstrate clinical benefit after  Week 104, a separate long-term 
extension study may become available in the future, subject to regulatory and Institutional Review 
Board (IRB) approval (Section 7.8 ).
5.1.5 Corticosteroid Use and Tapering Schedules
5.1.5.1 Corticosteroid Use in the Induction Period 
Prednisone ‚â§ 20 mg/day or budesonide MMX ‚â§ 9 mg/day are allowed, p rovided the dose is stable 
for 2 weeks prior to randomization ( Section 7.7.2 ), and thereafter stable during the induction 
period. Corticosteroid taperi ng is not allowed during the induc tion period.
Protocol Amendment No.: 03
Date: 14-Apr-2021 69
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
5.1.5.2 Corticosteroid Tapering in the Maintenance Period
Subjects receiving corticosteroids during the induction period who achieve a clinical response at 
Week 12 must initiate a corticos teroid taper by Week 14, according to a standardized tapering 
schedule. Corticosteroids must be discontinued by Week 24, unless the sub ject has evidence of 
adrenal insufficiency. 
If a subject experiences disease worsening during the corticosteroid taper, the corticosteroid dose 
may be increased back to the baseline corticosteroid dose (ie, the dose the subject received at
Week 0 [Day 1]), if clinically ind icated. This may only be done once . The investigator must 
recommence the corticosteroid taper as soon as possible, with t he intention of tapering 
corticosteroids by Week 24. 
Failure to discontinue corticos teroids by Week 24 will be consid ered a treatment failure (defined 
in Section 5.1.6 ), unless the subject requires glucocorticoid treatment for adre nal insufficiency. 
Subjects who remain on corticosteroids at Week 24 to tr eat adrenal ins ufficiency must be discussed 
with the medical monitor to continue on the study. The recommended tapering schedules for prednisone (or equivalen t oral corticosteroid) and 
colonic-release budesonide are in Table 8 . 
Table 8 Recommended Corticosteroid Tapering Schedule
Medication Starting Dose Schedule 
Prednisonea‚â• 15 mg QD POTaper daily dose by 5 mg/week until 
10 mg/day; continue tapering at 
2.5 mg/week until 0 mg/day
Prednisonea11 mg - 15 mg QD POTaper daily dose to 10 mg/day for 
1 week; continue tapering at 2.5 mg/week until 0 mg/day
Prednisonea< 10 mg QD POTaper daily dose by 2.5 mg/week until 0 mg/day
Budesonide MMXb‚â§ 9 mg QD PO9 mg every other day for 1-2 weeks; 
continue tapering 9 mg every third 
day for 1-2 w eeks until 0 mg/day
MMX = Multi-Matrix System; PO = oral; QD = every day
aOr equivalent oral corticosteroid
bUceris extended release or equivalent colonic-release corticost eroid 
5.1.5.3 Corticosteroid Tapering in the Open-label Treatment Arm
Subjects receiving corticosteroids during the induction period who do not have a clinical response 
at Week 12 may be elig ible to enter the open-label tr eatment arm. Such subjects must initiate a 
corticosteroid taper at Week 24 or earlier, according to the sta ndardized tapering schedule 
described in Table 8 (Section 5.1.5.2 ). Corticosteroids must be discontinued by Week 36 unless 
the subject has evidence of adrenal insufficiency. As discussed in Section 5.1.5.2 , 1 corticosteroid 
Protocol Amendment No.: 03
Date: 14-Apr-2021 70
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
dose escalation to the baseline (Week 0/Day 1) corticosteroid dose  is allowed, but the 
corticosteroid taper must be recommenced as soon as possible, w ith the intention of tapering 
corticosteroids by Week 36. Failure to discontinue corticosteroids by Week 36 will be considered 
a treatment failure (defined in Section 5.1.6 ), unless the subject requires glucocorticoid treatment 
for adrenal insufficiency. Such subjects must be discussed with  the medical monitor.
Subjects receiving corticosteroids in this open-label study arm  who experience disease worsening 
(as defined in Table 5 ) at Week 36 (and thereafter) will permanently discontinue study  treatment. 
They will enter the post-tr eatment follow-up period (see Section 5.1.4.1 ) and should be referred 
for appropriate treatment.
5.1.6 Treatment Failure 
For study purposes, treatment failure will be defined as:
1) Requirement for corticosteroid r escue therapy due to increased UC activity or failure to taper 
corticosteroids:
a) For subjects who are on an allowed, stable dose of corticoste roids at randomization: A 
requirement for the dose of corticosteroids to be increased abo ve that baseline dose to 
treat UC during the induction period (Section 5.1.5.1 ) or more than 1 corticosteroid dose 
increase during the maintenance period (Section 5.1.5.2 )
b) For subjects who are noton corticosteroids at randomization and in sub jects who have 
tapered corticosteroids to 0 mg/day during the maintenance perio d: A course of systemic 
corticosteroids (> 24 hours in duration) or more than 1 discrete exposure to systemic 
corticosteroids (< 24 hours in duration) required to treat UC 
c) Failure to taper corticosteroids during the maintenance perio d by Week 24 unless the 
subject has adrenal insufficiency (in which case, the subject m ust be discussed with the 
medical monitor)
d) Failure to taper corticosteroids during the maintenance perio d by Week 36 in the Week 12 
nonresponder open-label arm, unless the subject has adrenal ins ufficiency (in which case, 
the subject must be discu ssed with medical monitor)
2) Requirement for an alternative, efficacious therapy for UC
5.1.7 Data Monitoring Committee and Other External Committees
An external DMC will be used in this study t o perform safety monitoring by unblinded treatment 
group. 
Unblinded data summaries and listings will be provided to the DMC to f acilit ate their safety 
assessment at the regularly scheduled times, and on an ad hoc ba sis if needed. The safety review 
includes all AEs and events of special interest, focusing on ea rly signal detection. Further details 
on the frequency, content, and met hods of d ata reports to the DMC  will be outlined in the DMC 
charter along with the processes and procedures the committee w ill follow.
Protocol Amendment No.: 03
Date: 14-Apr-2021 71
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
5.2 Number of Subjects
Approximately 120 subjects will be randomized. The sample size j ustification is in  Section 10.1 . 
Subjects who have completed screening procedures and met inclus ion/exclusion criteria will be 
randomized in a 2:1 ratio t o receive BMS- 986165 6 mg BID PO or p lacebo BID PO during the 
induction period of 12 weeks. Current standard of care treatments may be continued as long as the 
dosing has been stable and allow ed per the conc omitant medicati ons section of the protocol 
(Section 7.7 ). 
Randomization will be stratified based on corticosteroid use (y es/no) and prior exposure to 
biologics indicated for the treatment of UC (ie, no prior expos ure, exposure to 1 biologic, or 
exposure to > 1 biologic; see Section 7.2 ). JAK inhibitors are considered as a biologic for 
stratification purposes. (Note: failure or loss of response to JAK inhibitors is exclusionary, but 
prior exposure without failure or loss of response is not exclu sionary.)
To ensure real-world subpopulations are well represented in thi s study (ie, biologic-naive subjects 
and biologic-exposed subjects), approximately 40% biologic-naive  subjects and 60% biologic-
exposed subjects will be randomized.
5.3 End of Study Definition
The duration of study participation f or individual subjects may be up to approximately 112 weeks 
(784 days).
The start of the study is defined as the first visit for the first subject screened. The end of the study 
is defined as the last scheduled procedure shown in the Schedule  of Activities ( Section 2 ) for the 
last subject. Study completion is defined as the final date on which data were or are expected to be 
collected (Week 108 for co llection of potential AEs and SAEs).  
5.4 Scientific Rationale for Study Design
This is a Phase 2 randomized, double-bli nd, placebo-controlled study to assess the safety and 
efficacy of BM S-986165 6 mg BID in subjects with moderate to se vere UC. The primary objective 
is to assess the effect of BMS-986165 on clinical remission at W eek 12. Subjects who have 
completed screening procedures and met eligib ility criteria will be randomized in a 2:1 ratio to 
receive oral BMS-986165 6 mg BID or placebo BID during the 12-week induction peri od. The 
dose chosen for this study was done so with the intent to maint ain exposure at or above the IC50 
of the target engagement. 
This Phase 2 study in subjects with UC will provide evidence of  biologic act ivity of BM S-986165 
in a relevant disease population a nd w ill help determine the safet y and efficacy of the BMS-986165 
dose of 6 mg BID. Inhibition of TYK2 is expected to provide therapeutic benefit f or patients with UC for multiple 
reasons: 1) IL-12 and IL-23 have been implicated in the pathoge nesis of UC
8, 9, 10, 11; 2) Biologic 
agents targeting IL-23p19 and IL-12/IL-23p40 cytokines have bee n shown to be efficacious in UC 
and CD, and ustekinumab targeting IL-12/IL-23p40 has been appro ved for the treatment of CD12
Protocol Amendment No.: 03
Date: 14-Apr-2021 72
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
and UC; and 3) BMS-986165 has been shown to be efficacious in p soriasis, an IL-23-mediated 
disease, in a recent Phase 2 study.14
The eligibility and rando mization criteria of this study are de signed to ensure that subjects have 
the expected level of UC activity and to minimize the risk for serious infections that may be 
associated with immunosuppressive therapies.
The Mayo score is a combined endoscopic and clinical scale that is designed to assess UC severity. 
This score was first proposed by Schroeder et al16and has since become widely accepted and used 
in many clinical trials and in clinical practice.  
 
 
 
The modified Mayo score is a composite of 
SF, RB, and ES s ubscores. Further deta ils on the  modified Mayo score are 
in Section 9.1 and APPENDIX 9 . The modified Mayo score will be used to assess disease severity 
for study eligibili ty and will be used to assess clinical remission and clinical response.  
A plan for corti costeroid tapering is i ncluded to allow subjects to discontinue corticosteroid 
throughout the m aintenance period of the  study ( Section 5.1.5.2 ). Corticosteroid doses are required 
to be stable for at least 2 weeks prior to the randomization vis it and must be at or below the allowed 
doses prior to the first dose of study treatment on Week 0 (Day 1) of the induction period (see 
Section 7.7.2 ). Subjects who take corticosteroid under the above mentioned co nditions during the 
induction period and who achieve clinical response at Week 12 (Day 85) ar e to undergo 
recommended corticosteroid tapering during the start of the main tenance period ( Section 5.1.3 and 
Table 8 ). This eventual corticosteroid withdrawal will make it possibl e to isolate the effects of 
assigned study treatments and to assess the effect of the IP in  eliminati ng the nee d for corticosteroid 
use while maintaining disease control.
5.5 Justification for Dose
Subjects randomized for  treatment in the  induction period w ill receive 1 of 2 treatments: 
BMS-986165 at 6 mg BID or placebo BID during the induction perio d. 
The following points were considered for dose selection:
1. The preclinical studies of BMS-986165 showed an exposure-resp onse relationship between 
BMS-986165 PK, target engagement assays, and efficacy indicator s of interest in animal 
models of IBD.
2. Psoriasis is a disease highly dependent upon IL-17/IL-23 path way;19thus, the observed 
efficacy and dose response observed in psoriasis are assumed to be informative for dose 
selection in UC. In data from the psoriasis trial IM011011, an association was shown between 
the average concentration (Cavg) of BMS-986165 and efficacy. Ba sed on this finding and the 
very limited information available to identify the exposure mea sure that best correlates with 
efficacy for TYK2 inhibition, the assumption that Cavg is corre lated with efficacy is the most 
Protocol Amendment No.: 03
Date: 14-Apr-2021 73
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
reasonable assumption to make. Because preclinical studies of B MS-986165 indicate that 24-
hour coverage of the IC50 of the target engagement assay is cor related with a robust response, 
additional consideration was given to trough observed plasma co ncentration (Ctrough) to 
ensure that an adequate range of Ctrough spanning the IC50 was also captured in this trial.
3. The primary target engagement measurement used for dose selection based on the IL-12/IL-23 
pathway was the inhibition of IL-12/IL-18 induced interferon ga mma (IFNŒ≥) production 
measured in an ex-vivo assay in the FIH study. It is assumed th at the inhibition of IL-12/IL-18 
assay is associated with efficacy in IBD. This assumption is su pported by preclinical studies 
of BMS-986165 and the clinical improvements observed in UC and CD clinical trials 
conducted using biologic therapies directed against either the p40 subunit shared between 
IL-12 and IL-23 or p19, IL-23 only. Using the PK and target eng agement data from the single 
ascending dose and multiple ascending dose portions of the FIH studies, a direct effect (Emax) 
model was developed to characterize the concentration-response relationship in the FIH study. 
Results of the analysis showed that the estimated IC50 for IL-1 2/IL-18-induced IFNŒ≥ 
production was approximately 6 ng/mL. With the assumption that t he IC50 should be similar 
between healthy sub jects and those with UC, the selected treatment level of 6 mg BI D is 
expected to provide a median Cavg up to approximately 5.8 √ó the IC50 for this selected assay. 
The selected dose is also exp ected to provide a  median Ctrough of approximately 2.6 √ó the 
IC50 for the assay.
The ideal amount of target inhibition in patients with UC using  a selective inhibitor of TYK2 is 
not known because BMS-986165 is the first compound of this class. A higher dose (6 mg BID) 
was chosen as UC typically requires higher doses than in psoriasis (eg, ustekinumab) and greater target engagement to observe efficacy.
6 STUDY POPULATION
Eligibility criteria for this study have been carefully conside red to ensure both the safety of the 
study subjects and the validity of the study results. It is imp erative that subjects fully meet all 
eligibility criteria.
All screening and randomization evaluations must be completed a nd reviewed by the responsible 
investigator to confirm t hat potential subjects meet all eligibility criteria. The investigator will 
maintain a screening log to rec ord d etails of all subjects scre ened and to confirm eligibility or 
record reasons for screening failure, as applicable. Procedures  conducted as part of the subject‚Äôs 
routine clinical management (eg, blood count) and obtained before signi ng of the ICF may be used 
for pre-screening purposes to allow predicting for potential el igibility during the screening period.
The duration of t he screening period is up to 4 weeks. If eligi bility parameters cannot be obtained 
within this time period, the screening peri od may be extended by up to 5 days if approved by the 
medical monitor. Rules for retesting and rescreening are provid ed in Section 6.5.1 .
To be eligible for the study, subjects must meet all criteria in Sections 6.1 and 6.2. To be 
randomized into the study on Week 0 (Day 1), subjects must meet the criteria in Section 6.3 .
Protocol Amendment No.: 03
Date: 14-Apr-2021 74
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
6.1 Inclusion Criteria
In order to be eligible to participate in this study, an indivi dual must meet all of the following 
criteria:
1) Signed Written Informed Consent
a) Willing to participate in the study and sign the ICF
b) Willing and able to complete all study specific procedures and visits
2) Type of Subject and Target Disease Characteristics
a) Not applicable (N/A) per Revised Global Protocol v3.0b) N/A per Revised Global Protocol v3.0 c) Active UC extending ‚â• 15 cm from the anal verge and confirmed by a screening/baseline 
colonoscopy/sigmoidoscopy pr ior to the randomization visit
d) N/A per Revised Global Protocol v3.0e) N/A per Revised Global Protocol v3.0 f) Documented diagnosis of U C of at least 3 m onths‚Äô duration pri or to screening, confirmed 
by:
1. Source: Medical records with report of an endoscopy, which s hows features consistent with UC, 
as determined by the procedure performing physician, AND
2. Source: Me dical rec ord documentation of a histopathology report showing features c onsistent 
with UC, as determined by the local pathologist
Note: If a histopathology report is not available, histologic samples can be obtained at the 
screening endoscopy and sent to a local laboratory to confirm d iagnosis of UC before 
proceeding to randomization. The screening endoscopy must show features consistent with 
UC, and medic al records must s till document a clinical diagnosis of UC of at least 
3 months‚Äô durat ion prior to screening.
g) Must have acti ve moderate to severe UC, as defined  by a modified Mayo score of 5 to 
9 points (inclus ive; see APPENDIX 9 ), which incl udes all of the following subscore 
values:
‚Ä¢A stool freq uency (SF) subscore of ‚â• 2, and
‚Ä¢A rectal ble eding (RB) subscore ‚â• 1, and
‚Ä¢A screening  endoscopic (ES) subscore of ‚â• 2 
h) Documentation of an inadequate response, loss of re sponse, or intolerance to a tr eatment 
course of 1 or more of the following standard of ca re medications; specific criteria and 
dosing details a re in APPENDIX 5 :
‚Ä¢Oral 5-amin osalicylic acids (5-ASAs) (eg, mesa lamine, sulfasalazine, olsalazine, or 
balsalazide)
‚Ä¢Corticostero ids (eg, prednisone [or equivalent] or budesonide [or equivalent])
‚Ä¢Immunomo dulators (eg, azathioprine [AZA ], 6-mercaptopurine [6-MP], or 
methotrexate [MTX])
Protocol Amendment No.: 03
Date: 14-Apr-2021 75
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
‚Ä¢Anti-tumor necrosis factor-alpha (TNF-Œ±) agents (eg, infliximab , adalimumab, or 
golimumab)
‚Ä¢Integrin inhibitors (eg, vedolizumab)
‚Ä¢Anti-interleukin (IL)-12/IL-23p40 antibodies (eg, ustekinumab);  subjects can only be 
included if they were intolerant to treatment. Inadequate respo nse or loss of res ponse 
is exclusionary.
i) Subjects currently using concomitant salicylates, probiotics,  or oral corticosteroid 
(‚â§ 20 mg prednisone or equivalent, ‚â§ 9 mg budesonide MMX or equiva lent) at stable doses 
prior to the ra ndomization visit are eligible provided they are on stable dose s for the time 
period specified in Section 7.7.2
3) Age and Reproductive Status
a) N/A per Revised Global Protocol v3.0
b) Women of childbearing potential (WOCBP) must have a negative serum or urine 
pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic 
gonadotropin) within 24 hours prior to the start of study treatment.
c) Women must not be breastfeeding, la ctating, or planning pregna ncy during the study 
period.
d) N/A per Revised Global Protocol v3.0 e) N/A per Revised Global Protocol v3.0f) Azoospermic males are exempt from cont raceptive requir ements. WOCBP who are 
continuously not heterosexually active are also exempt from con traceptive requirements, 
and st ill must  undergo pregnancy testing as described in this section. 
g) Males and females ag es 18 (or age of majori ty) to 80 years, i nclusive, at the time of 
screening
h) WOCBP must agree to follow instructions for method(s) of cont raception for the duration 
of treatment with study t reatment(s) (BMS-986165 or placebo).
Investigators sh all couns el WOCBP on the impo rtance of pregnanc y prevention and the 
implications of an unexpected pregnancy. Investigato rs shall advise on the  use of highly effective 
or less than highly effect ive methods of contraception  (APPENDIX 4 ). 
6.2 Exclusion Criteria
An individual who meets any of the following criteri a will be excluded fro m participation in this 
study:
1) Target Disease
a) N/A per Revised Global Protocol v3.0
b) Current or recent (within 12 weeks prior to the randomization visit) evidence of fulminant 
colitis, abdominal abscess, toxic megacolon, or bowel perforati on
c) History or evidence of any extensive colonic resection, subto tal or total colectomy, with or 
without presence of a stoma or ileoanal pouch. Current need for , or anticipated need for, 
surgical interve ntion for  UC during the study
d) N/A per Revised Global Protocol v3.0
Protocol Amendment No.: 03
Date: 14-Apr-2021 76
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
e) N/A per Revised Global Protocol v3.0
f) Current or recent (within 3 months before the first dose) gast rointestinal disease, including 
gastrointestinal surgery, which could impact the absorption of study treatment, or c urrent 
or recent (within 6 months before the first dose) gastrointestinal resections
g) Previous/current documented diagnosis of CD, indeterminate co litis, ischemic colitis, or 
pseudomembranous colitis other than associated with Clostridium difficile (C. difficile). 
(See Section 6.2  5 )h)Physical and Laboratory Test Fi ndings for specific C. difficile
exclusion criterion.)
h) History of diverticulitis within 60 days prior to the randomi zation visit. (Previous 
diverticulitis that has been su ccessfully t reated with a local standard course of antimicrobial 
therapy is permitted; however, the course of antimicrobial therapy must be completed at least 60 days prior to the  randomization visit.)
i) Current colonic adenomas, dysplasia, or past confirmed coloni c dysplasia that has not been 
eradicated (subjects who have had UC > 8 years should have had a  colonoscopy to screen 
for dysplasia within 1 year pri or to the randomization visit, o r this can be performed as part 
of the screening colonoscopy). A subject with prior history of adenomatous polyps will be 
eligible if the polyps have been completely removed (documented ), and the subject is free 
of polyps and without evidence of dysplasia on histology at randomization.
j) Receiving tube feeding, defined formula diets, or total paren teral alimentation
2) Medical Conditions and History
a) Women who are pregnant or breastfeeding
b) Any major illness/condition or evidence of an unstable clinic al condition (eg, renal, 
hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, immunologic, 
psychiatric), or local active infection/infectious illness that , in the investigator‚Äôs judgment, 
will substantially increase the risk to the subject if he or sh e participates in the study
c) Any major surgery (requiring general anesthesia) within the l ast 30 days prior to the 
randomizatio n visit, or any other major surgery planned during the course o f the study
d) History of bleeding disorders or recent use of anti-pl atelet  or anti-thrombotic agents that in 
the investigator‚Äôs judgment preclude safely performing endoscop ic procedures and biopsy 
within the timeframe outlined in the study protocol
e) Cancer or history of cancer or lymphoproliferative disease wi thin the previous 5 years 
(other than adequately treated cutaneous basal cell or squamous cell carcinoma or resected 
cervix carcinoma in situ with no evidence of recurrence)
f) Class III or IV congestive heart failure, as classified by th e New York Heart Association 
(NYHA) Functional Classification or any recent onset of heart f ailure resulting in NYHA 
Class III/IV symptoms
g) Acute coronary  syndrome (eg, myocardial  infarction, unstable angina pectoris) and/or any 
history of significant cerebrovascular disease (eg, stroke, cer ebral hemorrhage, transient 
ischemic attack) within 24 weeks before screening
h) Female subjects with a breast cancer screen suspicious for ma lignancy, and in whom the 
possibility of malignancy cannot  be reasonably excluded after a dditional clinical, 
laboratory, or other diagnostic evaluations
Protocol Amendment No.: 03
Date: 14-Apr-2021 77
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
i) Significant blood loss (> 500 mL) or blood transfusion within 4  weeks prior to the 
randomization visit
j) Inability to toler ate oral medication
k) Inability to undergo ve nipuncture and/or tolerate venous acce ss
l) Drug or alcohol abuse, as determined by the investigator, wit hin 6 months prior to 
Week 0 (Day 1). (Note: medical marijuana is not allowed.) 
m) Any other sound medical, psychiatric, and/or social reason as determined by the 
investigator
3) Prior/Concomitant Therapy
a) Inability to comply with re strictions and prohibited treatmen ts, as listed in  Section 7.7
b) Previous exposure to BMS-986165 in any study
c) Prior exposure to treatment with TYK2 inhibitorsd) N/A per Revised Global Protocol v3.0e) Failure or loss of response to JAK inhibitors, such as tofaci tinib. Prior exposure is not 
exclusionary.
f) N/A per Revised Global Protocol v3.0g) N/A per Revised Global Protocol v3.0h) Use of topical r ectal treatment with 5-ASA or cor ticosteroid within 2 weeks prior to the 
randomization visit
i) Current use of corticosteroid at a dose of > 20 mg/day for pre dnisone or equivalent or 
> 9 mg/day for budesonide MMX or equivalent
j) N/A per Revised Global Protocol v3.0k) N/A per Revised Global Protocol v3.0l) Previous stem cell transplantationm) Receipt of either lymphocyte apheresis or selective monocyte,  granulocyte apheresis (eg, 
Cellsorba‚Ñ¢) is prohibited within 12 months prior to the randomi zation visit.
n) Use of therapeutic enema or suppository , other than required for ileocolonoscopy, within 
7 days prior to the randomization visit
o) N/A per Revised Global Protocol v3.0 p) Inadequate response or loss of  response to med ications that t arget the same pathway as 
BMS-986165, such as anti-IL-12/IL-23p40 antibodies (eg, ustekin umab, briakinumab) or 
anti-IL-23p19 antibodies (eg, guselkumab, risankizumab, tildrak izumab, brazikumab 
[MEDI2070], and mirikizumab [LY3074828]). However, subjects who  have been exposed 
to the medications listed above, but who have not had a treatme nt failure (ie, an inadequate 
response or loss of res ponse) may be eligible for inclusion. Similarly, subjects who h ave 
experienced intolerance to the medications listed a bove (eg, an i nfusion reactio n) without 
a treatment failure may be eligible for inclusion.
q) Use of other investigational agents within 4 weeks or 5 half- lives, whichever is longer, 
prior to randomization ( APPENDIX 7 ) 
r) Use of immunomodulators (AZA, 6-MP, or MTX) within 4 weeks prior to ra ndomization 
(APPENDIX 7)
Protocol Amendment No.: 03
Date: 14-Apr-2021 78
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
s) Use of a biologic agent within the minimum washout period prio r to randomization, as 
listed in APPENDIX 7
t) Fecal transplant is considered an ‚Äúinvestigational‚Äù biologic agent, and the washout period 
must be ‚â• 4 weeks prior t o the randomization visit.
4) Infections/Immune-related Exclusions
a) Evidence of active or latent tuberculosis (TB), as follows:
‚Ä¢History of active TB prior to the s creening visit, regardless o f completion of adequate 
treatment
‚Ä¢Has signs or symptoms of active TB as judged by the investigato r
‚Ä¢A chest x-ray obtained during the screening period or anytime wi thin 6 months before 
screening, with documentation, with evidence of current active or old active 
pulmonary TB
‚Ä¢Latent TB infection (LTBI) defined as positive IFNŒ≥ release ass ay (IGRA) such as 
QuantiFERON¬Æ - TB Gold, QuantiFERON¬Æ - TB Gold Plus, or T-Spot¬Æ at s creening, 
or other diagnostic test in the absence of clinical manifestati ons
Note: such subjects ma y be eligible i f (1) there are no current signs or symptoms 
of active TB and (2) the subject has received adequate documente d treatment 
for LTBI within 5 years of screening OR has i nitiated  prophylact ic treatment 
for LTBI per local guidelines and is rescreened now after 1 mont h of treatment. 
The subject must agree to complete a locally recommended course  of treatment 
for LTBI to continue in the study. 
‚Ä¢An indeterminate IGRA result at screening with no signs or symptoms of active TB
‚Ä¢Note: A subject with an indeterminate IGRA test result must be retested for 
confirmation. If the second resu lt is again indeterminate, the subject will be excluded 
from the study. If the sec ond result is positive, the subject should be treated as having  
LTBI. If the second result is negative, the subject may be elig ible provided no other 
exclusion criterion for TB is met.
b) N/A per Revised Global Protocol v3.0
c) N/A per Revised Global Protocol v3.0d) Positive for human immunodeficiency virus (HIV) by antibody t esting (HIV-1 and 2 Ab) 
at screening. NOTE: Subjects who are newly found to be HIV-posi tive should be directed 
to appropriate follow-up. 
e) Currently on any therapy for chronic infection (eg, pneumocys tis, cytomegalovirus, herpes 
simplex, herpes zoster, invasive bacterial or fungal infections , or atypical mycobacteria)
f) History of congenital or acquired immunodeficiencyg) N/A per Revised Global Protocol v3.0h) Previous history of herpes zoster, herpes simplex, or influen za infection within 12 weeks 
before the first dose of study treatment or a history of dissem inated/complicated herpes 
zoster infection (multidermatomal involvement, ophthalmic zoste r, central nervous system 
involvement, or post-herpetic neuralgia)
Protocol Amendment No.: 03
Date: 14-Apr-2021 79
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
i) Administration of a live vaccine within 90 days or an inactiv ated vaccine within 30 days 
before the first dose of study t reatment administration. Heat-k illed, or otherwise inactivated 
or protein vaccines (eg, influenza and pneumococcal vaccines) m ay be received at any time 
on study. Furthermore, live vaccines s hould not be used during the study and within the 
2 months following last dose, and any other inactivated vaccines  (eg, tetanus, etc.) should 
be used according to local guidelines during the treatment period. 
j) Evidence of, or positive test for, hepatitis B virus (HBV) at  screening as defined per 
APPENDIX 8 .
k) Evidence of, or positive test for, hep atitis C virus (HCV) at screening. A positive test for 
HCV is defined as:
(1) Positive for HCV antibody (anti-HCV) and
(2) Positive via a confirmatory test for HCV (eg, detectable HCV  R N A ,  H C V  
polymerase chain reaction) (see APPENDIX 8 ).
l) Known serious infection, defined as any infection requiring h ospitalization or treatment 
with parenteral (intramuscular [IM] or IV) an timicrobial agents (eg, antibiotics, antiviral, 
antifungal, or antiparasitic agents) within 30 days of the firs t dose of study treatment, or 
completion of oral antimicrobial ag ents within 2 weeks of the f irst dose of study treatment. 
Antibiotics used to cover a procedure such as endoscopy would not exclude the subject.
(1) In the case of prior SARS-CoV-2 infection, symptoms must hav e completely 
resolved 4 weeks prior to screening and based on investigator as sessment in 
consultation with the medical m onitor, there must be no sequela e that would place 
the participant at a higher risk of receiving BMS-986165. See Section 9.8 for 
additional information regarding retesting subjects who have pr ior SARS-CoV-2 
infection.
5) Physical and Laboratory Test Findings
a) Evidence of organ dysfunction or any clinically significant d eviation from normal in 
phys ical examination, vital signs, ECG, chest x-ray, or clinical laboratory determinations 
beyond what is consistent with the target population
b) Clinically significant a bnormalities on chest x-ray or ECG
c) N/A per Revised Global Protocol v3.0d) N/A per Revised Global Protocol v3.0e) Any other significant laboratory a bnormalities that, in the opinion of the investigator, might 
place the subject at unacceptable risk for participation in thi s study 
f) Clinically significant abnormalities in laboratory testing including:
‚Ä¢Serum alanine aminotransferase (ALT) > 2√ó upper limit of normal  (ULN) 
‚Ä¢Serum aspartate aminotransferase (AST) > 2√ó ULN 
‚Ä¢Serum total bilirubin > 2√ó ULN (E xception: subjects can be included if they have a 
confirmed diagnosis of Gilbert Syndrome that is documented, and  when other causes 
of isolated bilirubin elevation have been excluded.)
‚Ä¢Alkaline phosphatase > 2.5√ó ULN
Protocol Amendment No.: 03
Date: 14-Apr-2021 80
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
‚Ä¢Serum creatinine > 2√ó ULN and/or renal impairment based on an estimated glomerular 
filtration rate (eGFR) <45 mL/min (calculated using the Modific ation of Diet in Renal 
Disease [MDRD] equation)
‚Ä¢Hemoglobin level < 9.0 g/dL 
‚Ä¢Absolute white blood cell count < 3000/mm3 
‚Ä¢Absolute lymphocyte count < 750/mm3
‚Ä¢Neutrophil count < 1000/mm3
‚Ä¢Platelet count  < 100,000/mm3 
g) Positive stool culture for enteric pathogens (not including f lora that are considered 
commensal within a study region) at screening visit; subjects m ay rescreen 30 days after 
completion of a standard treatment course with antimicrobial agents without recurrence of 
clinical symptoms.
h) Stool positive for C. difficile toxin at screening visit; subj ects may be rescreened 30 days 
after completion of an institutional standard of care course wi th antibiotics, and subsequent 
negative testing for C. difficile stool toxin and a C. difficil e nucleic acid amplification test. 
Test results should be discussed with the medical monitor prior  to rescreening.
6) Allergies and Adverse Drug Reaction
a) N/A per Revised Global Protocol v3.0
b) History of any significant drug allergy (eg, anaphylaxis) or significant adverse drug 
reaction (eg, hepatotoxicity)
7) Other Exclusion Criteria
a) Prisoners or subjects who are involuntarily incarcerated. (Note: under certain specific 
circumstances a person who has been imprisoned may be included or permitted to continue 
as a subject. Strict conditions apply, and Bristol-Myers Squibb approval is required.)
b) Subjects who are compulsorily detained for treatment of eithe r a psychiatric or physical 
(eg, infectious disease) illness
Eligibility criteria for this study have been carefully conside red to ensure the safety of the study 
subjects and that the results of the study can be used. It is i mperative that subjects fully meet all 
eligibility criteria.
6.3 Randomization Criteria
Eligible subjects must meet the fo llowing criteria  on Week 0 (Day 1) before randomization and 
the first dose of study treatment: 
1) The subject continues to satisfy all eligibility criteria 
2) Previous therapy must follow the rules outlined below:
a) Dose stabilization: 
‚Ä¢5-ASAs must be at stable doses for at least 2 weeks prior to ra ndomization.
‚Ä¢Probiotics must be at stable doses for at least 2 weeks prior t o randomization.
‚Ä¢Prednisone ‚â§ 20 mg QD PO (or equivalent) or budesonide MMX ‚â§ 9 mg QD PO (eg, 
Uceris extended release or equivalent) must be stable for at lea st 2 weeks prior to 
randomization.  
Protocol Amendment No.: 03
Date: 14-Apr-2021 81
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
b) Washout periods for immunomo dulator and biologic treatments: Subjects must comply 
with the washout periods outlined  in APPENDIX 7 .
6.4 Lifestyle Restrictions
No restrictions are required.
Smoking can have an influence on the severity of UC disease sym ptoms. Consequently, use of 
tobacco products w ill be assessed at each study visit. Use of a nicotine p atch should be recorded 
as a concomitant medication.Study treatment may be taken without regard to meals. However, subjects are required to fast for 
a minimum of 10 hours before visits on which fasting lipid and fa sting glucose samples will be 
drawn; at 2 of these visits (Week 0 [Day 1] and Week 12 [Day 85])  
.
6.5 Screen Failures
Screen failures are defined as subjects who consent to particip ate in the clinical study but who are 
not subsequently randomized in the study. A minimal set of scre en failure information is required 
to ensure transparent reporting of screen failure subjects, to meet the Consolidated Standards of
Reporting Trials (CONSORT) publishing requirements, as applicab le, and to respond to queries 
from regulatory authorities. Minimal information includes date of consent, demography, screen 
failure details, eligibility criteria, and any SAEs. 
6.5.1 Retesting During the Screening Period and Rescreening 
This study permits the rescreening of a subject who has been de emed as ineligible (screen failure) 
during the screening period (ie, the subject has not been rando mized/has not been treated). The 
subject must be re-consented.
For laboratory parameters and/or assessments ( Table 1 ) that initially do not meet eligibility 
requirements, a single retest within the 28-day screening perio d is permitted in an effort to find all 
possible well-qualified subjects, unless otherwise noted. Consu ltation with the medical monitor 
may be needed to identify whether repeat testing of any particu lar parameter is clinically relevant. 
A subject can only be rescreened 1 t ime (ie, if the sub ject fails 1 rescreening attempt, no additional 
rescreening is allowed). If a subject is rescreened, the endoscopy previously performed at the 
initial screening may be used for rescreening purposes. This is permitted if the 
randomization following rescreening occurs within 14 days of th e initial screening 
endoscopy. 
NOTE: Use of the initial screening endoscopy for rescreening pu rposes should be discussed 
with the medical monitor before randomization occurs. 
Duration of existing treatments and required discontinuation pe riods shall be considered relative 
to the successful screening visit and/or rando mization. 
If a subject is positive for C. difficile toxin, they can be rescreened 30 days after completing a full 
course of standard treatment for C. difficile colitis and subsequently testing negative for C. difficile
Protocol Amendment No.: 03
Date: 14-Apr-2021 82
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
stool toxin and a C. difficile nucleic acid amplification test. The subject must be re-consent ed and 
will be assigned a new identif ication number , and a full screening visit must be performed again. 
The most current result prior to randomization is the value by which study inclusion will be 
assessed, as it represents the subject‚Äôs most current clinical state. 
7 TREATMENT
Study treatment is defined as any investigational treatment(s),  marketed product(s), placebo or 
medical device intended to be administered to a study subject a ccording to the study randomization 
or treatment allocation. 
An investigational product (IP), also known as an investigational medicinal product (IMP) in some 
regions, is defined as a pharmaceutical form of an active substance or placebo being tested or used 
as a reference in a clinical study, including products already with a marketing authorization but 
used or assembled (formulated or packaged) differently than the  authorized form , or used for an 
unauthorized indication, or when used to gain further informati on about the authorized form.
IM011024 consists of IP study t reatments BMS- 986165 and placebo  (see Table 9 ). Information 
about the pharmacology and previous experience with BMS-986165 is provided in Section 3.2.1
and Section 3.2.2 .
Other medications used as support or escape medicati on for preventative,  diagnostic, or therapeutic 
reasons, as components of the standard of care for a given diag nosis, may be considered as non-IPs.
Table 9 Study Treatments for IM011024
Product 
Description/
Class and 
Dosage FormPotency IP/
Non-IPBlinded or 
Open-labelPackaging/Appearance Storage 
Conditions
(per label)
BMS-986165 
oral tablet6m g  
(as the 
free base)IP Blinded Bottle containing 68 (6 mg) 
active tablets required for 
daily dosingStore 15¬∞ to 25¬∞C; 
Store in a tightly closed container; Protected from 
light
Placebo 
matching BMS-986165 
oral tabletNot 
applicableIP Blinded Bottle containing 68 (6 mg) 
placebo tablets required for daily dosingStore 15¬∞ to 25¬∞C; 
Store in a tightly closed container; Protected from
light
BMS-986165 oral tablet6m g  
(as the 
free base)IP Open-label Bottle containing 68 (6 mg) 
active tablets required for daily dosingStore 15¬∞ to 25¬∞C; 
Store in a tightly closed container; Protected from 
light
IP = investigational product
Protocol Amendment No.: 03
Date: 14-Apr-2021 83
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
7.1 Treatments Administered
During the induction peri od, sub jects w ill take BMS- 986165 6 mg BID or placebo BID over 
12 weeks ( Section 5.1.2 ), once in the morning and once in the evening. Dose information  for each 
treatment  group in the inducti on period is provided in Table 10.  
Study treatment w ill be s upplied in bottles, each containing 68 film-coated active or placebo 
tablets. Bottles are to be stored at 15 C to 25¬∞C and protected from light.
If a subject forgets a dose, but remembers within 4 hours of the expected dose, the dose should be 
taken. If it is past 4 hours, that dose should be missed, and t he next expected dose should be taken 
at the usual time.
Study treatment will be administered in the maintenance period, as described in  Section 5.1.3 and 
illustrated in Figure 1.
Clinical Responders at Week 12: S ubjects who achieve a clin ical response at Week 12 ( Table 5 ) 
who enter the double-blind, placebo-controlled maintenance peri od, w ill take the same blinded 
study treatment (BMS-986165 6 mg BID or placebo BID) that was as signed during the induction 
period. 
Clinical Nonresponders at Week 12 : Subjects who do not achieve a clinical response at Week 12 
(Table 5 ) may be eligible to receive BMS-986165 6 mg BID in the open-lab el study arm, 
regardless of the initial treatment regimen received during the  12-week induction period.
Study treatment will be administered in the OLE period as descri bed in Section 5.1.4 and 
illustrated in Figure 2.
Table 10 Selection and Timing of Dose
Study Treatment Unit dose 
strengthDosage formulation
Frequency of AdministrationRoute of 
Administration
6 mg BID 
BMS-9861656 mg 1 active tablet; BID Oral
Placebo BID Not applicable 1 placebo tablet; BID Oral
BID = twice daily
7.2 Method of Treatment Assignment
At the time of the screening vi sit, immediately a fter informed consent is obtained and before any 
study-related procedures are performed, the investigative site will access the interactive response 
technology (IRT) system for assignment of the subject number. T his number will be unique across 
all sites. All subjects who sign informed consent will be assigned sequential subject numbers. The 
subject number may not be used for any other subject. If a potential subject is rescreened, they will be given a new subject number. 
Protocol Amendment No.: 03
Date: 14-Apr-2021 84
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Eligible subjects w ill be centr ally randomized using IRT at a 2:1 randomization ra tio to receive 
oral treatment during the induction period with either BMS-9861 65 6 mg BID or placebo BID, 
according to a computer-generated block randomization scheme and  in accordance with 
stratification criteria. Rando mization numbers will be assigned  prior to dosing. Randomization 
will be stratified by cort icosteroid use (yes/ no) and prior exposure to bi ologics indicated for 
treatment of UC; biologics includes JAK inhibitors f or stratification purposes. Stratification 
groups: no prior biologic exposure (0), exposure to 1 biologic ( 1), or exposure to mo re than 1 (> 1) 
biologic.
Before the st udy is init iated, each user (at investigative sites) will receive log-in i nformation and 
directions on how to access the IRT. Study treatment will be di spensed at study visits as shown in 
Section 2 (Schedule of Activities). 
Subjects who have completed the 12-week induction period w ill be eligible to enter the 
maintenance peri od. Their assigned maintenance treatment w ill be based on whether or not they 
achieved clinical response at Week 12 ( Section 9.1.1 ). Responders will continue on their assigned 
double-blind treatment wh ile nonres ponders will be given the option to switch to open-la bel 
BMS-86165 6 mg BID through Week 52 or may choose to discontinue the study.
For subjects who are entered int o the open-label portion of the  study, BMS- 986165 w ill be supplied 
in bottles of 6 mg tablets and subjects w ill take the requisite number of tablets for their daily 
dosing. These bottles will be assigned through the IRT to each subject during their dosing visits. 
Subjects who have completed the 52-week maintenance period will  be eligible to enter the 52-week 
open-label extension period. Eligibility will be based on the i nvestigator's assessment of clinical 
benefit at Week 52 ( Section 5.1.4 ). 
7.3 Blinding
7.3.1 Maintaining the Blind
Blinded treatment assignments will be managed using IRT. 
All tablets (BMS-986165 6 mg and placebo) are ident ical in app earance and will be supplied in 
bottles (see Section 7.1 ). Investigative site staff, Sponsor and designee personnel, and subjects and 
their families will remain blinded to treatment assignments. 
7.3.2 Circumstances for Unblinding
Blinding of treatment assignment is critical to the integrity o f this clinical study. However, in the 
event of a medical emergency or pregnancy in an individual subj ect in which knowledge of the IP
is critical to the sub ject‚Äôs management, the blind for that subject may be broken by the investigator. 
The subject‚Äôs safety takes priori ty over any other consideratio ns in determining if a treatment 
assignment should be unblinded.
Before breaking the blind of an individual subject‚Äôs treatment,  the investigator should determine 
that the unblinded information is necessary, ie, that it w ill alter the sub ject‚Äôs immediate 
management. In many cases, particularly when the emergency is clearly not related to the IP, the 
Protocol Amendment No.: 03
Date: 14-Apr-2021 85
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
problem may be properly managed by assuming that the subject is receiving activ e product. It is 
highly desirable that the decision to unblind tr eatment assignment be discussed with the medical 
monitor, but the investigator always has ulti mate authority for the decision to unblind. The 
Principal Investigator should only call in for emergency unblinding AFTER the decision to 
discontinue the subject has been made.
In case of an emergency, the investigator has unrestricted acce ss to randomization information via 
IRT and is capable of breaking the blind through the IRT system  without prior approval from the 
Sponsor. After the unblinding, the investigator shall notify th e medical monit or and/or study 
director. The method of unblinding for emergency purposes is described in the IRT manual. 
Subject and unblinded treatment information and the reason for the blind being broken, must be 
recorded on the appropriate study status page of the electronic  case report form (eCRF). After 
unblinding via IRT, the investigator shall notify the medical m onitor.
In cases of accidental unblinding, contact the medical monitor,  and ensure every attempt is made 
to preserve the blind. Any request to unblind a subject for non emergency purposes must be 
discussed with the medical monitor.
7.4 Dosage Modification and/or Interruption
There is no provision for dose modif ication of study tr eatment. Titration of corticosteroid and its 
use as rescue therapy are discussed in Section 5.1.5.2 and Section 5.1.5.3 . Modification of other 
background UC therapies or dose regimens is not permitted during  study participation. Subjects 
should continue to tak e their assigned treatment even if they e xperience flares and/or are unable to 
taper their corticosteroid dose, unless any of the criteria in Section 8.1 are met. If a subject‚Äôs 
clinical condition worsens (eg, flares) during the induction pe riod to the extent that rescue therapy 
is required based on the investigator‚Äôs judgment, the subject m ust discontinue study treatment (IP 
or placebo) for appropriate alternative available treatment. 
If treatment is interrupted for a sub ject due to an AE, study treatment can be restarted in 
consultation with the medical monitor.
7.5 Preparation/Handling/Storage/Accountability
The IP should be stored in a secure area according to local regulations. It is the responsibility of 
the investigator to ensure that IP is only dispensed to study su bjects. The IP must be dispensed 
only from official study sites by authorized personnel accordin g to local regulations.
The product storage manager should ensure that the study treatm ent is stored in accordance with 
the environmental conditions (temperature, light, and humidity)  as determined by BMS. If 
Protocol Amendment No.: 03
Date: 14-Apr-2021 86
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
concerns regarding the quality or appearance of the study treat ment arise, the study tr eatment 
should not be dispensed and BMS should be contacted immediately .
Study treatment not supplied by BMS will be stored in accordanc e with the package insert.
IP documentation (whether supplied by BMS or not) must be mainta ined that includes all processes 
required to ensure drug is accurately administered. This includ es documentation of drug storage, 
administration and, as applicable, storage temperatures, recons titution, and use of required 
processes (eg, required diluents, administration sets).
Further guidance and information for final disposition of unuse d study treatment are provided in 
APPENDIX 2 and the Study Reference Manual.
7.5.1 Retain ed Samples for Bioavailability/Bioequivalence
Not applicable.
7.6 Treatment Compliance
Study treatment comp liance will be monitored as indicated in th e Schedule of Activities 
(Section 2 ) using standard drug accountability procedures (comparing the number of tablets 
returned to number dispensed, considering the expected regimen and any reported missed doses). 
Drug accountability will be reviewed by the investig ative site staff at each visit to confirm 
treatment compliance. Site staff w ill discuss any discrepancies with the subject and remind the 
subject of the importance of compliance with the assigned regim en. A real-time monitoring 
platform may be used.
7.7 Concomitant Therapy
All medications taken from within 4 weeks before the first dose  of study treatment un til 30 days 
after the last dose of IP or last visit (whichever comes later) must be recorded on the eCRF.
Other than existing treatment for UC (with restrictions as desc ribed in the eligibility criteria 
[Section 6 ]), concomitant medications (prescription, over-the-counter [OT C], or herbal) should be 
administered during the study only if they are prescribed for treatment of specific medical reasons 
separate from UC.
7.7.1 Prohibited and/or Restricted Treatments
Restrictions and prohibitions on prior and concomitant medications are summar ized in Table 11 .
Table 11 Prohibited and/or Restricted Treatments
Prohibited Treatments 
Medication/Formulation Notes 
BMS-986165 or other TYK2 inhibitors Prior exposure is prohibited
Corticosteroids: oral > 20 mg/day prednisone (or 
equivalent) or > 9 mg/day budesonide MMX (or 
equivalent)Prohibited during the study; subjects are allowed to reduce 
their oral corticosteroid dose to ‚â§ 20 mg/day ( Section 7.7.2 ) 
Protocol Amendment No.: 03
Date: 14-Apr-2021 87
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Table 11 Prohibited and/or Restricted Treatments
Prohibited Treatments 
Medication/Formulation Notes 
and be rescreened for study entry. Only 1 rescreening is 
allowed ( Section 6.5.1 )
Corticosteroids: IV, IM, intra-articular, intrabursalProhibited during the study; use of IV corticosteroid is also 
prohibited within 2 weeks prior to the screening period
Corticosteroid or 5- ASA/top ical rectal treatmentProhibited within 2 weeks of the randomization visit and during study
Immunomodulatory drugs Prohibited within required washout period s (APPENDIX 7 )
Biologic drugs Prohibited within required washout periods ( APPENDIX 7)
Live vaccinesProhibited 90 days prior to the randomization visit; during the induction period, maintenance period, or OLE; or within 
the 2 months after the last dosea
ApheresisReceipt of either lymphocyte apheresis or selective 
monocyte, granulocyte apheresis (eg, Cellsorba‚Ñ¢) is 
prohibited within 12 months prior to the randomization visit
Investigational agentsProhibited within 4 weeks or 5 half-lives (whichever is longer) before the randomization visit
Over-the-counter medications orherbal preparations Prohibited within 1 week prior to the randomization visit; 
any exceptions to this must be cleared by the medical 
monitor
Restricted Treatments
Medication Notes 
Corticosteroids/topical or inhaled to treat non-UC medical conditionsAllowed but must be discussed with the medical monitor
Systemic corticosteroids (< 7 days in duration) to treat non-UC medical conditions Allowed but must be discussed with the medical monitor to 
determine if the intercurrent illness affects the safety of the  
subject, or if the corticosteroid treatment is likely to 
confound efficacy assessment
Nonsteroidal anti-inflammatory drugs (NSAIDs) for 
indications other than UC-related pain (eg, 
headache)May be used on an as-needed basis during the study, but 
use is not recommended. If a subject enters the study on a stable dose of NSAIDs, they may continue this dose throughout the study after discussing with the medical monitor. NSAID dosing may be decreased or discontinued 
if due to NSAID toxicity
5-ASA = 5-aminosalicyclic acid; COVID-19 = coronavirus disease 2019; IM = intramuscular; IV = intravenous;
MMX = Multi-Matrix System; NSAID = nonsteroidal anti-inflammatory dr ug; OLE = open-label extension; TYK2 = 
tyrosine kinase 2; UC = ulcerative colitis
aHeat-killed (or otherwise inactivated) or protein or subunit va ccines such as influenza and pneumococcal vaccines, 
nucleic acid vaccines that do not encode potentially infectious  virus, and replication-incompetent recombinant 
vector vaccines may be received at any time during the study. Th e efficacy of  vaccination in sub jects who are 
receiving BMS-986165 is unknown. For COVID-19 vaccine informati on refer to  APPENDIX 19 .
Protocol Amendment No.: 03
Date: 14-Apr-2021 88
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
7.7.2 Existing Therapies for Ulcerative Colitis
Use of concomitant 5- ASAs, probiotics, and oral corticosteroi ds (prednisone ‚â§ 20 mg/day or 
equivalent, or budesonide MMX [‚â§ 9 mg/day or equivalent]) is permit ted. All subjects will 
continue their existing UC treatment(s) during the study (provided the treatment complies with the 
eligibility criteria; Section 6 ), unless dose modification or discontinuation is required for subject 
safety reasons, as follows:
‚Ä¢5-ASAs: Must be at stable doses for at least 2 weeks prior to th e randomization visit; stable 
doses must be maintained during t he induction pe riod. D uring the maintenance period, a dose 
decrease is permitted if due to moderate to severe drug-related  toxicity.
‚Ä¢Probiotics: Must be at stable doses for at least 2 weeks prior t o the randomization visit; stable 
doses must be maintained during the induction period. During th e maintenance period, a dose 
decrease is permitted if due to moderate to severe probiotics r elated toxicity.
‚Ä¢Oral corticosteroids: Prednisone ‚â§ 20 mg QD PO (or equivalent) o r budesonide
MMX ‚â§ 9 mg QD PO (eg, Uceris extended release or equivalent) must be  stable for at least 
2 weeks prior to the randomization visit; stable doses must be ma intained during the induction 
period ( Section 5.1.5.1 ). Corticosteroid tapering must occur in the maintenance period , as 
described in Section 5.1.5.2.
‚Ä¢If a subject has recently st opped taking a ny of the above medications (5-ASAs, probiotics, oral 
corticosteroids), he/she must have been stopped for ‚â• 4 weeks pr ior to the randomization visit.
‚Ä¢Prior exposure to immunomodulator and bio logic treatments: Sub jects must comply with the 
washout periods outlined in Section 5.1.1 and APPENDIX 7 . 
7.8 Treatment After the End of the Study
At the conclusion of the study, subjects who continue to demonst rate clinical benefit will be 
eligible to receive BMS-supplied study treatment. Study treatme nt will be  provided via an 
extension of the study, a rollover study requiring approval by responsible h ealth aut hority and 
ethics committee or through another mechanism at the discretion  of BMS.
BMS reserves the right to terminate access to BMS supplied stud y treatment if a ny of the following 
occur: a) the study is terminated due to safety concerns; b) th e development of BMS-986165 is 
terminated for any reason, including but not limited to lack of eff icacy and/or not meeting the 
study objectives; c) the subject can obtain med ication from a government sponsored or private 
healt h program. In all cases BMS will follow local regulations.
8 DISCONTINUATION CRITERIA
8.1 Discontinuation from Study Treatment
Subjects MUST discontinue IP (and non-IP at the discretion of t he investigator) for any of the 
following reasons: 
‚Ä¢Subject‚Äôs request to stop study treatment. Subjects who request  to discontinue study treatment 
will remain in the study and must continue t o be followed for p rotocol-specified post-treatment 
Protocol Amendment No.: 03
Date: 14-Apr-2021 89
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
follow-up procedures ( Section 5.1.4.1 ). The only exception to this is when a subject 
specifically withdraws consent for any further contact with him /her or persons previously 
authorized by subject to provide this information.
‚Ä¢Subject meets 1 of the following criteria for laboratory abnorm alities in 2 sequent ial laboratory 
measurements taken 3 to 5 days apart: 
‚Ä¢White blood cell count < 1.5 √ó 109/L (< 1,500/mm3)
‚Ä¢Absolute neutrophil count < 0.75 √ó 109/L (< 750/mm3)
‚Ä¢Absolute lymphocyte count < 0.5 √ó 109/L (< 500/mm3)
‚Ä¢Hemoglobin < 8.0 g/dL or a decrease of > 30% from baseline
‚Ä¢Platelet count < 75 √ó 109/L (< 75,000/mm3)
‚Ä¢An increase in serum creatinine > 50% over the average of screen ing and baseline 
(Week 0/Day1) values and an absolute increase in serum creatinine  > 0.5 mg/dL 
(> 44.2 Œºmol/L)
‚Ä¢Creatine kinase elevations > 10 √ó ULN, unless the causality is k nown not to be medically 
serious (eg, exercise induced)
‚Ä¢Subject who develops a serious infection during the study defin ed as any infection (viral, 
bacterial, and fungal) requiring pare nteral antimicrobial thera py, hospitalization for treatment, 
or meeting other criteria that require the infection to be clas sified as an SAE
‚Ä¢Any drug-related rash or hypersensitivity reaction (eg, anaphyl axis, angioedema, urticaria, 
Stevens-Johnson syndrome, Drug Rash with Eosinophilia and Systemic Symptoms [DRESS], 
Toxic Epidermal Necrolysis [TEN]) deemed by the investigator to  be severe or life threatening
‚Ä¢Any clinical AE, laboratory abnormality, or intercurrent illnes s which, in the opinion of the 
investigator, indicates that continued participation in the stu dy is not in the best interest of the 
subject
‚Ä¢Termination of the study by BMS
‚Ä¢Loss of ability to fr eely provide consent through imprisonment or involuntarily inca rceration 
for treatment of either a psychiatric or physical (eg, infectio us disease) illness
‚Ä¢Unblinding of a subject‚Äôs treatment assignment for any reason (emergency or nonemergency)
‚Ä¢Inability or failure to comply with protocol requirements
‚Ä¢Pregnancy, positive pregnancy test, or subject expresses an int erest in becoming pregnant 
(Refer to Section 9.2.5 Pregnancy)
‚Ä¢Requirement for any rescue therapy during the induction period
‚Ä¢Requirement for additional rescue therapy during the maintenanc e period, other than as 
specified in Section 5.1.5.2
‚Ä¢Requirement for any rescue therapy during the open-label extens ion period
‚Ä¢Subject meets any of the criteria  for treatment failure defined  in Section 5.1.6
‚Ä¢Abnormal liver tests suggestive of drug-i nduced liver injury (DILI), as defined Section 9.2.7, 
or if the investigator believes that it is in the best interest  of the subject
Protocol Amendment No.: 03
Date: 14-Apr-2021 90
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Refer to the Schedule of Activities  (Section 2, Table 4 ) for data to be collected at the time of 
treatment discontinuation and follow-up and for any further eva luations that would be completed.
All subjects who discontinue study  treatment should comply with  protocol-specified follow-up 
procedures as outlined in the Schedule of Activities ( Section 2 ). The only exception to this 
requirement is when a subject withdraws consent for all study p rocedures including post-treatment 
study follow-up or loses the ability to consent freely (ie, is imprisoned or involuntarily incarcerated 
for the treatment of either a psychiatric or physical illness). Repl acement of subjects is not 
permitted ( Section 8.4 ). 
If study treatment is discontinued prior to the subject‚Äôs compl etion of the study, the reason for the 
discontinuation must be documented in the subject‚Äôs medical rec ords and entered on the 
appropriate eCRF page.
8.1.1 Post-Study Treatment Study Follow-Up
Subjects who discontinue study treatment will continue to be fo llowed for 28 days post last dose 
of study medicatio n, or longer, as required, and in line with Section 9.2.3 (Follow-up of AEs and 
SAEs).
8.2 Discontinuation from the Study
Subjects who request to discontinue study treatment ( Section 8.1 ) will remain in the study and 
continue to be followed for protocol-specified post-treatment fol low-up procedures. The only 
exception to this is when a subject specifically withdraws cons ent for any further contact with 
him/her or persons previously authorized by subject to provide this information. 
‚Ä¢Subjects s hould notify the investigator of the decision to withdraw consent from future follow-
up in writing, whenever possible.
‚Ä¢The withdrawal of consent should be explained in detail in the medical rec ords by the 
investigator and entered on the appropriate eCRF page.
‚Ä¢In the event that vital status (whether the subject is alive or  dead) is being measured, publicly 
available information should be used to determine vital status only as appropriately directed in 
accordance with local law.
‚Ä¢If the subject withdraws consent for disclosure of future information, the Sponsor may retain 
and continue to use any data collected before such a withdrawal  of consent.
8.2.1 Temporary Discontinuation
The following criteria for temporary interruption of study trea tment apply:
‚Ä¢For those subjects who present with signs and/or symptoms of CO VID-19 during the study, 
the study treatment should be temporarily interrupted wh ile the sub ject undergoes diagnostic 
testing for SARS-CoV-2 (see Section 9.8).
‚Ä¢Study treatment must be temporar ily interrupted f or subjects wh o test positive for 
SARS-CoV-2 until complete recovery (if symptomatic), and a negat ive molecular test result is 
Protocol Amendment No.: 03
Date: 14-Apr-2021 91
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
obtained. Study treatment may be restarted at investigator disc retion following consultation 
with the BMS medical monitor/designee provided that the subject  meets the cri teria outlined 
in Section 9.8.
8.3 Lost to Follow-Up
‚Ä¢All reasonable efforts must be made to locate subjects to deter mine and report their ongoing 
status. This include s follow-up with pers ons authorized by the subject.
‚Ä¢Lost to follow-up is defined by the inability to reach the subj ect after a minimum of 
3documented phone calls, faxes, or emails as well as lack of res ponse by subject to 1 registered 
mail letter. All attempts should be documented in the subject‚Äôs  medical records.
‚Ä¢If it is d etermined that the subject has died, the site will use permissi ble local methods to obtain 
date and cause of death.
‚Ä¢If investigator‚Äôs use of third-party representative to assist i n the follow- up portion of the study 
has been included in the sub ject‚Äôs informed consent, then the i nvestigator may use a Sponsor 
retained third-party representative to assist site staff with o btaining subject‚Äôs contact 
information or ot her public vital status data necessary to comp lete the follow- up porti on of the 
study. 
‚Ä¢The site staff and representative will consult publicly availab le sources, such as public h ealth 
registries and databases, to obtain updated contact information .
‚Ä¢If after all attempts, the sub ject remains lost to fo llow-up, then the last known alive date as 
determined by the investigator should be re ported and documented in the subject‚Äôs medical 
records.
8.4 Replacement of Subjects
Subject replacement is not permitted.
8.5 Discontinuation of Study Conduct/Study Stopping Rules
There will be a DMC to provide oversight of the safety in this trial as outlined in Section 5.1.7 of 
the protocol. The DMC is responsible for assessing the ongoing acceptability of the benefit/risk 
profile for the study  drug in an unblinde d manner. Subjects, investigators, site sta ff, and Sponsor 
all remain blinded to study treatment throughout the conduct of  the trial. 
The DMC will review unblinded study treatment information and s afety data to  adjudicate study 
treatment relatedness and to mak e a recommendation regarding the appropriateness of continuing 
the study, with or without study modifications, or stopping the  study under the following 
circumstances, which are not clearly related to the underlying UC:
‚Ä¢Two or more subjects experience an SAE of the same preferred te rm and that is considered 
related to the study treatment by the investigator (for example , not explained by intercurrent 
medical condition or concomitant medication)
‚Ä¢Two or more sub jects are discontinued due to the same laborator y abnormality as defined by 
criteria in  Section 8.1
Protocol Amendment No.: 03
Date: 14-Apr-2021 92
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Full details of the DMC data review can be found in the DMC Cha rter.
9 STUDY ASSESSMENTS AND PROCEDURES
Study procedures and timing are summarized in the Schedule of Activities ( Section 2 ). Waivers or 
exemptions from protocol-required evaluations are not allowed.
All immediate safety concerns must be discussed with the medica l monitor immediately  upon 
occurrence or awareness to determine if the subject should cont inue or discontinue treatment.
Adherence to the study design requirements, including those spe cified in the Schedule of Activities 
(Section 2 ), is essential and requ ired for study conduct.
All screening evaluations must be completed and reviewed to con firm that potential subjects meet 
all eligibility criteria before ra ndomization. The investigator will maintain a screening log to record 
details of all subjects screened and to confirm eligibility or record reasons for screening failure, as 
applicable.Procedures conducted as part of the subject‚Äôs routine clinical management (eg, blood count) and 
obtained before signing of inform ed consent may be utilized for  screening or baseline purposes 
provided the procedure meets the protocol-defined criteria and has been performed with in the 
timeframe defined in the Schedule of Activities ( Section 2 ).
The study data includes all the i nformation that is collected as a result of the study, includin g 
subject demographics, disease characteristics (eg, Montreal cla ssification), clinical information, 
blood tests,  endoscopic videos, intestinal biopsies obtained d uring endoscopy, and 
other tests listed in Section 2 . Study data collected during this study w ill be used to help understand 
how BMS-986165 works in people with UC and related h ealth c onditions. The study data may 
also be used to help understand the biology of UC and related h ealth c onditions, study test 
performance i n people with UC, and for other relevant health research relati ng to BMS-986165 or 
these health conditions.
9.1 Efficacy Assessments
Every effort must be made to ensure that the same evaluator(s) complete the assessment for each 
subject. If the evaluator(s) is unable to complete the evaluati on, then a qualified individual with 
overlapping experience may perform the evaluation. Documentatio n of who performed the 
evaluation is to be recorded in source documents. Assessments a r e  t o  b e  p e r f o r m e d  a t  
approximately the same time of day throughout the duration of t he study. 
Baseline assessments must be performed per protocol (standard o f care assessments may not be 
used for baseline). Procedures not specified in the protocol th at are part of standard care may be 
performed if they do not interfere with study procedures; any d ata arising from such procedures 
are not to be reported in the eCRF. 
The following procedures or tools will be used to assess subjec ts‚Äô UC activity during the study 
(see Schedule of Activities  in Section 2 ): 
Protocol Amendment No.: 03
Date: 14-Apr-2021 93
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
‚Ä¢Mayo Scores: Details regarding the calculation of the modified  Mayo score  and the 
recording of the  individual Mayo s core components (SF, RB, ES ) 
are provided in  APPENDIX 9 . Electronic diaries w ill be provided to each subject for daily 
recording of SF and RB. Each day, a subject w ill enter his/her number of stools and RB 
assessment into the electronic subject diaries, according to in struction in  APPENDIX 9 . Should 
the subject miss daily entries prior to a visit, the investigat or will assess if the visit should be 
rescheduled to ensure an adequate number of daily entries are recorded. 
‚àíModified Mayo Score 18: The modified Mayo score is an adapted total Mayo score that is 
a composite of the following components (each scored on a scale  of 0 to 3 points): 
‚ô¶SF subscore 
‚ô¶RB subscore 
‚ô¶ES subscore
The modified Mayo score is a 9-point scale in which a score of 5 to 9 points denotes moderate to 
severe disease. 
Timings of SF and RB assessments, endoscopy, and the modified M ayo score calculations are 
provided in the Schedule of Activities ( Section 2 ).
‚Ä¢Geboes Score21: Biopsies for histological assessment will be taken on the days indicated in the 
Schedule of Activities ( Section 2 ). This assessment will be carried out by the  
 group. Further d etails on the biopsy co llection and processing for this histolo gical 
assessment are provided in the Histopathology Image Review Char ter.
 
 
Protocol Amendment No.: 03
Date: 14-Apr-2021 94
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
‚Ä¢Serum hsCRP levels
The  group is the central vendor responsible for reading and scoring all 
endoscopies and biopsies . These procedures are 
described in the Endoscopy Image Review Charter and Histopatholog y Image Rev iew Charter.
9.1.1 Clinical Response Assessment
Clinical response for efficacy analysis will be determined with the modified Mayo  score (defined 
in Section 9.1 andAPPENDIX 9 ) calculated with an ES subscore derived from the central read of 
endoscopies. The central read of the endoscopy will be used for efficacy analysis at all time points.
Protocol Amendment No.: 03
Date: 14-Apr-2021 95
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
At Week 12, clinical response for the determinat ion of m aintena nce period treatment assignment 
will be determined with the modified Mayo score calcu lated with an ES subscore derived from a 
local read of endoscopies. 
9.2 Adverse Events
The definitions of an AE or SAE ca n be found in APPENDIX 3 .
AEs will be reported by the sub ject ( or, when appropriate, by a caregive r, surrogate, or the subject‚Äôs 
legally authorized representative). 
The investigator and any designee s are responsible for detecting, d ocumenting, a nd reporting 
events that meet the definition of an  AE or SAE and remain responsibl e for following up AEs that 
are serious, considered related to t he study treatment or the study, o r that caused the subject to 
interrupt or discontinue study treat ment before completing the study. 
Contacts for SAE reporting are s pecified in  APPENDIX 3 .
9.2.1 Time Period and Frequency for Collecting AE an d SAE Information
The collection o f nonserious AE inf ormation should begin at initiation  of study treatment until the 
follow-up visit at Week 108 or th e last visit, at the time point s specified in the Schedule of 
Activities ( Section 2 ). Nonserious AE information should also be collected from the start of the 
treatment period at Day 1. The Re ference Safety Information in S ections 5.6.1 and 5.6.2 of the IB 
should be used to determine the expectedness of SAEs for expedited reporting.15
All SAEs must be collected from the time of signing the consent , including those thought to be 
associated with protocol-specified procedures, and within 30 da ys of discontinuation of dosing. 
All AEs and SAEs related to SARS-CoV-2 infection must be collec ted from the time of signing 
the consent to the end of the safety follow-up period (30 days after treatment discontinuati on) or 
roll-over into an extension study.
The investigator must report any SAE that occurs after these ti me periods and that is believed to 
be related to study drug or protocol-specified procedure (eg, a follow-up skin biopsy).
‚Ä¢Medical occurrences that begin before the start of study treatment but after obtaining informed 
consent will be recorded on the appropriate section of the eCRF module.
‚Ä¢All SAEs will be recorded and reported im mediately to Sponsor or d esignee but no later than 
24 hours after awareness of the event, as i ndicated in APPENDIX 3 . 
‚Ä¢The investigator will submit any updated SAE data to the Sponsor or designee immediately
but no later than 24 hours of updated infor mation being available.
Investigators are not obligated to actively seek AEs or SAEs in  former study subjects. However, 
if the investigator learns of any SAE, including a d eath, at any time after a subject has been 
discharged from the study, and he/she considers the event reaso nably related to the study treatment 
or study participation, the investigator must promptly notify t he Sponsor or designee.
Protocol Amendment No.: 03
Date: 14-Apr-2021 96
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
The method of evaluating and assessing causality of AEs and SAE s and th e procedures for 
completing and reporting/transmitting SAE reports are provided in APPENDIX 3 .
9.2.2 Method of Detecting AEs and SAEs
Adverse events can be spontaneously reported  or elicited  during open-en ded questioning, 
examination, or evaluation of a subject. (To prevent reporting bias, subjects should not be 
questioned regarding the specific occurrence of one or more AEs .)
9.2.3 Follow-up of AEs and SAEs
‚Ä¢Nonserious AEs should be followed to resolution or stab ilization or reporte d as SAEs if they 
become serious (see APPENDIX 3 ).
‚Ä¢Follow-up is also required for nonserious AEs that cause interr uption or d iscontinuation of 
study treatment and for those present at th e end-of-study treatment as appropriate.
‚Ä¢All identified nonserious AEs must be recorded and described on  the nonse rious AE page of 
the case report form (CRF). Completion of supplemental CRFs may be re quested for AEs 
and/or laboratory abnormalities t hat are reported/identified du ring the course of the study.
After the initial AE/SAE re port, the investigator is re quired to proactively follo w each subject at 
subsequent visits/contacts. All SAEs and nonserious AEs of spec ial interes t (as defined in 
Section 9.2.8 ) will be followed until resolution, until the c ondition stabilizes, until the event is 
otherwise explained, or until the subject is lost to follow-up (as defined in Section 8.3).
Further informatio n on follow- up procedures is given in  APPENDIX 3 .
9.2.4 Regulatory Reporting Requirements for SAEs
‚Ä¢Prompt notification by the investigator to the Sponsor of SAEs is essential so that legal 
obligations and ethical responsibilities toward the safety of su bjects and the safety of a product 
under clinical investigation are met.
‚Ä¢An investigator who receives an i nvestigator safety report desc ribing SAEs or other specific 
safety information (eg, summary  or listing of SAEs) from the S ponsor w ill file it along with 
the IB and will notify the Institutional Review Board (IRB)/Inde pendent E thics Committee 
(IEC), if appropriate according to local requirements.
Sponsor or designee will be reporting AEs to regulatory authori ties and et hics committees 
according to local applicable laws including European Directive  2001/20/EC a nd FDA Code of 
Federal Regulations 21 CFR Parts 312 and 320. A suspected, unex pected serious  adverse reaction 
(SUSAR) is a subset of SAEs and will be reported to the appropriate regulator y authorities and 
investigators f
ollowing local and global guidelines and require ments.
9.2.5 Pregnancy
If, following initiation of the study treatment, it is subseque ntly discovered tha t a participant is 
pregnant or may have been pregnant at the time of study exposur e, includin g during at least 
5 half-lives after study product ad ministration, the investigator  must immediately notify Drug 
Protocol Amendment No.: 03
Date: 14-Apr-2021 97
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Safety of this event and complete and forward a Pregnancy Surveillance Form to Drug Safe ty 
within 24 hours of awareness of the event and in accordance with  SAE reporting procedures 
described in APPENDIX 3 .
Protocol-required procedures f or study disconti nuation and foll ow-up must be performed on t he 
subject.
Follow-up information regarding the course of the pregnancy, in cluding perinatal and neonat al 
outcome and, where applicable, offspring information must be re ported on the Pregnan cy 
Surveillance Form (see APPENDIX 3 ).
Any pregnancy that occurs in a female partner of a male study s ubject should be reported to  
Drug Safety. In order for the Sponsor or designee to collect an y pregnancy surveillan ce 
information from the female part ner, the fe male partner must si gn an ICF for disclosure of th is 
information. Information on this pre gnancy will be collected on  the Pregnancy Surveillance Form 
in APPENDIX 3 .
9.2.6 Laboratory Test Result Abnormalities
The following laboratory test result abnormalities should be ca ptured on the AE eCRF page:
‚Ä¢Any laboratory test result that is clinically significant or me ets the definition of an AE or SA E 
‚Ä¢Any laboratory test result abnormality that required the subjec t to have study treatme nt 
discontinued or interrupted
‚Ä¢Any laboratory test result abnorm ality that required the subjec t to receive specific corrective 
therapy
If a laboratory test result meets the definition of an AE or SA E, the laboratory test result should be 
reported as an AE or SAE and submitted to Drug Safety, as specified in APPENDIX 3 . 
It is expected that wherever possible, the clinical rather than laboratory term would be used by t he 
reporting investigator (eg, anemia versus low hemoglobin value) .
9.2.7 Potential Drug-Induced Liver Injury (DILI)
Wherever possible,  timely confirmation  of initial liver-rel ated laboratory  abnormalities s hould 
occur prior to the reporting of a potential DILI event. All occurrences of potential DILIs, meeting 
the defined criteria, must be reported as SAEs (see Section 9.2 and APPENDIX 3 for reporting 
details).
Potential DILI is defined as: 1. ALT or AST elevation > 3 √ó ULN,
3) AND4. Total bilirubin > 2 √ó ULN, without initial findings of cholest asis (elevated serum alkaline 
phosphatase),
Protocol Amendment No.: 03
Date: 14-Apr-2021 98
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
AND
5. No other immediately apparent possible causes of ALT or AST e levation and 
hyperbilirubinemia, including, but not limited to, viral hepati tis, pre-existing chronic  or acute 
liver disease, or the administration of other drug(s) known to be hepatotoxic.
9.2.8 Adverse Events of Interest (Clinical Safety Program)
All AEs and SAEs that arise in the study will be reported and i nvestigated. However, because of 
the characteristics of the disease under study and BMS-986165 i n particular, some AEs are 
considered AEIs. Adverse events of interest may be serious or n onserious. Such events may require 
further investigation to better characterize and understand the m. In the BMS-986165 clinical 
development program, certain skin-related AEs (eg, acne) and in fection AEs have been identified 
as potential AEIs; however, there has been no definitive assess ment on the causal relationship 
between these events and treatment with BMS-986165. 
In addition, given that immunosuppression is consistent with th e mechanism of action of 
BMS-986165, malignancies are considered to be an important pote ntial risk of therapy with 
BMS-986165 and s hould be monitored as AE Is. Malignancies were n ot identified as adverse 
findings in nonclinical studies and no serious adverse reactions of malignancy have been reported 
to date in clinical studies of BMS-986165.
For purposes of reporting these AEIs, specialized eCRF pages will be required to collect additional 
information related to char acterization, social/family history,  risk factors, signs/symptoms, 
diagnostics, and treatments. 
9.2.9 Other Safety Considerations
Any significant worsening noted during interim or final physical examinations, ECG, x-ray 
filming, any other potential safety assessment required or not required by protocol should also be 
recorded as a nonserious AE or SAE, as appropriate, and reported accordingly.
9.3 Overdose
For this study, any dose of BMS-986165 that is more than 2-days‚Äô worth of study treatment within 
a 24-hour time period will be considered an overdose.
In the event of an overdose the investigator should do the foll owing:
1. Contact the medical monitor immediately
2. Closely monitor the subject fo r AEs/SAEs and laboratory abnormalities until BMS-986165 
can no longer be detected systemically (at least 3 days)
3. Document the quantity of the excess dose as well as the durat ion of the overdosing in the eCRF.
Decisions regarding dose interruptions or modifications will be  made by the investigator in 
consultation with the medical monitor based on the clinical eval uation of the subject.
Protocol Amendment No.: 03
Date: 14-Apr-2021 99
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
9.4 Safety
Planned time points for all safety assessments are listed in th e Schedule of Activities ( Section 2 ). 
All urgent safety concerns must be discussed with the Sponsor i mmediately upon occurrence or 
awareness to determine if the subject should continue or discontinue treatment.
Safety evaluations that will be performed in addition to AE mon itoring are physical examination 
(Section 9.4.1 ), TB screening (Section 9.4.2 ), vital signs ( Section 9.4.5 ), ECGs ( Section 9.4.6 ), 
concomitant medication use ( Section 7.7 ), laboratory tests (S ection 9.4.3 ).
9.4.1 Physical Examinations
Schedules for physical examinations are provided in the Schedul e of Activities ( Section 2 ). 
Complete physical examinations may be performed by a Doct or of Medicine (MD), or someone 
who is authorized to perform the examinations by training and h as been delegated this task by the 
Principal Investigator. Key aspects of the examination should e valuate important body systems as 
clinically indicated. Every effort s hould be made to ensure the s ame evaluator will complete the 
examination for eac h subject at all visits throughout the study . Documentation of who performed 
the examination is to be recorded in source notes.
9.4.2 Tuberculosis Screening and Chest X-ray
A chest x-ray and physical examination are part of the process to assess a subject‚Äôs eligibility, as 
outlined in Section 2 , and as defined in the Exclusion Criteria, Section 5.2) . A chest x-ray at the 
screening visit is required if not already performed and docume nted within 6 months of obtaining 
written informed consent. A subject must not have active signs or symptoms of TB, as judged by 
the investigator, to be eligible for the study.
In addition to a complete physical examination and medical hist ory to evaluate exposure to TB, all 
subjects will have a screening test, an IGRA (eg, T-spot¬Æor QuantiFERON¬Æ-TB Gold, or 
QuantiFERON¬Æ-TB Gold Plus) performed centrally. If unable to obtain central laboratory results,
an IGRA test could be obtained locally, after consultation with  the medical monit or. A subject 
with an indeterminate IGRA test result must be retested for con firmation. If the second result is 
again indeterminate, the subject w ill be excluded from the stu dy. If the second result is positive, 
the subject should be treated as having LTBI provided there are  no signs or symptoms of active 
TB. If the second result is negative, the subject may be eligible provided no other exclusion 
criterion for TB is met.
9.4.3 Clinical Safety Laboratory Assessments
‚Ä¢A central laboratory will perform safety laboratory assessments  (except pregnancy tests) and 
provide reference  ranges and laboratory reports.
‚Ä¢Investigators must document their review of each laboratory saf ety report.
‚Ä¢Any laboratory test result that the investigator considers clin ically relevan t for safety is to be 
recorded on the appropriate AE page of the eCRF ( Section 9.2.6 ). 
Protocol Amendment No.: 03
Date: 14-Apr-2021 100
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
‚Ä¢Results of clinical laboratory tests performed during the scree ning period must be available 
prior to randomization.
The laboratory parameters t o be assessed are as follows: 
‚Ä¢Hematology: hemoglobin, hematocrit, total leukocyte count (incl uding absolute neutrophil 
count and absolute lymphocy te count), platelet count, RBC count , and manual differential 
(separate smear) 
‚Ä¢Chemistry: AST, ALT,  gamma glu tamyltransferase, total bilirubin , direct bilirubin, alkaline 
phosphatase, lactate dehydrogenase, creatinine, blood urea nitr ogen, uric acid, total protein, 
albumin, sodium, potassium, chloride, calcium, phosphorus, magn esium, creatine kinase, 
creatinine clearance (screening only) with eGFR calculated usin g the MDRD equation, and
thyroid-stimulating hormone (TSH) bl ood test (with reflex T3/T4 testing for abnormal TSH 
results at screening) 
‚Ä¢Coagulation: prothrombin time, international normalized ratio, and either partial 
thromboplastin time or activate d partial thromboplastin time
‚Ä¢Tests performed after a ‚â• 10-hour fast: lipid panel (total chole sterol, high-density li poprotein 
cholesterol, low-density lipoprotein cholesterol, and triglycerides) and glucose 
‚Ä¢Urinalysis: protein, glucose, b lood, leukocyte es terase, specif ic gravity, pH; microscopic 
examination of the sediment if blood, protein, or leukocyte est erase are positive on dipstick; 
spot urine will be assessed for urine protein and urine creatin ine 
‚Ä¢Serology to be performed at screening: hepatitis B surface antig en (HBsAg), hepatitis B 
surface antibody (HBsAb) (only in Japan and s elected countries ), hepatitis B core antibody 
(HBcAb), reflex to HBV deoxyribonucleic acid (DNA); anti-HCV, HCV ribonucleic acid 
(RNA) if anti-HCV is positive or indeterminate; HIV-1 and HIV- 2 antibody; and IGRA 
testing
‚Ä¢Quantitative serum immunoglobulins (Igs): IgG, IgM, IgA, and Ig E
‚Ä¢T cells, B cells, and natural killer cells (TBNK)
‚Ä¢Serum high-sensitivity C-reactive protein (hsCRP)
Urine and/or serum pregnancy testing will be performed f or WOCBP, a nd FSH will be measured 
to confirm postmenopausal status (as applicable; at screening o nly). 
9.4.4 Imaging Safety Assessment
Not applicable.
9.4.5 Vital Signs
Refer to  Schedule of Activities  in Section 2 .
9.4.6 Electrocardiograms
Refer to  Schedule of Activities  in Section 2 .
Protocol Amendment No.: 03
Date: 14-Apr-2021 101
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr-2021 102
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr-2021 103
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr-2021 104
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr-2021 105
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr-2021 106
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr-2021 107
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr-2021 108
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr-2021 109
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
9.8 SARS-CoV-2 Testing
Diagnostic testing for SARS-CoV-2 infection refers to a molecul ar test (PCR or nucleic acid 
amplification test [NAAT]) or an antigen test for SARS-CoV-2 inf ection, performed according to 
local standard of care. PCR testing is preferred. Antibody test ing is not acceptable as a diagnostic 
test for SARS-CoV-2 infection.
Diagnostic testing for SARS-CoV-2 infection should be performed  a s  c l o s e  a s  p o s s i b l e  t o  
randomizatio n and must be confirmed as ‚Äúnegative‚Äù prior to rand omization.
Subjects will be screened for AEs (including signs and symptoms of COVID-19) at each st udy 
visit. Subjects will be instru cted to contact the investigator at any time if they develop an  
Protocol Amendment No.: 03
Date: 14-Apr-2021 110
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
intercurrent illness, including a diagnosis, or signs and symptoms of COVID-19, which will enable 
close monitoring and additional screening for the infection bet ween study visits.
The investigator should obtain a diagnostic test for SARS-CoV-2 infection if COVID-19 is 
clinically suspected . If a s ubject reports havi ng recent direct contact with someone known to have 
COVID-19, the subject should undergo diagnostic testing for SAR S-CoV-2. 
Investigational product should be temporarily interrupted in subjects who present with signs and/or 
symptoms suggestive of COVID- 19 while the subject undergoes diagnostic testing for 
SARS-CoV-2 infection. This testing should be performed as soon as feasible.
Investigational product must be temporarily interrupted in subje cts who test positive for 
SARS-CoV-2 infection. Such subjects should continue to be follo wed by the investigator. Such 
subjects must meet all the criteria outlined below prior to res tarting IP. The final decision to restart 
IP must be made in consultation with the BMS medical monitor/de signee.
Subjects with a positive diagnostic test for SARS-CoV-2 infecti on during the screening period 
may be considered eligible fo r the study once they meet all eligibility criteria related to active 
infection, and after meeting the criteria outlined below.
Criteria to rescreen or recommence IP after a positive SARS-CoV -2 test:
‚Ä¢At least 10 days (20 days for severe/critical illness) have pas sed since symptoms first appeared 
or positive test result, and
‚Ä¢At least 24 hours have passed since last fever without the use of fever-reducing medications, 
and
‚Ä¢Acute symptoms (eg, cough, shortness of breath) have resolved, and
‚Ä¢In the opinion of the investigator, there are no COVID-19 seque lae that may place the subject 
at a higher risk from receiving i nvestigational treatment, and
‚Ä¢There are no COVID-19 sequelae that may confound the assessment of safety or efficacy 
within the study, and
‚Ä¢Negative follow-up molecular test for COVID-19 based on institu tional, local, or regional 
guidelines, and
‚Ä¢The above must be discussed with the BMS medical monitor prior to rescreening or 
recommencing IP (as applicable)
10 STATISTICAL CONSIDERATIONS
10.1 Sample Size Determination
Sample size was determined based on providing exposure to a sufficient number of subjects to be 
able to observe a true difference in the rate of clinical remis sion (modified Mayo score) after 
12 weeks of treatment. With the assumption that the observed pla cebo population will have similar 
clinical remission rate as seen in current UC investigative tri als (mirikizumab),9it is expected that 
the placebo response rate will be 5%. Assuming that BMS-986165 will provide similar efficacy as 
Protocol Amendment No.: 03
Date: 14-Apr-2021 111
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
observed in current UC trials (mirikizumab and upadacitinib),9, 28the expected treatment difference 
of BMS-986165 6 mg BID vs placebo is assumed to be 15%.
Approximately 120 subjects  will be randomized in a 2:1 ratio to  BMS-986165 6 mg BID or 
placebo, respectively (80 subjects on BMS-986165 and 40 on place bo). In this p roof of concept 
study, if the observed response rates are the same as the assum ed rates given above, the total 
number of 120 subjects (80 subjects on BMS-986165 and 40 on plac ebo) w ill provide 
approximately 82% power to detect a 15% treatment difference in clinical remissi on at Week 12 
with a 1-sided 0.1 level of significance.
10.2 Populations for Analyses
For purposes of analysis, the fo llowing populations  are defined  in Table 23
Table 23: Analysis Populations 
Population Description
Enrolled Set All subjects who sign informed consent.
Full Analysis Set (FAS) All subjects who are randomized to study  treatment; subjects will be 
grouped according to the treatment to which they are randomized  
within the IRT. The FAS population is the primary efficacy analysis 
population.
Safety Analysis Set All randomized subjects who receive at least  1 dose of double-blind 
study treatmen t. Subjects w ill be analy zed according to treatment 
received.
FAS = full analysis set; IRT = interactive response technology
10.3 Endpoints
Study endpoints are defined in Section 4.
10.4 Statistical Analyses
The SAP will be developed and finalized before database lock an d will describe the selection of 
subjects to be included in the analyses, and procedures for acc ounting for missing, unused, and 
spurious data. 
Protocol Amendment No.: 03
Date: 14-Apr-2021 112
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Categorical data w ill be su mmarized as frequency counts and percentages. Continuous data will 
be summarized using n, mean, standard deviation, median, minimu m, and maximum unless 
otherwise specified.
During the induction period, data will be presented for the fol lowing treatments:
‚Ä¢BMS-986165 6 mg BID
‚Ä¢Placebo
After Week 12, subjects continuing into the maintenance period of the study (see Section 5.1.3 for 
details) will have their data presented as follows:
‚Ä¢Responders at Week 12 continuing blinded treatment:
‚Ä¢BMS-986165 6 mg BID ‚Üí BMS-986165 6 mg BID
‚Ä¢Placebo ‚Üí Placebo
‚Ä¢Nonresponders at Week 12 continuing open-lab el treatment:
‚Ä¢BMS-986165 6 mg BID ‚Üí BMS-986165 6 mg BID
‚Ä¢Placebo ‚Üí BMS-986165 6 mg BID
After Week 52, subjects  with clinical benefit continuing open-l abel treatmen t during the open-
label extension peri od of the s tudy (see Section 5.1.4 for details) will have their data presented as 
follows:‚Ä¢Responders at Week 12, clinical benefit at Week 52 continuing o pen-label treatment:
‚Ä¢BMS-986165 6 mg BID ‚Üí BMS-986165 6 mg BID‚Üí BMS-986165 6 mg BID
‚Ä¢Placebo ‚Üí Placebo‚Üí BMS-986165 6 mg BID
‚Ä¢Nonresponders at Week 12, clinical benefit at Week 52 continuin g open-label treatment:
‚Ä¢BMS-986165 6 mg BID ‚Üí BMS-986165 6 mg BID‚Üí BMS-986165 6 mg BID
‚Ä¢Placebo ‚Üí BMS-986165 6 mg BID ‚Üí BMS-986165 6 mg BID
10.4.1 Efficacy Analyses
Efficacy data will be summarized using the FAS population unles s otherwise stated. Variables will 
be summarized for all visits in which the variable is assessed.  Efficacy data will be listed by study 
period and treatment group. 
A summary of planned statist ical analyses  of the primary and secondary endpoints is in Table 24. 
Baseline values are defined as the last non-missing value prior to the first dose of study drug unless 
otherwise indicated. 
Protocol Amendment No.: 03
Date: 14-Apr-2021 113
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Table 24 Planned Statistical Analyses of the Primary and Secondary 
Endpoints
Endpoint Statistical Analysis Methods
Primary General An alysis Methodology
The proportion of subjects w ho achieve the primary e ndpoint, clinical 
remission (modified Mayo score), will be analyzed using a stratified Cochran-
Mantel-Haenszel test. Clinical remission (modified Mayo score) responder 
rates at Week 12 between the BMS-986165 6 mg BID group and placeb o group 
will be compared adjusting fo r the randomization stratification  factors 
(corticosteroid use [yes/no] and prior exposure to biologics [0 , 1, > 1]); 
JAK inhibitors are considered as a biologic for stratification p urposes. If 
expected cell c ounts are not sufficient for each  strata level, then str ata levels 
will be combined for analysis. The assessment of statistical si gnificance will be 
based upon a 1-sided, 0.1 alpha, which is in alignment with the sample size 
calculation. The odds ratio and corresponding 2-sided 95% CI wil l be provided 
for descriptive purposes.
Supportive analyses using logistic regression may be performed to incorporate 
additional covariates of interest and to confirm primary analys is results. The 
model will include tr eatment, geographic re gion, corticosteroid use (yes/no), 
prior exposure to biolog ics (0, 1, > 1) as well as other covariates as applicable. 
The odds ratio and the corresponding 2-sided 95% CI will be pro vided.
Imputation Method
Occurrence of intercurrent events may have an impact on the est imand of 
interest. For the following types of subjects:
‚Ä¢Subjects who discontinue treatment or study early (ie, prior to Week 12)
‚Ä¢Subjects who start a protocol prohibited med ication/therapy pri or to the 
evaluation of the primary endpoint (clinical remission [modifie d Mayo 
score]) at Week 12
‚Ä¢Subjects who are lost to follow-up or have otherwise missing en dpoint data 
at or prior to the Week 12 assessment
The primary endpo int (clinical r emission [modified Mayo score]) will be 
determined using the ‚ÄúComposite Strategy‚Äù as defined in Interna tional Council 
for Harmonisation (ICH) E9R1 addendum29. Subjects with the identified 
intercurrent events will have their clinical remission endpoint  imputed as being 
a ‚Äúnonresponder.‚Äù This is commonly known as nonresponder imputat ion
(NRI).
Sensitivity analyses using different imputation methods may be performed and 
will be defined in the SAP.
Protocol Amendment No.: 03
Date: 14-Apr-2021 114
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Table 24 Planned Statistical Analyses of the Primary and Secondary 
Endpoints
Endpoint Statistical Analysis Methods
Secondary General Analysis Methodology
The secondary endpoints  will use the same a nalysis approach as the primary 
endpoint analysis with missing d ata, due to the incurrent events as defined 
above, being imputed as nonresponders.
Testing Strategy for Secondary Endpoints
Statistical analysis of sec ondary endpoints w ill be pe rformed in a hierarchical 
fashion to control for Type I error rate inflation. The statist ical testing of the 
primary endpoint w ill be the serial gatekeeper for pro ceeding to the testing of 
the secondary endpoints. Each secondary endpoint w ill be tested sequentially 
in a fixed-sequence order, as ou tlined below, using a 1-sided alpha = 0.1 for 
significance testing. No further testing will be performed once  a test fails to 
show significance at the alpha level stated above.Secondary endpoints will be tested in the following order:
1. Clinical response
2. Endoscopic response3. Histologic improvement
BID = twice d aily; CI = confidence in terval; ICH = Intern ational Council for Harmonisation; JAK = Janus kinase; 
SAP = statistical analysis plan
10.4.1.1 Subgroup Analyses
Subgroup analyses will be conducted for the primary and seconda ry efficacy endpoints on the FAS 
population. Subgroups will not be further stratified based on t he factors used for randomization. 
Subgroups to be evaluated include the following:
1. Sex
2. Age categories (< 65, ‚â• 65)3. Race4. Prior exposure to biologics (0, 1, > 1); JAK inhibitors are considered as a biologic for 
stratification purposes
5. Prior corticosteroid use (yes/no)6. Subjects taking corticosteroid at baseline who discontinue use after induction period7. Baseline modified Mayo score (‚â§ 7, > 7)
Protocol Amendment No.: 03
Date: 14-Apr-2021 115
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
A complete list of subgroups w ill be d etailed in the SAP.
10.4.2 Safety Analyses
Safety data for each peri od will be summarized separately and combined. All safety data will be 
listed by study period and treatment group.
10.4.2.1 Adverse Events
Treatment-emergent AEs (TEAEs) are defined as AEs that occur aft er the subject received first 
dose of study t reatment  or if a pre-existi ng condition worsens in severit y or becomes serious after 
receiving the first dose of s tudy treatment up to 30 days after  the last dose of study treatment. All 
reported TEAEs, SAEs and deaths,  AEs leading to study treatment  discontinuation, and target 
AEIs will be summarized by the M edical Dictionary for Regulator y Activities system organ class 
and preferred term.
10.4.2.2 Vital Signs and ECGs
Vital signs and ECGs will be summarized as raw, change from baseline, includi ng the maximum 
postbaseline value. Baseline values are defined as the last non- missing value prior to the first dose 
of study drug. The number and proportion of s ubjects with vital signs and ECG a bnormalities will 
be summarized at each scheduled visit.
10.4.2.3 Clinical Laboratory Tests
Laboratory analytes will be summarized as raw, change from base line, including the maximum 
post-baseline value. Incidence of a bnormal, hi gh, or low values will be summarized. Shift tables 
will also be provided. Baseline values are defined as the last n on-missing value prior to the first 
dose of study drug. The number and proporti on of sub jects with clinical laboratory  abnormalities 
will be summarized at each scheduled visit.
10.4.4 Interim Analyses 
In addition to the primary efficacy analysis conducted when sub jects have either completed 
Week 12 efficacy assessments or have discontinued prior to Week 1 2 (as outlined above), an 
interim analysis may be performed after 50% of subjects, approximately 60 subjects, have reached 
Protocol Amendment No.: 03
Date: 14-Apr-2021 116
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
this milestone. The purpose of this interim analysis will be to  help in early planning for further 
clinical development of the compound.
To maintain the overall probability of Type I error at the spec ified 0.1 level, a modified 
Haybittle-Peto method30will be used as the alpha-spending function, which assigns alph a = 0.001 
to each interim analysis, and the remaining alpha to the final ( Week 12) analysis of the primary 
efficacy endpoint.The SAP for the study will be f inalized prior to any interim an alysis. The details (including the 
timing) of the interim analyses will be provided in an interim analysis plan prior to the database 
lock for any interim analysis. The study will not be stopped on  the basis of overwhelming efficacy 
findings at the interim analysis. The results of the interim an alysis will be reviewed by an 
unblinded internal BMS team that is independent of the study tea m responsible for the conduct of 
the study. The study team members, including the medical monito rs and other study pers onnel, 
will remain blinded and will not have access to any unblinded i nterim analysis results or data until 
the final database lock for the Week 52 data has occurred.
10.4.5 Analysis and Reporting
A database lock (12-week database lock) will occur once all ran domized subjects have completed 
the Week 12 eff icacy assessments or have discontinued prior to Week 12. Analy ses of the collected 
efficacy and safety results duri ng the 12-week induction period  will be performed to aid in 
planning for subsequent clinical development. Details of these a nalyses will be described in the 
SAP. The study team responsible for managing the study, includi ng medical monitors, will remain 
blinded to treatment assignment and the results of this analysis throughout the study.
Protocol Amendment No.: 03
Date: 14-Apr-2021 117
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
11 REFERENCES
1. Roda G, Jharap B, Neeraj N, et al. Loss of response to anti-T NFs: definition, epidemiol ogy, 
and management. Clin Transl Gastroenterol 2016;7:e135.
2. Min X, Ungureanu D, Maxwell S, et al. Structural and function al characterization of the 
JH2 pseudokinase domain of JAK family tyrosine kinase 2 (TYK2). J Biol Chem 
2015;290(45):27261-70.
3. Shaw MH, Boyartchuk V, Wong S, et al. A natural mutation in t he Tyk2 pseudokinase 
domain underlies altered susceptib ility of B 10.Q/J mice to infection a nd autoimmunity. 
Proc Natl Acad Sci U S A 2003;100(20):11594-9.
4. Tokarski JS, Zupa-Fernandez A, Tredup JA, et al. Tyrosine kin ase 2-mediated signal 
transduction in T lymphocytes is blocked by pharmacological sta bilization of its 
pseudokinase domain. J Biol Chem 2015;290(17):11061-74.
5. Watford WT, Hissong BD, Bream JH, et al. Signaling by IL-12 a nd IL-23 and the 
immunoregulatory roles of STAT4. Immunol Rev 2004;202:139-56.
6. Baker KF, Isaacs JD. Novel therapies for immune-mediated infl ammatory diseases: What 
can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus 
erythematosus, psoriasis, Crohn's disease and ulcerative coliti s? Ann Rheum Dis 
2018;77(2):175-87.
7. Burke JR, Cheng L, Gillooly KM, et al. Autoimmune pathways in  mice and humans are
blocked by pharmacological stabilization of the TYK2 pseudokina se domain. Sci Transl 
Med 2019;11(502).
8. Sandborn WJ. Mirikizumab shows efficacy in moderate-to-severe UC [abstract]. Presented 
at Digestive Disease Week; 02-05 June 2018; Washington, D.C. Ab stract 882.
9. Sandborn WJ, Ferrante M, Bhanda ri BR, et al. Efficacy and saf ety of anti-interleukin-23 
therapy with mirikizumab (LY3074828) in patients with moderate- to-severe ulcerative 
colitis in a Phase 2 study [abstract]. Presented at Digestive D isease Week  (DDW) 2017. 
Gastroenterology 2018;154(6 Suppl 1):Abstract 882, S1360-S1.
10. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009;361(21):2066-78.
11. Ramos GP, Papadakis KA. Mech anisms of disease: Inflammatory bowel diseases. Mayo 
Clin Proc 2019;94(1):155-65.
12. Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as indu ction and maintenance 
therapy for Crohn's disease. N Engl J Med 2016;375(20):1946-60.
13. Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as i nduction and maintenance 
therapy for ulcerative colit is. N Engl J Med 2019;381(13):1201- 14.
Protocol Amendment No.: 03
Date: 14-Apr-2021 118
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
14. Papp K, Gordon K, Thaci D, et al. Phase 2 trial of selective  tyrosine kinase 2 inhibition in 
psoriasis. N Engl J Med 2018;379(14):1313-21.
15. BMS-986165 Investigator's Brochure , Version 05. Bristol-Myers  Squibb Company, 2019. 
16. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosa licylic acid therapy for 
mildly to moderately active ulcerative colitis. A randomized st u d y .  N  E n g l  J  M e d  
1987;317(26):1625-9.
 
 
 
19. Kim J, Krueger JG. Highly effective new treatments for psori asis target the IL-23/type 17 
T cell autoimmune axis. Annu Rev Med 2017;68:255-69.
, et al. Development and validat ion of a histological index 
for UC. Gut 2017;66(1):50-8.
21. Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment 
of inflammation in ulcerative colitis. Gut 2000;47(3):404-9.
 
 
 
  
 
26. Bodger K, Ormerod C, Shackcloth D, et al. Development and va lidation of a rapid, generic 
measure of disease control from the patient's perspective: the IBD-control questionnaire. 
Gut 2014;63(7):1092-102.
 
Protocol Amendment No.: 03
Date: 14-Apr-2021 119
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
28. Sandborn WJ, Ghosh S, Pan√©s J, et al. Efficacy and safety of  upadacitinib as an i nduction 
therapy for patients with moderately-to-severly active ulcerati ve colitis: data from the 
phase 2B study U-ACHIEVE. Presented at the 26th UEG Week; IBD c linical trials I; 20-
24 October 2018; Vienna, Austria. Abstract OP195.
29. ICH E9 (R1) addendum on estimands and sensitivity analysis i n clinical trials to the 
guideline on statistical principles f or clinical trials. Europe an Medicines Agency 
Committee for Human Medicinal Products. Step 2b, Published 30 A ugust 2017. 
Publication EMA/CHMP/ICH/436221/2017.
30. Schulz KF, Grimes DA. Multiplicity i n randomised trials II: s ubgroup and interim analyses. 
Lancet 2005;365(9471):1657-61.
31. Scherl EJ, Pruitt R, Gordon GL, et al. Safety and efficacy o f a new 3.3 g b.i.d. tablet 
formulation in patients with mild-to-moder ately-active ulcerative colitis: a multicenter, 
randomized, double-bli nd, placebo-controlled study. Am J Gastroenterol 
2009;104(6):1452-9.
32. Guideline on the development of new medicinal products for t he treatment of u lcerative 
colitis. European Medicines Agency Co mmit tee for Medicinal Products for Human Use 
(CHMP). Adopted 28 June 2018. Publication CHMP/EWP/18463/2006 Rev. 1.
Protocol Amendment No.: 03
Date: 14-Apr-2021 120
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
12 APPENDICES
Protocol Amendment No.: 03
Date: 14-Apr-2021 121
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
APPENDIX 1 ABBREVIATIONS AND TRADEMARKS
Term Definition
5-ASA 5-aminosalicylic acid/aminosalicylate
6-MP 6-mercaptopurine
AE adverse event
AEI adverse event of interest
ALT alanine aminotransferase
Anti-HCV hepatitis C virus antibody
AST aspartate aminotransferase
AUC area under the concentration-time curve
AZA azathioprine
BCRP breast cancer resistance protein
BID twice daily
BMS Bristol-Myers Squibb
C. difficile Clostridium difficile
Cavg average concentration
CD Crohn‚Äôs disease
CFR Code of Federal Regulations
CI confidence interval
CONSORT Consolidated Standards of Reporting Trials 
COVID-19 coronavirus disease 2019
CRF case report form
CSR clinical study report
Ctrough trough observed plasma concentration 
CYP450 cytochrome P450
DDI drug-drug interaction
DILI drug-induced liver injury
DMC Data Monitoring Committee
DNA deoxyribonucleic acid
Protocol Amendment No.: 03
Date: 14-Apr-2021 122
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Term Definition
DRESS Drug Rash with Eosinophilia and Systemic Symptoms
ECG electrocardiogram
eCRF electronic case report form
eGFR estimated glomerular filtration rate
ES endoscopic (Mayo score component)
ET early termination 
FAS full analysis set
FDA Food and Drug Administration
FIH first-in-human
FSH follicle stimulating hormone
HBcAb hepatitis B core antibody
HBsAb hepatitis B surface antibody
HBsAg hepatitis B surface antigen
HBV hepatitis B virus 
HCV hepatitis C virus
HIV human immunodeficiency virus
h hour
hsCRP high-sensitivity C-reactive protein
IB Investigator‚Äôs Brochure
IBD inflammatory bowel disease
IC50 half-maximal inhibitory concentration
ICF informed consent form
ICH International Council for Harmonisation
IEC Independent Ethics Committee
IFN interferon
IFNŒ≥ interferon gamma
Ig immunoglobulin
IgA immunoglobulin A
Protocol Amendment No.: 03
Date: 14-Apr-2021 123
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Term Definition
IgE immunoglobulin E
IgG immunoglobulin G
IgM immunoglobulin M
IGRA interferon gamma release assay
IL interleukin
IM intramuscular
IMP investigational medicinal product
IP investigational product 
IRB Institutional Review Board
IRT interactive response technology
IV intravenous
JAK Janus kinase
KLH keyhole limpet hemocyanin
LTBI latent tuberculosis infection
MDRD Modification of Diet in Renal Disease
Min minute(s)
MMX Multi-Matrix System
MTX methotrexate
N/A not applicable
NAAT nucleic acid amplification test
NOAEL no-observed-adverse-effect-level
NSAID nonsteroidal anti-inflammatory drug
NYHA New York Heart Association
OLE open-label extension
OTC over-the-counter
PASI Psoriasis Activity and Severity Index
PCR polymerase chain reaction
PD pharmacodynamics
PGA Physician‚Äôs Global Assessment
Protocol Amendment No.: 03
Date: 14-Apr-2021 124
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Term Definition
PK pharmacokinetic(s) 
PO oral
PRO patient-reported outcome
QD every day
RB rectal bleeding (Mayo score component)
RBC red blood cell
RNA ribonucleic acid 
SAE serious adverse event
SAP statist ical analysis plan
SARS-CoV-2 severe acute resp iratory syndrome coronavirus 2
SF stool frequency (Mayo score component)
SLE systemic lupus erythematosus
STAT signal transducer and activator of transcription
SUSAR Suspected, unexpected serious adverse reaction
TB tuberculosis
TBNK T cells, B cells, and natural killer cells 
TDAR T-cell-dependent anti body response 
TDM therapeutic drug monitoring
TEAE treatment-emergent AE
TEN Toxic Epidermal Necrolysis
TNF tumor necrosis factor 
TNFi tumor necrosis factor inhibitor(s)
TSH thyroid-stimulating hormone
TYK2 tyrosine kinase 2
UC ulcerative colitis
Protocol Amendment No.: 03
Date: 14-Apr-2021 125
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Term Definition
ULN upper limit of normal
WOCBP women of childbearing potential
Protocol Amendment No.: 03
Date: 14-Apr-2021 126
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
APPENDIX 2 STUDY GOVERNANCE CONSIDERATIONS
REGULATORY AND ETHICAL CONSIDERATIONS
GOOD CLINICAL PRACTICE
This study will be conducted in accordance with:
‚Ä¢Consensus ethical principles derived from international guideli nes, including the Declaration 
of Helsinki and Council for International Organizations of Medi cal Sciences (CIOMS) 
International Ethical Guidelines
‚Ä¢Applicable International Council fo r Harmonisation (ICH) Good Cli nical Pract ice (GCP)
Guidelines
‚Ä¢Applicable laws, regulations, and requirements
The study will be conducted in compliance with the protocol. Th e protocol and any amendments 
and the subject informed consent will receive approval/favorabl e opinion by Institutional Review 
Board/Independent Ethics Committee (IRB/IEC), and regulatory au thorities according to 
applicable local regu lations prior to i nitiation of the study.
All potential serious breaches  must be reported to Sponsor or d esignee immediately. A potential
serious breach is defined as a Quality Issue (eg, protocol deviation) that is likely to affect, to a 
significant degree, one or more of the following: (1) the right s, physical safety or mental integrity 
of one or more particip ants; (2) th e scientific value of the cl inical trial (eg, reliability and 
robustness of generated data ). Items (1) or (2) can be associat ed with either GCP regulation(s) or 
trial protocol(s).Personnel involved in conducting this study w ill be qu alified by education, 
training, and experience to perform their respective tasks.
This study will not use the services of study personnel where s anctions have been invoked or where 
there has been scientific misconduct or fraud (eg, loss of medi cal licensure, debarment). 
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE
Before study initiation, the investigator must have written and  dated approval/favorable opinion 
from the IRB/IEC for the protocol, Investigator‚Äôs Brochure, pro duct labeling information, ICF, 
subject recruitment m aterials (eg, advertis ements), and any other written information to be 
provided to subjects. 
The investigator, Sponsor, or de signee should als o provide the I RB/IEC with reports, updates, and 
other information (eg, expedited safety reports, amendments, ad ministrative letter s) annually, or 
more frequently, in accordance with regulatory requirements or institution procedures.
The investigator is responsible for providing oversight of the conduct of the st udy at the site and 
adherence to requirements of the following where applicable:
‚Ä¢ICH guidelines, 
‚Ä¢United States Code of Federal Regulations, Title 21, Part 50 (2 1CFR50)
‚Ä¢European Union Directive 2001/20/EC; or
Protocol Amendment No.: 03
Date: 14-Apr-2021 127
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
‚Ä¢European Regulation 536/2014 for clinical studies (if applicable), 
‚Ä¢European Medical Device Regulation 2017/745 for clinical device  research (if applicable),
‚Ä¢the IRB/IEC
‚Ä¢and all other applicable local regulations.
COMPLIANCE WITH THE PROTOCOL AND PROTOCOL REVISIONS
The investigator should not imp lement any deviation or change t o the protocol without prior 
review and documented approval/favorable opinion of an amendmen t from the IRB/IEC (and if 
applicable, also by local health authority) except where necess ary to eliminate an immediate 
hazard(s) to study subjects. 
If a deviation or change to a protocol is implemented to elimin ate an immediate hazard(s) prior to 
obtaining relevant approval/favorable opinion(s) the deviation or change will be submitted, as soon 
as possible to:
‚Ä¢IRB/IEC for 
‚Ä¢Regulatory Authority(ies), if applicable by local regulations ( per national requirements)
Documentation of approval/favorable opinion signed by the chair person or designee of the 
IRB(s)/IEC(s) and if applicable, also by local health authority  must be sent to BMS.
If an amendment substantially alters the study design or increa ses the potential risk to the subject: 
(1) the consent form must be revised and submitted to the IRB(s )/IEC(s) for review and 
approval/favorable opinion; (2) the revised form must be used t o obtain consent from subjects 
currently enrolled in the study if they are affected by the ame ndment; and (3) the new form must 
be used to obtain consent from new subjects prior to enrollment .
If the revision is done via an administrative letter, investiga tors must inform their IRB(s)/IEC(s).
FINANCIAL DISCLOSURE
Investigators and subinvest igators will provide the S ponsor with sufficient, accurate financial 
information in accordance with local regulations to allow the Sponsor to submit comp lete and 
accurate financial certification or disclosure statements to th e appropriate h ealth aut horities. 
Investigators are responsible for provi ding information on fina ncial interests during the course of 
the study and for 1 year after  completion of the study.
INFORMED CONSENT PROCESS
Investigators must ensure that subjects are clearly and fully i nformed about the purpose, potential 
risks, and other critical issues regardi ng clinical studies in which they volunteer to participate. 
The sponsor or designee will provide the investigator with an appropriate (ie, Global or Local) 
sample informed consent form which will include all elements required by ICH, GCP, and
applicable regulatory requirements. The sample i nformed consent  form will adhere to the ethical 
principles that have their origin in the Declaration of Helsink i.
Protocol Amendment No.: 03
Date: 14-Apr-2021 128
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
The investigator or his/her representative must:
‚Ä¢Obtain IRB/IEC written approval/favorable opinion of the writte n ICF and any other 
information to be provided to the participant prior to the beginning of the study and after any 
revisions are completed for new information.
‚Ä¢Provide a copy of the ICF and written i nformation a bout the study in the language in which 
the participant is proficient pr ior to clinical study participa tion. The language must be 
nontechnical and easily understood. 
‚Ä¢Explain the nature of the study to the participant and answer al l questions regarding the study.
‚Ä¢Inform participant that his/her participation is voluntary. Par ticipant will be required to sign a 
statement of informed consent that meets the requirements of 21  CFR 50, local regulations, 
ICH guidelines, Health Insurance Portability and Accountability  Act (HIPAA) requirements, 
where applicable, and the IRB/IEC or study center.
‚Ä¢Allow time necessary for participant to inquire about the detail s of the study.
‚Ä¢Obtain an ICF signed and personally dated by participant and by the person who conducted 
the informed consent discussion. 
‚Ä¢Include a statement in participant‚Äôs medical record that written  informed consent was obtained 
before participant was enrolled in the study and the date the written consent was obtained. The 
authorized person obtaining the informed consent must also sign the ICF.
‚Ä¢Re-consent participant to the most current version of the ICF(s ) during his/her participation in 
the study, as applicable.
Revise the ICF whenever important new information becomes avail able that is relevant to the 
subject‚Äôs consent. The investigator, or a person designated by the investigator, should fully inform 
the subject of all pertinent aspects of the study and of any ne w information relevant to the subject‚Äôs 
willingness to continue participation in the study. This commun ication should be documented. 
The confidentiality of records that could identify subjects mus t be protected, respecting the privacy 
and confidentiality rules applicable to regulatory requirements , the subjects‚Äô signed ICF and, in 
the US, the subjects‚Äô signed HIPAA Authorization.
The ICF must also include a statement that BMS and local and for eign regulatory authorities have 
direct access to subject records. The rights, safety, and well-being of the study subjects are th e most important considerations and 
should prevail over interests of science and society.SOURCE DOCUMENTS
Source documents provide evidence for the existence of the part icipant and substantiate the 
integrity of the data collected. Source documents are filed at t he investigator‚Äôs site.
Data reported on the  CRF or entered in the electronic CRF (eCRF) that are transcrib ed from source 
documents must be consistent with the source documents or the d iscrepancies must be explained. 
‚Ä¢The investigator may need to request previous medical records o r transfer records, depending 
on the study. Also, current medical records must be available.
Protocol Amendment No.: 03
Date: 14-Apr-2021 129
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
The investigator is responsible for ensuring that the source da ta are accurate, legible, 
contemporaneous, original and attr ibutable, whether the data ar e hand-written on paper or entered 
electronically. If source  data are created (first entered), modified, maintained, archived, retrieved, 
or transmitted electronically via computer ized systems (and/or any other kind of electronic 
devices) as part of regulated clinical trial activities, such s ystems must be compliant with all 
applicable laws and regulations governing use of electronic rec ords and/or electronic signatures. 
Such systems may include, but are not limited to, elect ronic medical/health records (EMRs/EHRs), 
adverse event tracking/reporting, protocol-required assessments , and/or drug accountability 
records).
When paper records from such systems are used in place of electronic format to perform regulated 
activities, such paper records should be certified copies. A ce rtified copy consists of a copy of 
original information that has been verified, as indicated by a dated signature, as an exact copy 
having all of the same attributes a nd information as the original. 
STUDY TREATMENT RECORDS
Records for study treatments (whether supplied by BMS, its vendors, or the site) must substantiate 
study treatment integrity and traceability from receipt, prepar ation, administration, and through 
destruction or return. Records must be made available for revie w at the request of BMS/designee 
or a Health Authority.
If Then
Supplied by BMS (or its vendors): Records or logs must comply wi th applicable 
regulations and guidelines and should include:
‚Ä¢amount received and placed in storage 
area
‚Ä¢amount currently in storage area
‚Ä¢label identification number or b atch 
number
‚Ä¢amount dispensed to and returned by each 
subject, including unique subject 
identifiers
‚Ä¢amount transferred to another area/site for dispensing or storage
‚Ä¢nonstudy disposition (eg, lost, wasted) 
‚Ä¢amount destroyed at study site, if applicable
‚Ä¢amount returned to BMS
‚Ä¢retain samples for 
bioavailability/bioequivalence, if 
applicable 
Protocol Amendment No.: 03
Date: 14-Apr-2021 130
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
If Then
‚Ä¢dates and initials of person responsible for 
Investigational Product dispensing/accountability, as per the Delegation of Authority Form.
Sourced by site, and not supplied by BMS or 
its vendors (examples include IP sourced from the sites stock or commercial supply, or a 
specialty pharmacy)The investigator or designee accepts 
responsibilit y for documenting traceability and 
study treatment integrity in accordance with 
requirements applicable under law and the 
SOPs/standards of the sourcing pharmacy.
BMS or designee will provide forms to facilitate inventory cont rol if the investigational site does 
not have an established system that meets these requirements.
CASE REPORT FORMS
An investigator is required to prepare and maintain adequate and accurate case histories designed 
to record all observations and other d ata pertinent to the investig ation on each indi vidual treated 
or entered as a control in the investigation. Data that are der ived from source documents and 
reported on the CRF must be consistent with the source document s or the discrepancies must be 
explained. Additional clinical information may be collected and  analyzed in an effort to enhance 
understanding of product safety. CRFs may be requested for AEs and/or laboratory abnormalities 
that are reported or identified during the course of the study.
For sites using the Sponsor or designee electronic data capture  tool, electronic CRFs w ill be 
prepared for all data collection fields except for fields speci fic to SAEs and pregnancy, which will 
be reported on the  electronic SAE form and paper Pregnancy Surveillance Form, respectively . If 
electronic SAE form is not availab le, a paper SAE form can be u sed.
The confidentiality of records that could identify subjects mus t be protected, respecting the privacy 
and confidentiality rules in accordance with the applicable reg ulatory requirement(s).
The investigator will maintain a s ignature sheet to document si gnatures and initials of all persons 
authorized to make entries and/or corrections on CRFs. The completed CRF, SAE/pregnancy CRFs, must be promptly reviewe d, signed, and dated by the 
investigator or qualified physicia n who is a subinvestigator an d who is delegated this task on the 
Delegation of Authority Form. Subinvestigators in Japan may  not be delegated the CRF approval 
task. For electronic CRFs, review and approval/signature is comp leted electronically through the 
electronic data capture tool. The investigator must retain a co py of the CRFs including records of 
the changes and corrections.
Protocol Amendment No.: 03
Date: 14-Apr-2021 131
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Each individual electronically si gning electronic CRFs must mee t Sponsor or designee training 
requirements and must only access the electronic data capture t ool using the unique user account 
provided by Sponsor or designee. User accounts are not to be sh ared or reassigned to other 
individuals.
MONITORING
Sponsor or designee representativ es will review data centrally to identify potential issues to 
determine a schedule of on-site visits for targeted review of s tudy records. 
Representatives of BMS must be allowed to visit all study site locations periodically to assess the 
data quality and study integrity. On -site they will review study records and directly compare them 
with source documents, discuss the conduct of the study with th e investigator, and verify that the 
facilities remain acceptable. 
Certain CRF pages and/or electronic files may serve as the source documents.In addition, the study may be evaluated by Sponsor or designee internal auditors and government 
inspectors who must be allowed access to CRFs, source documents , other study files, and study 
facilities. BMS audit reports will be kept confidential.
The investigator must notify BMS promptly of a ny inspections scheduled by regulatory aut horities, 
and promptly forward copies of inspection reports to Sponsor or  designee. 
RECORDS RETENTION
The investigator (or head of the study site in Japan) must reta in all study records and source 
documents for the maximum period required by applicable regulat ions and guidelines, or 
institution procedures, or for the period specified by BMS or d esignee, whichever is longer. The 
investigator (or head of the study site in Japan) must contact BMS prior to destroying any records 
associated with the study.
BMS or designee will notify the investigator (or head of the st udy site in Japan) when the study 
records are no longer needed.
If the investigator withdraws from the study (eg, relocation, r etirement), the records sh all be 
transferred to a mutually agreed upon designee (eg, another inv estigator, study site, IRB). Notice 
of such transfer will be given in writing to BMS or designee. 
RETURN OF STUDY TREATMENT
For this study, study treatments (those supplied by BMS, a vend or or sourced by the investigator) 
such as partially used study treatment containers, vials, and sy ringes may be destroyed on site. 
Protocol Amendment No.: 03
Date: 14-Apr-2021 132
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
If... Then
Study treatments supplied by BMS (including 
its vendors)Any unused study tr eatments s upplied by BMS 
can only be destroyed after being inspected and reconciled by the responsible Study Monitor unless study treatments containers must be 
immediately destroyed as required for safety, 
or to meet local regulations (eg, cytotoxics or biologics).
If study treatments will b e returned, the return 
will be arranged by th e responsible Study 
Monitor.
Study treatments sourced by site, not supplied 
by BMS (or its vendors) (examples include 
study treatments sourced from the sites stock 
or commercial supply, or a specialty 
pharmacy)It is the investigator‚Äôs or designee‚Äôs responsibility to dispose of all containers 
according to the institutional guidelines and 
procedures.
It is the investigator‚Äôs or designee‚Äôs responsibility to arrang e for disposal, provided that procedures 
for proper disposal have been established according to applicab le federal, state, local, and 
institutional guidelines and procedures, and provided that appropriate records of disposal are kept. The following minimal standards must be met:
‚Ä¢On-site disposal practices must not expose humans to risks from  the drug.
‚Ä¢On-site disposal practices and procedures are in agr eement with applicable laws and 
regulations, including any special requirements for controlled or hazardous substances.
‚Ä¢Written procedures for on-site disposal are available and follo wed. The procedures must be 
filed with the site‚Äôs SOPs and a copy  provided t o BMS upon request.
‚Ä¢Records are maintained that allow for traceability of each cont ainer, including the date 
disposed of, quantity disposed, and identif ication of the person disposing the containers. The 
method of disposal, ie, incinerator, licensed sanitary landfill, or licensed waste disposal vendor 
must be documented.
‚Ä¢Accountability and disposal records are complete, up-to-date, a nd available for the Monitor to 
review throughout the clinical trial period.
It is the investigator‚Äôs or designee‚Äôs responsibility to arrange for disposal of all empty containers.
If conditions for destruction cannot be met, the responsible St udy Monitor will make arrangements 
for return of study treatments provided by BMS (or its vendors) . Destruction of non- study 
treatments s ourced by the site, not supplied by BMS, is solely the responsibility of the investigator 
or designee.
Protocol Amendment No.: 03
Date: 14-Apr-2021 133
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
CLINICAL STUDY REPORT
A Signatory Investigator must be selected to sign the clinical study report (CSR). 
For each CSR r elated to this protocol, the following criteria w ill be used to sel ect the Signatory 
Investigator:
‚Ä¢External Principal Investigator designated at protocol developm ent
‚Ä¢National Coordinating Investigator 
‚Ä¢Study Steering Committee chair or their designee
‚Ä¢Subject recruitment (eg, am ong the top quartile of enrollers)
‚Ä¢Involvement in trial design
‚Ä¢Regional representation (eg, amo ng top quartile of enro llers from a specified region or country)
‚Ä¢Other criteria (as determined by the study team)
The data collected during this study are confident ial and proprietary to Spons or or designee. Any 
publications or abstracts arising from this study must adhere to the publication requirements set 
forth in the clinical trial agreement (CTA) governing [Study si te or investigator] participation in 
the study. These requirements include, but are not limited to, submitting proposed publications to 
Sponsor or designee at the earliest practicable time prior to submission or presentation and otherwise within the time period set forth in the CTA.
SCIENTIFIC PUBLICATIONS
The data collected during this study are confidential and proprietary to t he Sponsor or designee. 
Any publications or abstracts arising from this study must adhe re to the publication requirements 
set forth in the Clinical Trial Agreement (CTAg) governing [stu dy site or investigator] 
participation in the study. These requirements include, but are  not limited to, submitting proposed 
publications to the Sponsor or designee at the earliest practic able time prior to submission or 
presentation and otherwise within the time period set forth in the CTAg.
Scientific publications (such as abstracts, congress podium presentations and posters, and 
manuscripts) of the study results will be a collaborative effor t between the study Sponsor and the 
external authors. No public presentation or publication of any interim results may be made by any 
Principal Investigator, sub-investigator, or any other member o f the study staff without the prior 
written consent of the Sponsor.
Authorship of publications at BMS is aligned with the criteria of the International Committee of 
Medical Journal Editors (ICMJE, www.icmje.org). Authorship sele ction is based upon significant 
contributions to the study (ie, ICMJE criterion #1). Authors mu st meet all 4 ICMJE criteria for 
authorship:1) Substantial intellectual contribution to the conception or de sign of the work; or the acquisition 
of data (ie, evaluable participants with quality data), analysi s, or interpretati on of data for the 
work (eg, problem solving, advice, evaluation, insights and conc lusion); AND
2) Drafting the work or revising it critically for important int ellectual content; AND
Protocol Amendment No.: 03
Date: 14-Apr-2021 134
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
3) Final approval of the version to be published; AND
4) Agreement to be accountable for all asp ects of the work in ensuring that questions related to 
the accuracy or integrity of any part of the work are appropria tely investigated and resolved.
Those who make the most significant contributions, as defined a bove, will be considered by BMS 
for authorship of the primary publication. Sub-investigators wi ll generally not be considered for 
authorship in the primary publication. Geographic representatio n will also be considered.
Authors will be lis ted by order of significant contributions (highest to lowest), with the exception 
of the last author. Authors i n first a nd last position have provided the most signif icant contributions 
to the work. 
For secondary analyses and related publications, author list an d author order may vary from 
primary to reflect additional contributions
Protocol Amendment No.: 03
Date: 14-Apr-2021 135
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
APPENDIX 3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, 
EVALUATING, FOLLOW-UP AND REPORTING
ADVERSE EVENTS
Adverse Event Definition:
An adverse event (AE) is defined as any new untoward medical oc currence or worsening of a 
preexisting medical condition in a clinical investigation parti cipant administered study drug and 
that does not necessarily have a causal relationship with this treatment. 
An AE can therefore be any unfavorable and unintended sign (suc h as an abnormal laboratory 
finding), symptom, or disease temporally associated with the us e of study drug, whether or not 
considered related to the study drug.
Events Meeting the AE Definition
‚Ä¢Any abnormal laboratory test results (hematol ogy, clinical chem istry, or urinalysis) or 
results from other safety assessments (eg, ECG, radiological sc a n s ,  v i t a l  s i g n s  
measurements), including those that worsen from baseline, consid ered clinically significant 
in the medical and scientific judgment of the investigator. Not e that abnormal lab tests or 
other safety assessments should only be reported as AEs if the final diagnosis is not 
available. Once the final d iagnosis is known, the reported term  should be updated to be the 
diagnosis. 
‚Ä¢Exacerbation of a chronic or intermittent pre-existing conditio n including either an increase 
in frequency and/or intensity of the condition.
‚Ä¢New conditions detected or diagnosed after study intervention a dministration even though it 
may have been present before the start of the study.
‚Ä¢Signs, symptoms, or the clinical sequelae of a suspected drug-d rug interaction.
‚Ä¢Signs, symptoms, or the clinical sequelae of a s uspected overdo se of either study intervention 
or a concomitant medication. Overdose, as a verbatim term (as r eported by the investigator), 
shoul d not be reported as an AE/SAE unless it is an intentional  overdose taken with possible 
suicidal/self-harming intent. Such overdoses should be reported  regardless of sequelae and 
should specify ‚Äúintentional overdose‚Äù as the verbatim term. 
Events NOT Meeting the AE Definition
‚Ä¢Medical or surgical proce dure (eg, endoscopy, appendectomy): th e condition that leads to 
the procedure is the AE.
‚Ä¢Situations in which an untoward medical occ urrence did not occur (so cial and/or 
convenience admission to a hospital).
DEFINITION OF SAE
If an event is not an AE per definition above, then it cannot b e an SAE even if serious conditions 
are met.
Protocol Amendment No.: 03
Date: 14-Apr-2021 136
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
SERIOUS ADVERSE EVENTS
A serious adverse event (SAE) is defined as any untoward medical occurrence that, at 
any dose:
Results in death
Is life-threatening (defined as an event in which the participant was at risk of deat h at the time 
of the event; it does not refer to an event which hypotheticall y might have caused death if it were 
more severe)
Requires inpatient hospitalizatio n or causes prolongation of ex isting hospitalization (see note 
below)
NOTE: 
The following hospitalizations are not  considered SAEs in BMS clinical studies: 
‚Ä¢A visit to the emergency room or other hospital department < 24 hours, that does not result 
in admission (unless considered an important medical or life-th reatening event)
‚Ä¢Elective surgery, planned prior to signing consent
‚Ä¢Admissions as per protocol for a planned medical/surgical proce dure
‚Ä¢Routine health asse ssment requiring admission for baseline/tren ding of health status (eg, 
routine colonoscopy)
‚Ä¢Medical/surgical admission other than to remedy ill health and planned pri or to entry into 
the study. Appropriate documentation is required in these cases .
‚Ä¢Admission encountered for another life circumstance that carries no bearing on health status 
and requires no medical/surgical in tervention (eg, lack of hous ing, economic inadequacy, 
caregiver respite, family circumstances, administrative reason)
‚Ä¢Admission for administration of anticancer therapy in the absen ce of any other SAEs (app lies 
to oncology protocols)
Results in persistent or significant disability or permanent da mage
Is a congenital anomaly/birth defect
Is an important medical event (defined as a medical event(s) th at may not be immediately life-
threatening or result in death or hospitalization but, based up on appropriate medical and 
scientific judgment, may jeopardize the participant or may require intervention [eg, medical, 
surgical] to prevent one of the other serious outcomes listed i n the definition above). Examples 
of such events include, but are not limited to, intensive treat ment in an emergency room or at 
home f or allergic bronchospasm; blood dyscrasias or co nvulsions that do not result in 
hospitalization. Potential drug-indu ced liver injury (DILI) is also considered an important 
medical event (see Section 8.2.7 for t he definition of potential DILI). 
Pregnancy and potential DILI must fo llow the same transmission timing and processes to BMS as 
used for SAEs (see Section 8.2.5 for r eporting pregnancies).
Protocol Amendment No.: 03
Date: 14-Apr-2021 137
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
EVALUATING AES AND SAES
Assessment of Causality
‚Ä¢The investigator is obligated to assess the relationship betwee n study intervention and each 
occurrence of each AE/SAE. 
‚Ä¢A ‚Äúreasonable possibility‚Äù of a r elationshi p conveys that there are facts, evidences, and/or 
arguments to suggest a causal relationship rather than a relatio nship cannot be ruled out.
‚Ä¢The investigator will use clinical judgment to determine the re lationship.
‚Ä¢Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to st udy intervention administration 
will be considered and investigated.
‚Ä¢The investigator will also consult the Investigat or‚Äôs Brochure (IB) and/or Product 
Information, for mark eted products, in his/her assessment.
‚Ä¢For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality .
‚Ä¢There may be situations in which an SAE has occurred and the in vestigator has minimal 
information to include in the initial report to Sponsor. Howeve r, it is very important that the 
investigator always make an asse ssment of causality for every e vent before the initial 
transmission of the SAE data to Sponsor.
‚Ä¢The investigator may change his/her opinion of causality in lig ht of follow-up information 
and send a SAE follow-up report with the updated causality asse ssment.
‚Ä¢The causality assessment is one of the criteria used when deter mining regulatory reporting 
requirements.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported during the 
study and assign it to 1 of t he following categories: 
‚Ä¢Mild: An event that is easily tolerated by the participant, cau sing minimal discomfort and 
not interfering with everyday activities.
‚Ä¢Moderate: An event that causes sufficient discomfort and interf eres with normal everyday 
activities.
‚Ä¢Severe: An event that prevents normal everyday activities. An A E that is assessed as severe 
should not be confused with an SAE. Severe is a category utilize d for rating the intensity of 
an event, and both AEs and SAEs can be assessed as severe.
‚Ä¢An event is defined as ‚Äúserious‚Äù when it meets at least 1 of the  predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
Follow-up of AEs and SAEs
If only limited information is in itially availab le, follow-up r eports are required. Note: Follow-up 
SAE reports must include the same investigator term(s) initiall y reported. 
Protocol Amendment No.: 03
Date: 14-Apr-2021 138
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
If an ongoing SAE changes in its intensity  or relationship to study d rug or if new i nformation 
becomes available, the SAE re port must be updated and submitted  within 24 hours to BMS (or 
designee) using the same procedure used for transmitting the in itial SAE report.
All SAEs must be followed to resolution or stabilization. 
REPORTING OF SAES TO SPONSOR OR DESIGNEE
‚Ä¢SAEs, whether related or not related to st udy drug, and pregnan cies must be reported 
immediately to Drug Safety but  no later t han 24 hours of awareness of the event.
‚Ä¢SAEs must be recorded on the SAE Report Form.
oThe required method for SAE re porting is th rough the electronic case report form 
(eCRF). 
oThe paper SAE Report Form is intended only as a back-up option w hen the electronic 
data capture system is unavailable/not functioning for transmis sion of the eCRF to BMS 
(or designee).
‚Ä¢In this case, the paper form is transmitted via email or confirmed facs imile 
transmission.
‚Ä¢When paper forms are used, the original paper forms are to remain on site.
‚Ä¢Pregnancies must be recorde d on a paper Pregnancy Surveillance Form and transmitted via 
email or confirmed facsimile (fax) transmission to:
SAE Email Address: 
SAE Fax Number: 
Americas: 
Europe/East Asia Pacific:  
SAE Telephone Contact - For questions on SAE/pregnancy reporting, please call:
Americas: Europe/East Asia Pacific: 
Protocol Amendment No.: 03
Date: 14-Apr-2021 139
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
APPENDIX 4 WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS AND 
METHODS OF CONTRACEPTION
Appendix 4 provides general information and definitions related  to Woman of Childbearing 
Potential and methods of contraception that can be applied to m ost clinical trials. For information 
specific to this study regarding acceptable contraception requi rements for f emale and male 
participants, refer to  Section 5.1  of the protocol. Only the contraception methods as described i n 
Section 5.1  are acceptable for this study.
DEFINITIONS
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until beco ming post-menopausal unless 
permanently sterile. Permanent sterilization methods include hy sterectomy, bilateral 
salpingectomy, and bilateral oophorectomy.
Women in the following categories are not considered WOCBP‚Ä¢Premenarchal
‚Ä¢Premenopausal female wi th 1 of the following:
oDocumented hysterectomy
oDocumented bilateral salpingectomy
oDocumented bilateral oophorectomy
Note: Documentati on can come from the site personnel‚Äôs review of the subject‚Äôs medical records, 
medical examination, or medical  history interview.
‚Ä¢Postmenopausal female
oA postmenopausal state is defined as 12 months of ame norrhea in a woman over age 
45 years in the absence of other biological or physiological cau ses. In addition, females 
under the age of 55 years must h ave a serum follicle stimulating  hormone, (FSH) level 
> 40 mIU/mL to confirm menopause.
Note: Females treated with hormone replacement therapy (HRT) are  likely to have artificially 
suppressed FSH levels and may require a was hout period to obtain a physiologic FSH level. The 
duration of the washout period is a function of the type of HRT  used.  Suggested guidelines for 
the duration of the washout periods for HRT types are presented below. Investigators should use 
their judgement in checking serum FSH levels.
‚Ä¢1 week minimum for vaginal hormonal products (rings, creams, ge ls)
‚Ä¢4 week minimum for transdermal products
‚Ä¢8 week minimum for oral products
Other parenteral products may require washout periods as long a s 6 months. If the serum FSH 
level is > 40 mIU/mL at any time during the washout period, the w oman can be considered 
postmenopausal.
Protocol Amendment No.: 03
Date: 14-Apr-2021 140
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
End of Relevant Systemic Exposure
End of relevant systemic exposure is the timepoint where the In vestigational Medicinal Product 
(IMP) or any active major metabolites have decreased to a concent ration that is no longer 
considered to be relevant for human teratogenicity or fetotoxic ity. This should be evaluated in 
context of safety margins from the no-observed-adverse-effect l evel or the time required for 5 half-
lives of the IMP to pass.
CONTRACEPTION GUIDANCE FOR FEMALE SUBJECTS OF CHILD BEARING 
POTENTIAL
One of the highly effective or less than highly effective metho ds of contraception listed below 
should be continued until the end of study treatment. 
Local laws and regulations may require use of alternative and/o r additional contraception methods.
Highly Effective Contraceptive Methods That Are User Dependent 
Failure rate of <1% per year when used consistently and correctly.a
‚Ä¢Combined (estrogen- and progest ogen-containing) hormonal contrac eption associated with 
inhibition of ovulation and/or implantation. (This method of con traception can only be used 
by WOCBP participants in studies where hormonal contraception i s permitted by the study 
protocol.)b
‚Ä¢Oral (birth control pills)
‚Ä¢Intravaginal (rings)
‚Ä¢Transdermal
‚Ä¢Combined (estrogen- and progestogen-containing) hormonal contrac eption must begin at 
least 30 days prior to initiation of study therapy.
‚Ä¢Progestogen-only hormonal contraception associated with inhibit ion of ovulation. (This 
method of contraception can only be used by WOCBP participants in studies where 
hormonal contraception is permitted by the study protocol.)b
‚Ä¢Oral 
‚Ä¢Injectable 
‚Ä¢Progestogen-only hormonal contraception must begin at least 30 days prior to init iation of 
study therapy.
Highly Effective Methods That Are User Independent 
‚Ä¢Implantable progestogen-only hormonal contraception associated with inhibition of 
ovulation b
‚Ä¢Intrauterine device (IUD)c
‚Ä¢Intrauterine hormone-releasing system (IUS)c
‚Ä¢Bilateral tubal occlusion
Protocol Amendment No.: 03
Date: 14-Apr-2021 141
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
‚Ä¢Vasectomized partner 
A vasectomized partner is a highly effective contraception method provided that the partner 
is the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used. 
‚Ä¢Sexual abstinence 
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. 
The reliability of sexual abstinence needs to be evaluated in relation to the duration of the 
study and the preferred and usual lifestyle of the subject.
‚Ä¢Continuous abstinence must begin at least 30 days prior to init iation of study therapy.
‚Ä¢It is not necessary to use any other method of contraception whe n complete abstinence is 
elected. 
‚Ä¢WOCBP subjects who choose complete abstinence must continue to have pregnancy tests, 
as specified in Section 1.3. 
‚Ä¢Acceptable alternate methods of highly effective contraception must be discussed in the 
event that the WOCBP subjects chooses to forego complete abstin ence.
‚Ä¢Periodic abstinence (including, but not limited to, calendar, sym ptothermal, postovulation 
methods), withdrawal (coitus interruptus), spermicides only, an d lactational amenorrhea 
method (LAM) are not acceptable methods of contraception for this study.
NOTES: 
aTypical use failure rates may differ from those when used consi stently and correctly. Use should be 
consistent with local regulations regarding the use of contraceptive methods for subjects participating 
in clinical studies. 
bHormonal contraception may be susceptible to interaction with the study treatment, which may reduce 
the efficacy of the contraceptive method. Hormonal contraception  is permissible only when there is 
sufficient evidence that the IMP and other study medications will not alter hormonal exposures such 
that contraception would be ineffective or result in increased exposures that could be potentially 
hazardous. In this case, alternative methods of contraception s hould be utilized. For information specific 
to this study regarding permissibility of hormonal contraception , refer to .Sections 6.1 INCLUSION CRITERIA 
and 7.7.1 PROHIBITED AND/OR RESTRICTED TREATMENTS of the protoc ol.
cIUSs are acceptable methods of contraception in the absence of definitive drug interacti on studies when hormone 
exposures from intrauterine devices do not alter contraception effectiveness. For information specific to this 
study regarding permissibility of hormonal contraception, refer  to .Sections 6.1  INCLUSION CRITERIA and 
7.7.1 PROHIBITED AND/OR RESTRICTED TREATMENTS of the protocol.
Less Than Highly Effective Contraceptive Methods That Are User Dependent 
Failure rate of >1% per year when used consistently and correctly.
‚Ä¢Male or female condom with or without spermicide. Male and femal e condoms cannot be 
used simultaneously
‚Ä¢Diaphragm with spermicide
‚Ä¢Cervical cap with spermicide
‚Ä¢Vaginal Sponge with spermicide
Protocol Amendment No.: 03
Date: 14-Apr-2021 142
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
‚Ä¢Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the 
primary mechanism of action. (This method of contraception cann ot be used by WOCBP 
participants in studies where hormonal contraception is prohibi ted.)
Unacceptable Methods of Contraception
‚Ä¢Periodic abstinence (calendar, symptothermal , post-ovulation me thods)
‚Ä¢Withdrawal (coitus interruptus)
‚Ä¢Spermicide only
‚Ä¢Lactation amenorrhea method (LAM)
COLLECTION OF PREGNANCY INFORMATION
Guidance for collection of Pregnanc y Information and outcome of  pregnancy on the Pregnancy 
Surveillance Form is provided in Section 8.2.5 and APPENDIX 3 .
Protocol Amendment No.: 03
Date: 14-Apr-2021 143
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
APPENDIX 5 CRITERIA TO DEFINE INADEQUATE RESPONSE (PRIMARY), 
LOSS OF RESPONSE (SECONDARY), AND INTOLERANCE TO 
PREVIOUS STANDARD-OF-CARE MEDICATION(S)
Subject has demonstrated an inadequate response, loss of respon se, or intolerance to 1 or more of 
the following standard of care medications (including, but not l imited to):
‚Ä¢Oral 5-aminosalicy lic acids (5-ASAs) (eg, mesalamine, sulfasalazine, olsalazine, or 
balsalazide):
‚Ä¢Signs and symptoms of persistently active disease despite a his tory of at least one 4-
week regimen at highest dose (institutional practice)
‚Ä¢Documented history of intolerance
‚Ä¢Corticosteroids (eg, prednisone [or equivalent] or budesonide [or  equivalent]):
oSigns and symptoms of persistently active disease despite a his tory of at least one 4-week 
induction regimen that included a dose equivalent to oral predn isone ‚â• 30 mg/day (or 
equivalent) for 2 weeks, or intravenously (IV) for 1 week, or oral b udesonide
MMX 9 mg/day (or equivalent) for 2 weeks; OR
oAt least 2 failed  attempts to taper corticosteroids below a dos e that is equivalent to oral
prednisone 10 mg/day (or equivalent) or budesonide 3 mg/day (or  equivalent) on 2 separate 
occasions; OR
oD o c u m e n t e d  h i s t o r y  o f  i n t o l e r a n c e  o f  c o r t i c o s t e r o i d s  w h e r e  s u b j ect developed adverse 
reactions including, but not limited to, Cushing's syndrome, osteopenia/osteoporosis, 
hyperglycemia, insomnia, cataracts, refractory steroid acne, or  infection.
‚Ä¢Immunomodulators (eg, azathioprine [AZA], 6-mercaptopurine [6-MP] , or methotrexate 
[MTX]):
‚Ä¢Signs and symptoms of persistently active disease despite a his tory of at least one 8-
week regimen of oral AZA, oral 6-MP, or oral or injectable MTX (per country's 
approved label); OR
‚Ä¢History of intolerance of at least 1 immunomodulator (eg, nausea /vomiting, abdominal 
pain, pancreatitis, liver function test abnormalities, lymphope nia).
‚Ä¢Anti-tumor necrosis factor-alpha (TNF-Œ±) agents (eg, infliximab, ad alimumab, or golimumab):
‚Ä¢Signs and symptoms of persistently active disease despite an ad equate trial of i nduction 
treatment with an anti-TNF-Œ± agent (per country's approved labe l); OR
‚Ä¢Recurrence of symptoms during maintenance dosing following prio r clinical benefit;
OR
‚Ä¢History of intolerance (i ncluding, but not limited to, i nfusion-r elated reaction, 
demyelination, congestive heart failure, development of TNF inhibitor (TNFi) 
antibodies, or infection).
Protocol Amendment No.: 03
Date: 14-Apr-2021 144
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
‚Ä¢Integrin inhibitors (eg, vedolizumab):
‚Ä¢Signs and symptoms of persistently active disease despite an ad equate trial of induction 
treatment with an integrin inhibitor (per country's approved lab el); OR
‚Ä¢Recurrence of symptoms during maintenance dosing following prio r clinical benefit;
OR
‚Ä¢History of intolerance (including, but not limited to, infusion-r elated reaction, 
arthralgia, liver test abnormalities, or infection).
‚Ä¢Anti-interleukin (IL)-12/IL-23p40 antibodies (eg, ustekinumab):
‚Ä¢History of intolerance (including, but not limited to, infusion-r elated reaction, 
arthralgia, or liver test abnormalities).
Subjects who stop biologic treatment due to loss of funding wil l also be eligible for inclusion into 
the study.
Protocol Amendment No.: 03
Date: 14-Apr-2021 145
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
APPENDIX 6 COMMONLY USED CORTICOSTEROID EQUIVALENTS
Medication Dose Equivalence
Prednisone 20 mg
Cortisone 100 mg
Hydrocortisone 80 mg
Prednisolone 20 mg
Methylprednisolone 16 mg
Triamcinolone 16 mg
Dexamethasone 3 mg
Betamethasone 2 to 4 mg
Protocol Amendment No.: 03
Date: 14-Apr-2021 146
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
APPENDIX 7 EXAMPLES OF WASHOUT TIMES REQUIRED PRIOR TO 
RANDOMIZATION
Medication/treatments Discontinuation Prior to 
Randomization Notes
5-azathioprine (AZA) ‚â• 4 weeks 
6-mercaptopurine (6-MP) ‚â• 4 weeks 
Abatacept (CTLA4Ig) ‚â• 12 weeks
Adalimumaba ‚â• 8 weeks Washout period waived if undetectable levels on TDM assay
Alefacept ‚â• 8 weeks
Alemtuzumab ‚â• 12 months
AMG 623 ‚â• 12 weeks
Apheresis: lymphocyte apheresis or selective monocyte or granulocyte 
apheresis  (eg, Cellsorba‚Ñ¢)‚â• 12 months
Atacicept (TACI-Ig) ‚â• 48 weeks
Belimumab ‚â• 14 weeks
Certolizumab pegola ‚â• 8 weeks Washout period waived if undetectable 
levels on TDM assay
Cyclophosphamide ‚â• 4 weeks
Cyclosporine ‚â• 4 weeks
Danazol ‚â• 4 weeks
Dapsone ‚â• 4 weeks
Darvadstrocel ‚â• 24 weeks
Eculizumab ‚â• 12 weeks
Efalizumab ‚â• 8 weeks
Epratuzumabb ‚â• 18 weeks
Fecal transplant ‚â• 4 weeks This treatment is considered an investigational biologic agent for the 
purposes of this study.
Golimumaba ‚â• 8 weeks Washout period waived if undetectable 
levels on TDM assay
Infliximaba ‚â• 8 weeks Washout period waived if undetectable 
levels on TDM assay
Interferon ‚â• 12 weeks (or more than 5 half-lives, whichever is longer)
Intravenous globulin ‚â• 4 weeks
Protocol Amendment No.: 03
Date: 14-Apr-2021 147
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Medication/treatments Discontinuation Prior to 
Randomization Notes
Investigational therapies ‚â• 4 weeks (or 5 half-lives, whichever is longer) Subjects treated with investigational agents 4-12 weeks prior to first dose of 
study treatment must be discussed with the medical monitor.
IPP-201101 ‚â• 12 weeks
Janus kinase (JAK) inhibitorsc ‚â• 8 weeks Subjects treated with a JAK inhibitor 
8-12 weeks prior to first dose of study 
treatment must be discussed with the medical monitor.
Leflunomide ‚â• 12 weeks (or more than 5 half-lives, whichever is longer)
Lenalidomide with cholestyramine ‚â• 24 weeks
Memantine ‚â• 4 weeks
Methotrexate ‚â• 4 weeks
Mycophenolate mofetil ‚â• 4 weeks Washout period may be waived after discussion with medical monitor if undetectable mycophenolic acid (MMA) level on a relevant assay; test 
not provided within the study.
Natalizumab ‚â• 8 weeks
Ocrelizumaba ‚â• 24 weeks
Pimecrolimus ‚â• 4 weeks
Plasmapheresis 24 weeks
Retinoids ‚â• 4 weeks
Rituximab ‚â• 12 months
Sirolimus (rapamycin) ‚â• 4 weeks Washout period may be waived after discussion with medical monitor if 
undetectable sirolimus level on a relevant assay; test not provided within the study.
Tabalumab ‚â• 14 weeks
Tacrolimus ‚â• 4 weeks Washout period may be waived after 
discussion with medical monitor if 
undetectable tacrolimus level on a relevant assay; test not provided within the study.
Thalidomide ‚â• 4 weeks
Other TNF inhibitors ‚â• 8 weeks Washout period waived if undetectable levels on TDM assay
Tocilizumab ‚â• 12 weeks
Protocol Amendment No.: 03
Date: 14-Apr-2021 148
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Medication/treatments Discontinuation Prior to 
Randomization Notes
Ustekinumaba, d ‚â• 8 weeks For subjects who have received > 12 weeks of ustekinumab treatment: 
washout period waived if undetectable levels on a TDM assay
Vedolizumaba ‚â• 4 weeks Subjects who have received > 14 weeks 
vedolizumab treatment; or washout 
period waived if undetectable levels on a TDM assay
‚â• 8 weeks Subjects who have received ‚â§ 14 weeks of vedolizumab treatment
TDM = therapeutic drug monitoring; TNF = tumor necrosis factor
aThe washout period for this biologic can be waived for subjects  who have an undetectab le drug level on a TDM 
assay, performed either in routine clinical practice or during the screening period. If a TDM ass ay is used to waive the 
washout period for this biologic, the result of the TDM assay must be available in source docu ments, and the subject 
cannot receive another dose of that biologic after the TDM assay is obtained (Section 4.1.1.1).
bFor epratuzumab, ocrelizumab, and any other B-cell-depleting ag ent, follow the required washout or document 
recovery of B cells (CD19+) after discontinuation of these ther apies before a subject can be randomized.
cFailure or loss of response to previous treatment with JAK inhi bitors, such as tofacitinib, is exclusionary.
dFailure or loss of response to previous treatment with ustekinum ab (as well as other anti- IL-12/IL-23p40 antibodies 
or anti-IL-23p19 antibodies) is exclusionary.
Note: Investigators should consult with the medical monitor for  information about compounds not included in 
this list.
Protocol Amendment No.: 03
Date: 14-Apr-2021 149
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
APPENDIX 8 HBV AND HCV TEST RESULT INTERPRETATION
I. HBV
As BMS-986165 is predicted to have immunomodulatory effects in this study, subjects with 
potentially active h epatitis B (HBV) infection and subjects at risk of reactivation of HBV infection 
will be excluded (s ee Section 5.2).
Hepatitis B surface  antigen (HBsAg),  hepatitis B core antibody (HBcAb), and hepatitis B surface 
antibody (HBsAb)  are evaluated at s creening, with reflex to HB V DNA testi ng in subjects with 
HBsAg negative, HBcAb positive serology (as listed in the ‚ÄúInterpretation unclear‚Äù scenario, 
below). Notes on interpretation of HBV serology within this study are given below:
Susceptible ‚Äì does not meet exclusion criteria on HBV:
‚Ä¢HBsAg negative
‚Ä¢HBcAb negative
‚Ä¢HBsAb negative
Immune due to natural infection - does not meet exclusion criteria on HBV:‚Ä¢HBsAg negative
‚Ä¢HBcAb positive
‚Ä¢HBsAb positive
Immune due to hepatitis B vaccination - does not meet exclusion criteria on HBV:‚Ä¢HBsAg negative
‚Ä¢HBcAb negative
‚Ä¢HBsAb positive
Acutely infected ‚Äì meets exclusion criteria on HBV:
‚Ä¢HBsAg positive
‚Ä¢HBcAb positive
‚Ä¢IgM HBcAb positive
‚Ä¢HBsAb negative
Chronically infected - meets exclusion criteria on HBV:‚Ä¢HBsAg positive
‚Ä¢HBcAb positive
‚Ä¢IgM HBcAb negative
‚Ä¢HBsAb negative
Interpretation unclear:
‚Ä¢HBsAg negative
‚Ä¢HBcAb positive
‚Ä¢HBsAb negative
Protocol Amendment No.: 03
Date: 14-Apr-2021 150
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
HBV DNA testing will be performed in subjects with a negative H BsAg, but a positive HBcAb at 
screening. Subjects wit h detectable HBV DNA at screening are excluded. Subjects in this subgroup 
may be eligible for inclusion if HBV DNA is undetectable on thi s assay during screening.
Subjects with HBsAg negative, HB cAb positive serology and undetectable HBV DNA at 
screening will have follow-up HBV D NA testing throu ghout their participation in the study, as 
detailed in the Schedule of Activities ( Section 1.3). 
‚Ä¢During the study, subjects in this s ubgroup will have HBV DNA tested at Weeks 4, 8, 12, and
approximately every  3 months ther eafter.
‚Ä¢Subjects in this subgroup w ho have a clinical response at Week 12, who then enter the 
maintenance period and subsequently lose response and enter the  open-label Week 12 
responder arm will have addition al HBV DNA testi ng at the first  3 study visits after entry to 
this treatment arm.
‚Ä¢Subjects in this subgroup who do not have a clinical response a t Week 12 and who enter the 
open-label BMS-986165 6 mg BID PO study arm, will have HBV DNA testing at Weeks 16, 
20 and 24, and approximately e very 3 months thereafter.
‚Ä¢Subjects who enter the open-lab el extension period at Week 52 wi ll have HBV DNA tested at 
Weeks 56, 60 and 64, and approximately every  3 months thereafter.
‚Ä¢If subjects in this subgroup have detectable HBV DNA at any time, they must permanently 
discontinue study treatment, enter the post-treatment follow-up  period and the investigator 
should consider referring them for appropriate specialty care a nd follow-up.
II. HCV
Testing for HCV is a two-step pro cess: (i) anti-HCV antibody, a nd (ii) HCV RNA.
Subjects with a negative anti-HCV antibody may be eligible for the study.
Subjects with a positive or indeter minate anti-HCV antibody req uire additional HCV RNA testing 
to determine eligibility. Subjects with negative or undetectable HCV RNA may be eligible for the 
study. Subjects with positive or detectable HCV RNA have HCV in fection, are excluded from the 
study and should be referred for appropriate assessment and con sideration for treatment. 
Subjects who were previously treated with an approved, treatment regimen for HCV infection may be eligible to participate in the study provided they achieve a Week 24 Sustained Virologic 
Response; that is negative or undetectable HCV RNA 24 weeks aft er completion of a full course 
of an approved treatment regimen for HCV inf ection. Such sub jects must be discussed with the 
medical monitor prior to screening. 
Protocol Amendment No.: 03
Date: 14-Apr-2021 151
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
APPENDIX 9 MAYO SCORE: COMPONENT SUBSCORES AND ELECTRONIC 
SUBJECT DIARY ENTRY INSTRUCTIONS 
The Mayo score is a composite instrument designed to assess ulc erative colitis (UC) disease 
activity. It includes patient-reported outcomes (PROs), an obje ctive assessment of disease activity 
by endoscopy and a Physician‚Äôs Global Assessment (PGA). The May o score was first proposed 
by Schroeder et al.16Scherl et al.31proposed that the Mayo score should be modified by removing 
‚Äúmild friability‚Äù from the definition of an e ndoscopic (ES) subscore = 1. This was supported by 
draft guidance from th e US Food and Drug Ad ministration (FDA) th at states the presence of 
friability is not consistent with the concept of ‚Äúclinical remi ssion‚Äù (Lines 249-251).18As the PGA 
is neither a PRO nor an objective assessment of disease activit y, and the concept that it purports 
to measure is not dist inct from the other components of the mod ified Mayo score, use of the PGA 
as a component of the modified Mayo score is no longer recommend ed by US18or European 
regulatory authori ties.32
Consequently, disease activity assessments for inclusion and ef ficacy assessment w ill use the 
9-point modified Mayo score .  
 
Table 1 outlines the components and scoring used to calculate the modified Mayo score .
Table 1 Components of the Modified  Mayo Score  
Stool Frequency (SF)a
0 Normal number of stools for this patient
1 1 to 2 stools/day more than normal
2 3 to 4 stools/day more than normal
3 > 4 stools/day more than normal
Rectal Bleeding (RB)b
0 None
1 Streaks of blood with stool less than half the time
2 Obvious blood with stool most of the time
3 Blood alone passed
Findings of flexible proctosigmoidoscopy (endoscopy used to det ermine endoscopic [ES] subscore)
0 Normal or inactive disease
1 Mild disease (erythema, decreased vascular pattern)c
2 Moderate disease (marked erythema, absent vascular pattern, friability, erosions)
3 Severe disease (spontaneous bleeding ulceration)
Protocol Amendment No.: 03
Date: 14-Apr-2021 152
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
MAYO SCORES: DEFINITIONS
Two different versions of the Mayo score will be used as efficacy endpoints:
Modified Mayo Score : The modified Mayo score is a 9-point scale ; a score of 5 to 9 points 
(inclusive), which is required for randomization, denotes moder ate to severe disease (by protocol 
definition). The modified Mayo score is an adaptation of the tot al Mayo score (defined below) that 
excludes the PGA subscore.The modified Mayo score incorporates the following 3 components :
‚Ä¢Stool frequency (SF) subscore (0 to 3)
‚Ä¢Rectal bleeding (RB) subscore (0 to 3)
‚Ä¢Endoscopic (ES) subscore (0 to 3)
 
 
The modified  Mayo score  will be calculated using component sub scores entered into the
electronic case report form (eCRF).
MAYO SCORES: SF AND RB COMPONENT SUBSCORES
SF and RB data will be recorded and calculated using an electronic subject diary. 
Stool Frequency and Rectal Bleeding Subscores
Subjects will enter SF and RB data into the electronic subject diaries on a daily  basis throughout 
their participation in the study. Instructions for recording th e number of stools and worst rectal 
bleeding and definitions of SF and RB are provided in Table 2 . 
Protocol Amendment No.: 03
Date: 14-Apr-2021 153
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
NOTE : The subject daily diary information should be reviewed prior to each scheduled visit at 
which Mayo scores are to be calculated and during each study vi sit to ensure that subjects are 
successfully entering and uploading diary data. If adequate entries have not been made, the subject 
should be counseled about proper study procedures.
For eligibility and efficacy analysis purposes, the 3 most recent, valid (not necessarily 
consecutive), electronic subject diary entries recorded from th e 7 days prior to a study visit
will be used to calculate the SF and RB subscores. 
The following will be considered invalid data and excluded from  SF and RB subscore calculations:
‚Ä¢A day that medication(s) for c onstipatio n, diarrhea , or bowel irregularity are taken
‚Ä¢The 24 hours prior to the date of the endoscopy (to account for any preparation [eg, enema(s), 
laxative(s), clear liquid diet] that can affect bowel frequency  or blood content of the stool)
NOTE : Formal calculation of SF and RB subscores w ill be done using the electronic subject 
diaries. The averages of the 3 most recent, valid (not necessar ily consecutive) diary entries for SF 
and RB (recorded from the 7 days pri or to a st udy visit) will be calculated  and used to represent 
SF and RB subscores in Mayo score determination; averages will be rounded up and down at the 
0.5 cutoff. 
For the pre-endoscopy screening visit (ie, prior to the availab ility of electronic subject diary data): 
The baseline SF will be determined based on the number of stools a sub ject has in a 24-hour period 
when in remission from UC symptoms; orif a subject has notbeen in remission, they should be 
asked to identify the  number of stools they had in a 24-hour period before initial o nset of signs and 
symptoms of UC ( Table 2) . 
This baseline SF is used as the reference for subsequent SF subscores. 
For the endoscopy screening visit:
Best practice is to complete the other screening investigations  first and check results to ensure that 
a subject continues to be potentially eligible for the study pr ior to commencing bowel preparation 
for the endoscopy. When the endoscopy is schedule d, SF and RB data in the electroni c subject 
diary from the 7 days prior to the bowel preparation day for the endoscopy will be evaluated to 
ensure eligibility is maintained. Following endoscopy, the ES subscore will be received via email  from the central reader  
. This centrally read screening ES  subscore w ill be entered into  the eCRF, in 
addition to the SF and RB subscores, and the modified Mayo scor e calculated to determine subject 
eligibility.For subsequent study visits at which Mayo Scores are calculated :
For the Week 12, Week 52, and Week 104 visits, endoscopy timing should be reviewed prior to 
the visit to ensure adequate diary entries are available for SF and RB subscore determination. The 
averages of the 3 most recent, valid (not n ecessarily consecutive), electronic diary entries for SF 
Protocol Amendment No.: 03
Date: 14-Apr-2021 154
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
and RB data from the 7 days prior to the bowel preparation day for the endoscopy will be used. 
If adequate entries have not been made, the site should contact  the subject to reschedule the visit, 
and the subject should be counseled about proper study procedures. Following endoscopy, ES 
subscores will be emailed from the central ve ndor as noted a bove and entered into the eCRF 
together with the SF and RB subscores to calculate the modified Mayo score for a given visit.
Missing Data: 
Assessments with fewer than 3 valid, daily diary entries for SF  and RB from the 7 days prior to 
the bowel preparation day for endoscopy are considered missing data and will not count to ward
assessment of disease activity during the screening period or f or endpoint assessment at Week 12, 
Week 52, a nd Week 104. 
MAYO SCORES: ELECTRONIC SUBJECT DIARY ENTRY INSTRUCTIONS Standardized instructions for recording SF and RB data (based o n draft FDA Guidance for UC 
clinical endpoints)
18are in Table 2 .
Table 2 Standardized Instructions for Recording Number of Stools and 
Worst Rectal Bleeding (for the Mayo Scores) (Each Over a 24-hou r 
Period)
Completion of electronic subject diarySubjects will be trained on the completion of the electronic 
subject diary.
Stool Frequency (SF)
Definition of StoolA stool is defined as a trip to the toilet when the subject has  
either a bowel movement or passes blood alone, blood and 
mucus, or mucus only.
Determine Baseline SF (over 24 hours)At the screening visit, the number of stools the subject has in a 
24-hour period when in remission from UC symptoms should be 
entered in the electronic patient diary. 
If the subject has not been in remission, then the subject should 
be asked to identify the number of stools he/she had in a 24-ho ur 
period before initial onset of signs and symptoms of UC.
Record whether the baseline SF is based on the reported SF when  
the subject was in remission OR the reported SF before initial 
onset of signs and symptoms of UC.
Recording of SF assessmentsSubjects are to record the total number of stools for the previous 
24-hour period in the electronic subject diary on a daily basis . 
Subjects should make diary entries at the same time each day.NOTE: For eligibility and efficacy analysis purposes, the 
established baseline SF (defined above) will be used to calculate the number of stools above normal and subsequently assign a Mayo SF component score. This will be done automatically by the electronic diary and will not need to be calculated by the subject or study team. 
Protocol Amendment No.: 03
Date: 14-Apr-2021 155
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Table 2 Standa rdized Instructions for Recording Number of Stools and 
Worst Rectal Bleeding (for the Mayo Scores) (Each Over a 24-hour 
Period)
Rectal Bleeding (RB)
Most Severe Category of RB 
(in a given 24-hour period)Subjects should enter into the electronic subject diary the mos t 
severe category that describes the amount of blood they had in 
their stools for that given day.
Categories (subscore) of rectal bleeding are defined as follows :
‚Ä¢No blood seen (0)
‚Ä¢Streaks of blood with stool less than half the time (1)
‚Ä¢Obvious blood (more than just streaks) or streaks of blood 
with stool most of the time (2)
‚Ä¢Blood alone passed (3)
Subjects should enter ‚ÄúNo Blood Seen‚Äù in the rectal bleeding section if they do not have stool during a given day. 
Recording of RB assessmentsSubjects are to record their RB assessments in the electronic subject diary on a daily basis. Subjects should make diary entri es 
at the same time each day.
RB = rectal bleeding; SF = stool freq uency; UC = ulcerative colitis
Adapted from: Draft Guidance for Ind ustry, Ulcerative Colitis: Clinical Trial Endpoints US Departmen t of Health and 
Human Services, Food and Drug A dministration, Center for Drug Evaluation and Research. Draft A ugust 2016. 
Publication UCM515143.
Endoscopic (ES) Subscore 
ES subscores will be provided via email by the independent central endoscopy vendor  
 for all eligibil ity and efficacy assessments, at all time points. The endoscopy  
procedure from screening (cent ral read) will be used to determine the baseline (Week 0 [Day 1]) 
ES subscore component of the Mayo score. The ES subscores of the Mayo score will be modified 
so that the value 1 does not incl ude friability.
At Week 12 only: Local assessment of the endoscopy will be utilized to derive the ES compone nt 
of the Mayo Score; this is used for determination of treatment assignment during the maintenance 
period (see  Section 8.1.1 for details). The central read of the endoscopy will be used for effi cacy 
analysis at all time points.
Protocol Amendment No.: 03
Date: 14-Apr-2021 156
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr-2021 157
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr-2021 158
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr-2021 159
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr-2021 160
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr-2021 161
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
 
 
 
Protocol Amendment No.: 03
Date: 14-Apr-2021 162
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
 
 
 
 
 
Protocol Amendment No.: 03
Date: 14-Apr-2021 163
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr-2021 164
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr-2021 165
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr-2021 166
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr-2021 167
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr-2021 168
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr-2021 169
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr-2021 170
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr-2021 171
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr-2021 172
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr-2021 173
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr-2021 174
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr-2021 175
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr-2021 176
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr-2021 177
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
Protocol Amendment No.: 03
Date: 14-Apr-2021 178
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011024
BMS-986165 TYK2 Inhibitor
APPENDIX 19 COVID-19 VACCINES
If a subject has received a specific COVID-19 vaccination, the type of vaccine received should be 
recorded on the concomit ant medication page, if given during th e study, or the past history page, 
if given prior to enrollment.
‚Ä¢Administration of a live v accine is prohibited 90 days prior to the randomization visit; d uring 
the induction period, maintenance period, or OLE; or within 2 month s after the last dose of IP.
‚Ä¢Administration of a non-live vaccine is allowed during the stud y. However, the efficacy and 
safety of non-live vaccines (including non-live COVID-19 vaccin es) in subjects receiving 
BMS-986165 is unknown.
‚Ä¢The following are NOT live vaccines: inactivated vaccines (eg, heat-killed and formalin-killed 
vaccines), subunit vaccines (eg, influenza and pneumococcal vac cines), toxoid vaccines, 
nucleic acid vaccines that do not encode potentially infectious  virus (eg, Pfizer/BioNTech and 
Moderna COVID-19 vaccines) and r eplication-incompetent recombin ant vector vaccines (eg, 
AstraZeneca/University of Oxford COVID-19 vaccine).
‚Ä¢For COVID-19 vaccines requiring more than one dose, the full se ries (eg, both doses of a 
2-dose series) should be completed prior to enrollment when feas ible, and when a delay in 
enrollment would not put the study participant at risk. Ideally , adverse events attributable to a 
vaccine should have resolved prior to enrollment.
Please contact the medical monit or with any questions related to COVID- 19 vaccines.
Protocol Amendment No.: 03
Date: 14-Apr-2021 179
Approved 1.0 v Approved 1.0 v